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DIABETES PREVENTION AND CARDIOVASCULAR RISK REDUCTION  
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M. Kaye Kramer, DrPH 
University of Pittsburgh, 2007
 
Despite extensive research demonstrating that moderate lifestyle changes can reduce risk for 
Type 2 diabetes and cardiovascular disease these two chronic conditions continue to account for 
an overwhelming amount of morbidity and mortality worldwide.   Translation of successful 
prevention and risk reduction research into “real world” settings faces many challenges, while 
strategies for implementation are lacking.  For many reasons, the primary care practice venue 
provides an ideal environment for provision of prevention services on a permanent basis.  
The dissertation consists of three related projects; the first two examined the main 
components of diabetes prevention and cardiovascular disease risk reduction while the third 
investigated the relationship between perception of disease risk and lifestyle intervention 
performance.  Because current practices of prevention screening are often haphazard and tend to 
overlook those in greatest need, the first project focused on risk identification through prevention 
screening in a systematic manner.  Feasibility in the primary care practice setting as well as 
differences between those invited to attend prevention screening and those not invited was 
examined. 
The second project investigated the effectiveness and feasibility of provision of a lifestyle 
change intervention in a primary care practice setting.  The successful lifestyle intervention 
utilized in the Diabetes Prevention Program was modified for delivery in a group rather than 
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individual setting.  The effectiveness of the intervention was evaluated through risk assessment 
measures collected before and after participation in the intervention.   
Finally, motivation for making lifestyle changes remains a mystery and varies 
considerably from one individual to another.  It has been hypothesized that perceived risk, i.e., 
the probability of developing a disease or condition may influence an individual’s health 
behavior.  Utilizing a modified version of the Risk Perception Survey for Developing Diabetes 
(RPS-DD) the final project examined baseline differences in responses as well as the relationship 
between perception of risk and subsequent performance in the group lifestyle intervention.  
Differences in risk perception before and after participation were also examined.    
The projects are significant from a public health perspective in that they seek to begin to 
establish a foundation for implementation of diabetes prevention and cardiovascular risk 
reduction for the general population. 
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1.0  INTRODUCTION 
Two insidious peas in a pod, type 2 diabetes (T2D) and cardiovascular disease (CVD) are 
devastating chronic illnesses that affect millions of people worldwide.  Although distinct disease 
entities, T2D and CVD are often intertwined; in general, individuals afflicted with diabetes are 
two to four times more likely to develop CVD than the general population [1] with two-thirds to 
three-fourths dying of some sort of heart or blood vessel disease [2].  Despite research 
demonstrating that risk for T2D and CVD may be lowered through modest lifestyle changes, 
these conditions continue to wreak havoc on the health of millions and strategies to implement 
prevention in the “real world” are far from optimal. 
1.1 OVERVIEW OF DISSERTATION 
The focus of this dissertation is on the implementation of diabetes prevention and cardiovascular 
risk identification and reduction for patients in a primary care practice setting; it is presented in 
three related projects.   The first project evaluated the identification of those at risk for T2D and 
CVD through utilization of a systematic, organized screening approach.  The second assessed 
effectiveness and feasibility of a group lifestyle intervention delivered in a primary care practice 
setting, while the third project investigated the relationship between perception of risk for disease 
and performance in the group lifestyle intervention. 
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1.2 PUBLIC HEALTH SIGNIFICANCE 
Currently over 20 million people or about 7% of the total U.S. population are estimated to have 
diabetes; about 14.6 million have been diagnosed and 6.2 million are unaware that they have the 
disease [3].  The sixth leading cause of death in the United States [4], diabetes is also the leading 
cause of new blindness in those aged 20-74 years of age, the leading cause of kidney failure, and 
a major cause of lower limb amputation [3]. In 2002, estimated direct diabetes costs were almost 
$92 billion; indirect costs including disability, work loss and early mortality were approximately 
$40 billion, creating a colossal total diabetes financial cost in the US of $132 billion dollars [5].  
Type 1 diabetes, referred to in the past as “insulin-dependent” or “juvenile onset” diabetes 
accounts for approximately 5-10% of those diagnosed with diabetes.  Type 2 diabetes, previously 
known as “non-insulin dependent” or “adult onset” diabetes is much more prevalent and 
accounts for approximately 90-95% of those with diagnosed diabetes [6].   
 Often walking side by side with diabetes, cardiovascular disease, including diseases of 
the heart, stroke and hypertension, directly accounts for over 37% of annual deaths or one out of 
every 2.7 deaths in the US; it is estimated that one in three adult Americans has some form of 
CVD [2].  A major complication of diabetes, CVD is the leading cause of death for those with 
diabetes; individuals with diabetes are 2-4 times more likely to have heart disease or suffer a 
stroke than those without diabetes [7].  In fact it has been shown that patients with diabetes and 
no previous history of myocardial infarction (MI) have the equivalent risk of MI as non-diabetic 
patients with previous MI [8].  CVD is the most costly complication of diabetes, accounting for 
more than $17 billion of the $91.8 billion in annual direct medical costs for diabetes in 2002 [5]. 
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1.2.1 Risk States Prior to Diabetes Diagnosis 
While it is obvious that CVD is of major concern after diabetes diagnosis, research has shown 
that cardiovascular risk factors are often present in the interim stages prior to diagnosis with 
T2D.  In the San Antonio Heart Study, a population-based study of diabetes and CVD, 
cardiovascular risk factor status in initially non-diabetic Mexican Americans was studied.  After 
8 years of follow-up those individuals who subsequently developed T2D had higher levels of 
total and low-density lipoprotein (LDL) cholesterol, triglyceride, fasting glucose and insulin, 2-
hour glucose, body mass index (BMI) and blood pressure, as well as lower levels of high-density 
(HDL) cholesterol than subjects who remained non-diabetic, leading the authors to conclude that 
“pre-diabetic subjects have an atherogenic pattern of risk factors (possibly caused by obesity, 
hyperglycemia, and especially hyperinsulinemia), which may be present for many years and may 
contribute to the risk of macrovascular disease as much as the duration of clinical diabetes itself” 
[9].  Data from the Nurse’s Health Study also demonstrated a significantly increased risk for 
CVD beginning at least 15 years prior to diagnosis with T2D [10] while other studies have 
confirmed the relationship between elevated blood glucose levels and CVD in non-diabetic 
patients [11, 12].  Previously undiagnosed diabetes and impaired glucose tolerance have been 
found in patients with acute MI [13] and other studies have shown that diabetes and CVD risk 
factors are often intertwined in the risk for type 2 diabetes [9, 14] as well as CVD [15-17].   
Recently this relationship was confirmed again in the Dutch Transient Ischemic Attack Trial 
where stroke risk in a large clinical trial investigating two different aspirin doses and atenolol 
versus placebo was examined.   The authors found that the risk for stroke was almost doubled 
among people with impaired glucose tolerance when compared with those who had glucose 
levels within normal limits [18].   
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 The clustering of these conditions of risk including insulin resistance, dyslipidemia, 
obesity and hypertension has been referred to as syndrome X, insulin resistance syndrome and 
most commonly of late, metabolic syndrome.  While definitions of and criteria for inclusion in 
this disorder have varied [19-24] and even its very existence as a syndrome has been debated 
[25], research has supported the conclusion that the grouping of these risk factors generally 
places an individual at greatly increased risk for diabetes and CVD [26-29].  This relationship 
was confirmed again recently in a large 8-year follow-up investigation using data from the 
Framingham Offspring study.  The authors examined baseline and follow-up data for 3,323 
middle-aged men and women and concluded that metabolic syndrome (following NCEP ATP III 
criteria) was associated with an increased risk for T2D and CVD in both sexes, accounting for 
approximately half of new T2D and up to one third of CVD in men in this cohort [30].  This 
connection appears to be not only related to overt CVD, but sub-clinical disease as well.  
Recently, the relationship between metabolic syndrome and atherosclerosis was examined in the 
French MONICA study, a study involving 1,153 individuals without clinical evidence of CVD.  
The association of metabolic syndrome, using WHO and NCEP definitions, with number of 
carotid and femoral plaques, carotid intima-media thickness (IMT) and pulse wave velocity 
(PWV) was studied; the authors found that the presence of the metabolic syndrome almost 
doubled the risk of sub-clinical atherosclerosis [31].    
 Obviously a public health problem of considerable magnitude, a resolution does not 
appear to be on the horizon.  Current estimates from the Centers for Disease Control and 
Prevention suggest that about 54 million people in the US have pre-diabetes, thus are at higher 
risk for developing T2D, as well as heart disease and stroke [3].  It is anticipated that one in three 
Americans born in 2000 may develop diabetes in their lifetime, with minorities at even higher 
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risk [32].  These trends are already evident: from 1980-2004 the number of people in America 
with diabetes more than doubled from 5.8 million to 14.7 million [33], and parallel the overall  
increase in obesity [34].   In 1994 the majority of states in the U.S. had <5% diabetes prevalence, 
however in 2005 there is only one state with that rate and several are now exhibiting 8% 
prevalence and higher [35].  It has been projected that by the year 2030 there will be over 30 
million people with diabetes in the U.S. and 366 million cases worldwide [36].  In addition to the 
increase in obesity, one of the most important demographic changes related to the increase in 
diabetes prevalence is the increase in the proportion of people age > age 65 [36]. Total national 
costs for diabetes have been estimated to reach $156 and $192 billion by the years 2010 and 
2020 respectively, with predictions that the actual costs could be higher if health care outpaces 
the overall cost of living, or if the growing problem with obesity causes an increase in the 
prevalence of type 2 diabetes [5].   
 In 2002, the overall prevalence of the metabolic syndrome in adults in the US over age 20 
years was 24%, with a considerable increase for age-specific groups: the prevalence in 50-year-
old subjects was >30%, while the prevalence in subjects age 60 years and over was 40%.   In 
addition, the prevalence was highest in Hispanics and lower in non-Hispanic whites and in 
African Americans [37].   Further evaluation using National Cholesterol Education Program 
Adult Treatment Panel III diagnostic criteria showed increases in the prevalence of metabolic 
syndrome.  NHANES data from 1988-1994 showed the estimated unadjusted prevalence of 
metabolic syndrome in the US to be approximately 23%, while data from NHANES 1999-2000 
showed a significant increase to 26.7% (p= 0.043).   The age-adjusted prevalence increased by 
23.5% among women (p = 0.021) and 2.2% among men (p = 0.831) [38]. 
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1.2.2 Prevention 
T2D and CVD are serious and persistent diseases which progress gradually, usually with little or 
no perceptible symptoms until they have succeeded in causing often irreversible damage to their 
victims’ health.  While it may not be obvious at first glance, the fact that these conditions share 
such a lengthy “incubation” period is actually a potential public health windfall as there is 
considerable evidence that T2D and CVD can be prevented or delayed.  Lifestyle modification 
has been shown to be more effective in reducing risk for development of T2D and improving 
CVD risk status than medication in a number of studies.  Results from the DaQuing Impaired 
Glucose Tolerance (IGT) and Diabetes study first provided evidence that diabetes risk could be 
reduced through improved diet and exercise in people with impaired glucose tolerance [39].  The 
Finnish Diabetes Prevention Study determined that risk for diabetes development was decreased 
by 58% in individuals at high-risk for diabetes using intensive individual lifestyle intervention 
including diet and activity modification [40]; recent results published demonstrate a sustained 
effect with continued reduction in diabetes risk [41].  In the US, the Diabetes Prevention 
Program (DPP) again demonstrated that diabetes risk can be reduced in at-risk patients with an 
intensive individual lifestyle modification program [42].   The lifestyle intervention implemented 
in the DPP was also found to reduce risk for metabolic syndrome [43] and to improve CVD risk 
factor status [44].  More recently lifestyle intervention including weight loss and increased 
physical activity was found to be effective in reducing coronary heart disease risk factors in a 
small group of obese older adults [45], while another recent investigation found weight loss 
induced by calorie restriction or exercise training improved glucose tolerance and insulin action 
in non-obese, healthy, middle-aged men and women [46]. 
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 Several studies have examined the use of pharmacological interventions for diabetes 
prevention with varied levels of success [42, 47-49]; more recently results from the DREAM 
trial exploring diabetes prevention potential for the thiazolidinedione (TZD) rosiglitazone and/or 
the ACE inhibitor ramipril were published.  While ramipril demonstrated a significant increased 
regression to normoglycemia, it was not shown to have an effect on the primary end point-
development of diabetes or death  [50].  On the other hand, rosiglitazone  demonstrated a 60% 
reduction in the frequency of the primary end point (incident diabetes or death) when compared 
to placebo [51].   Furthermore, several pharmacological intervention studies have shown positive 
results for prevention of CVD in patients with and without existing heart disease and/or diabetes 
[52-58].   Recently published results from the Anglo-Scandinavian Cardiac Outcomes Trial–
Lipid-Lowering Arm (ASCOT-LLA) demonstrated that for patients with T2D and well-
controlled hypertension who did not have a history of CHD or greatly elevated cholesterol 
concentrations, the medication atorvastatin significantly reduced the risk of major cardiovascular 
events and procedures. The study found that the proportional reduction in risk was similar to that 
among participants who did not have diagnosed diabetes [59] . 
1.2.3 Cost of Prevention 
Because there is a lack of long-term data available from diabetes prevention research, the 
economic impact of prevention interventions are at the present time best assessed via computer 
simulation models.  In 2003 Herman, et al., examined the costs associated with primary 
prevention of diabetes in the Diabetes Prevention Program and found both the metformin and 
lifestyle interventions to be associated with moderate incremental costs.  Over three years, the 
direct medical cost of the metformin and lifestyle interventions were $2,542 per participant and 
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$2,789 per participant respectively, compared to a direct medical cost of $79 per participant for 
placebo. The authors estimated that from the perspective of a large health system, over three 
years, the cost of the metformin intervention in relation to the placebo intervention was $2,191 
per participant and the cost of the lifestyle intervention was $2,269 per participant.  Increased 
costs for the lifestyle intervention were associated with staff time for counseling and adherence 
monitoring, while the bulk of the cost for the metformin intervention was due to the cost of the 
medication itself. Costs for the lifestyle intervention decreased in each year and were 12% and 
7% less than metformin in years 2 and 3.  The authors speculated that the cost of the metformin 
intervention would decrease with the availability of less expensive formulations of generic 
metformin, while the costs of the lifestyle intervention could be reduced by improving the 
efficiency of staff time by using group visits.  [60].  A later analysis examined more closely the 
cost effectiveness of the interventions from a health system perspective and found that when 
considering the interventions as being implemented in routine clinical practice and from a 
societal perspective, the lifestyle and metformin interventions cost $13,200 and $14,300, 
respectively, per case of diabetes delayed or prevented and $27,100 and $35,000 per quality-
adjusted life-year (QALY) gained.  The authors concluded that over the short term of three years, 
both the lifestyle and metformin interventions were effective in preventing or delaying T2D and 
were cost-effective from the perspective of a health system and society [61].   
Another analysis in Canada used a Markov model to simulate the course of individuals 
with IGT under each of the following treatment strategies:  acarbose, an intensive lifestyle 
modification program, metformin or no intervention to prevent progression to diabetes.  The 
results of the model suggested that treatment of IGT in Canada was cost-effective and might 
generate savings.  The authors determined that while the pharmacological treatments tended to 
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be less costly, intensive lifestyle modification if maintained, provided the greatest health benefits 
at reasonable incremental costs [62].  In later analyses examining the cost-effectiveness of 
lifestyle intervention and metformin in the DPP, Herman et al. attempted to project the costs, 
health outcomes and cost-effectiveness of the DPP lifestyle and metformin interventions in 
relation to the placebo intervention over a lifetime.  Using a modified lifetime simulation model, 
the lifestyle and metformin interventions were estimated to delay the development of T2D by 11 
and 3 years, respectively and to reduce the absolute incidence of diabetes by 20% and 8%, 
respectively when compared to placebo.  The authors determined that the lifestyle intervention 
was highly cost-effective (cost per QALY approximately $1100) and that the metformin 
intervention was in a generally cost-effective range at $31,300 per QALY.  In addition, as in the 
short term analysis completed earlier, when the interventions were implemented as they might be 
in routine clinical practice, the cost-effectiveness over a lifetime improved.  The lifestyle 
intervention was found to be cost-saving in those < 45 years of age and cost-effective in all age 
groups, whereas metformin was found to be cost-effective for younger ages, but cost more than 
$100,000 per QALY for those older than 65 years.  The authors reported that if costs were 
reduced by providing the intervention in a closed group of 10 patients and assuming a reduction 
of 20 or 50% in effectiveness as compared to the DPP, the lifestyle intervention was calculated 
to be cost-saving relative to placebo while the metformin intervention would cost about $6,600 
to $21,000 per QALY.  Thus, the lifestyle intervention, when compared to metformin was 
considerably more cost-effective and resulted in a greater reduction in the risk for diabetes 
development as well as improved health outcomes [63].  A more recent study examined whether 
the lifestyle intervention could be offered in such a way that would be beneficial from a health-
payer perspective.  The authors determined that when compared to usual care, providing the DPP 
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lifestyle intervention to eligible adults at age 50 could prevent 37% of new cases of diabetes 
before age 65 at a cost of $1,288 per QALY gained [64].   The authors concluded that by using 
cost-sharing strategies to implement the DPP lifestyle intervention for eligible people age 50-64, 
financial return on investment could be seen for private payers as well as a long-term benefit for 
Medicare.   
In contrast, another analysis of the cost-effectiveness of the DPP interventions published 
later the same year using the Archimedes model found that when compared with not 
implementing any prevention program, the expected 30-year cost/QALY of the DPP lifestyle 
intervention from a health plan’s perspective would be quite high, at about $143,000.  The 
authors concluded that while “lifestyle modification is likely to have important effects on the 
morbidity and mortality of diabetes and should be recommended to all high-risk people…the 
lifestyle intervention utilized in the DPP may be too expensive to implement and other less 
expensive methods are needed” [65].   However, some have suggested that the discrepancies 
between the findings of these cost-effectiveness analyses may be related to different assumptions 
regarding the rate of glycemic progression in the Archimedes model (thus with underestimation 
of the long-term complications related to diabetes), the shortened time period utilized in the 
Archimedes model or lack of validity of the Archimedes model itself [66, 67].  
1.2.4 Rationale for Translation to Primary Care Practice 
While the rationale for diabetes prevention appears to be clear with both scientific and cost-
effective evidence to support the concept, implementation of diabetes prevention in a ‘real-
world’ setting is quite complex.  Translational research to examine these factors as well as the 
effectiveness and feasibility of “real-world” diabetes prevention is lacking.  For many reasons 
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the primary care practice venue provides an ideal environment for prevention administration on a 
permanent basis.  Primary care practices employ persons that generally have the knowledge and 
background to receive training to become preventionists.  In addition, patients look to primary 
care physicians and their staff for health information and advice when identified as being at risk.  
Furthermore patients are generally familiar with their primary care practice staff, routine, and 
location which could facilitate participation and retention.  Finally, one of the most important 
aspects of prevention intervention includes follow-up regarding progress in the program, as well 
as coordination of follow-up care as required.   
1.3 STUDY GOALS 
For the above noted reasons, a translational research investigation in a primary care practice 
setting was undertaken with a three-fold purpose: 1) to evaluate the efficacy and achievability of 
a prevention screening and risk identification program, 2) to examine the effectiveness and 
feasibility of a Diabetes Prevention Program based group lifestyle intervention program for at-
risk subjects and 3) to investigate the relationship between perceived risk and performance in a 
lifestyle intervention program delivered in a primary care practice setting.  To achieve these 
goals, data from the Screening, Training, Education and Prevention Services of the University of 
Pittsburgh (STEP UP) study was utilized.  STEP UP was a prospective study which examined a 
structured screening program for identification of those at risk for T2D and CVD and also 
evaluated the delivery of a modified DPP lifestyle intervention in four primary care practices in 
Western Pennsylvania.  Patients who were registered with the four practices and who were 
between the ages of 25-74 were invited for prevention screening using a computer driven 
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recruitment and screening program.  Individuals without previously reported diagnosis of 
diabetes, with BMI > 25kg/m2 and at least three of five components of the metabolic syndrome 
(based on National Cholesterol Education Program Adult Treatment Panel III) [20] were eligible 
for the Group Lifestyle Balance (GLB) program, an adaptation of the individual lifestyle 
intervention utilized in the DPP.   A total of 350 individuals attended screening, with 97 
determined to be eligible for the intervention; subsequently 43 subjects identified through 
screening as well as an additional 8 individuals referred by their Primary Care Physician (PCP) 
enrolled in the intervention component of the project.  Outcome measures included the collection 
of pre and post lipid profile and glucose (at least 2 hour fast requested), resting blood pressure, 
waist circumference and BMI; global risk was also assessed pre and post intervention.  In 
addition, two surveys were administered before and after the intervention: a modified Risk 
Perception Survey for Developing Diabetes (mRPS-DD) and the CDC’s 14-Item Health Related 
Quality of Life [68].  A third component of the project was the completion of a chart review of 
those subjects in the targeted screening group as well as another group who were not targeted for 
comparison. 
Specifically the goals were as follow: 
Paper 1:  Evaluate the efficacy and achievability of a prevention screening and risk 
identification program. 
a. It is hypothesized that a structured prevention screening program will facilitate the 
identification of those who are at risk for T2D and CVD in a primary care practice 
setting 
b. Prevention screening will identify individuals with previously unknown risk states 
which will be confirmed via chart review. 
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Paper 2:  Examine the effectiveness and feasibility of a Diabetes Prevention Program 
based group lifestyle intervention program for at-risk subjects. 
a. It is hypothesized that participation in a modified DPP group lifestyle intervention 
will have beneficial effects upon weight and global CVD risk for those subjects 
taking part, as well as upon the other specific outcomes/measures collected including 
glucose, blood pressure, lipids and waist circumference. 
b. Delivery of the Group Lifestyle Balance program will be feasible in a primary care 
practice setting. 
Paper 3:  Investigate the relationship between perceived risk and performance in a 
lifestyle intervention program delivered in a primary care practice setting. 
a. It is hypothesized that elevated risk perception for diabetes development will be 
correlated with performance in the GLB program. 
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2.0  REVIEW OF LITERATURE 
The review of literature encompasses a background of the classification and diagnosis of 
diabetes, type 2 diabetes and cardiovascular disease epidemiology and etiology as well as 
guidelines for prevention and the current state of diabetes prevention and cardiovascular risk 
reduction in primary care practice. 
2.1 DIABETES MELLITUS 
In very early times, diabetes mellitus was referred to as a condition of “honey urine” due to the 
fact that the urine of patients afflicted with diabetes often smelled and tasted sweet, like honey 
[69].  Well-known for thousands of years as a deadly disease, practitioners and scientists first 
recognized and later understood the signs, symptoms and complications of diabetes; however 
causality has not been completely explained.  Characterized by high blood glucose concentration 
(hyperglycemia) due to inefficient insulin secretion, target tissue insulin resistance or both, 
diabetes mellitus encompasses an assorted set of disorders.   
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2.1.1 Classification and Diagnosis 
Guidelines for the diagnosis and classification of diabetes were established by the National 
Diabetes Data Group (NDDG) in the late 1970’s [70] and were endorsed by the World Health 
Organization (WHO) in 1980 [71] and later by the WHO Study Group on Diabetes Mellitus [72].  
Two major forms of diabetes mellitus were recognized, insulin-dependent diabetes mellitus 
(IDDM, type 1) and non-insulin dependent diabetes mellitus (NIDDM, type 2).  These two 
conditions, though related by hyperglycemia, were noted to be heterogeneous with very different 
etiologic origins.  In addition, three other classifications for diabetes mellitus were recognized 
(gestational diabetes, diabetes caused by malnutrition and other types of diabetes), as well as the 
condition called impaired glucose tolerance (IGT) in which the glucose levels in the oral glucose 
tolerance test (OGTT) were elevated but not in a range considered to be diagnostic of diabetes.   
In 1995 an international Expert Committee was convened to examine the scientific 
literature available since establishment of the original classification and diagnosis of diabetes 
recommendations to determine if changes were necessary, and in 1997, the American Diabetes 
Association (ADA) published revised guidelines [73].  Of particular note regarding classification 
of diabetes, the terms IDDM and NIDDM were eliminated while the terms type 1 and type 2 
diabetes mellitus were retained.  In addition, the classification of gestational diabetes was 
continued however, based on scientific evidence the classification of diabetes caused by 
malnutrition was deleted.  The category for IGT was retained and the intermediate corresponding 
stage for fasting glucose was called impaired fasting glucose (IFG).   Furthermore, new criteria 
for diagnosis of diabetes were introduced and the level of fasting plasma glucose for diagnosis of 
diabetes was lowered from 140 mg/dl to 126 mg/dl, while IFG was defined between 110 mg/dl 
and 125 mg/dl.  These guidelines were essentially confirmed subsequently by WHO, although 
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diagnosis using the OGTT was the mandated preference for diagnostic testing rather than the 
fasting plasma glucose [74].  In 2003 the ADA introduced the term “pre-diabetes” to encompass 
the conditions of IFG and/or IGT indicating increased risk for the development of diabetes [75].  
The ranges for diagnosis with IFG and IGT were originally set at 110-125 mg/dL and 140-199 
mg/dL respectively, the ADA lowered the cut point for IFG to 100 mg/dL in order to optimize 
sensitivity and specificity for predicting future diabetes [76].  It was also felt that by decreasing 
the lower limit of IFG, thus subsequently increasing the proportion of people with IFG, the 
proportion of those with IGT that could be identified with a fasting glucose test would also 
increase [76].   The WHO has not yet adopted this criterion. 
Currently there are four generally recognized categories of diabetes:  type 1 diabetes, type 
2 diabetes, gestational diabetes mellitus (GDM) and diabetes of other specific types including 
genetic defects of the β-cell or with insulin action, diseases of the exocrine pancreas, 
endocrinopathies, drug or chemical induced diabetes and infections causing diabetes [77].  In 
contrast to previous terminology, current classification of diabetes is based on pathogenic 
processes rather than age at onset or treatment modality.  Diagnosis of diabetes is based on a 
fasting plasma glucose greater than 125mg/dl or 2-hour post load glucose during an OGTT 
greater than 199mg/dl with either test requiring confirmation on a separate day in the absence of 
unequivocal hyperglycemia.  In addition, the diagnosis of diabetes may be made based on a 
random or casual glucose greater than 199 mg/dl with diabetes symptoms, although it is 
recommended that the test be repeated for confirmation [6].   The use of the hemoglobin A1c 
(HbA1c) test is not currently recommended for diagnosis, although some have suggested its 
merit.  GDM is diagnosed using the OGTT with either a 100g or 75g glucose load [78]. 
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2.1.2 Type 1 Diabetes 
Type 1 diabetes (T1D) accounts for approximately 5-10% of those with diabetes and as 
previously mentioned was known as “insulin dependent” or “juvenile onset” diabetes [6]; it has 
also been referred to as type 1a diabetes [79] and accounts for >  90% of all cases of T1D [80].  
T1D is characterized by autoimmune destruction of the β-cells of the pancreas typically leading 
to absolute insulin deficiency, with subsequent exogenous insulin therapy required [81].  The 
rate of β-cell destruction varies from quite rapid progression as typically seen in infants and 
children to a much slower process observed mainly in adults [6]. The result of an autoimmune 
process caused by a combination of genetic and environmental factors [81], T1D is usually 
diagnosed in children or young adults; however this condition can occur in people of all ages.   A 
small number of those with T1D fall into a category of unknown etiology, with most being of 
African or Asian ancestry; this type of diabetes is referred to as idiopathic or T1Db diabetes [77].  
Although these patients may have permanent insulinopenia and may be prone to ketoacidosis, 
they have no evidence of autoimmunity.  Insulin dependency is variable with insulin replacement 
therapy being necessary at times but may not be a permanent component to care.  Incidence of 
T1D is highest in the Scandinavian countries and lowest in China and parts of South America 
[80] In parallel with T2D, T1D appears to also be increasing worldwide both in high and low 
incidence populations [82], however not at the rate seen with T2D.  
2.1.3 Type 2 Diabetes 
T2D encompasses those with insulin resistance and insulin deficiency which is relative rather 
than absolute.  The deficiency in β-cell function which occurs over time is not related to 
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autoimmune processes as in T1D; usually initially and often throughout a lifetime, many patients 
with T2D do not require insulin to survive [6].  Most patients with T2D are obese or overweight; 
more than 80% of all people diagnosed with T2D were overweight before the disease developed 
[83].  Secretion of insulin in T2D patients is defective and does not counteract insulin resistance. 
Thought in the past to affect adults only, T2D is now being diagnosed in children as well as 
adolescents [84].   T2D will be discussed in further detail below. 
2.1.4  Gestational Diabetes and Other Types of Diabetes 
Additional diabetes classifications include GDM as well as a general ‘other’ category for certain 
specific types of diabetes.  GDM is defined as “any degree of glucose intolerance with onset or 
first recognition during pregnancy”[6].   Both the National Diabetes Data Group (NDDG) and 
the World Health Organization (WHO) guidelines mandate that this classification is appropriate 
despite treatment during pregnancy or whether the condition persists after pregnancy.  In the 
United States, GDM occurs in about 4% of pregnancies, resulting in approximately 135,000 
cases annually [6].  Gestational diabetes is more common among women who are African 
American, Hispanic/Latino American or American Indian and for those who are obese and/or 
have a family history of diabetes.  For women afflicted with GDM, approximately 5% to 10% of 
women with gestational diabetes are found to have T2D after pregnancy, and women who have 
had gestational diabetes have a 20% to 50% chance of developing diabetes in the next 5–10 years 
[3].   
Other specific and less common types of diabetes include those whose origins are found 
in specific genetic defects in insulin secretion or action, diseases of the exocrine pancreas such as 
pancreatitis, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis and fibrocalculous 
 18 
  
pancreatopathy [85] and endocrinopathies including acromegaly, Cushing’s syndrome and 
hormone secreting tumors of thyroid, pancreas, adrenal glands [86].  One subtype of diabetes, 
maturity onset diabetes of the young (MODY) is characterized by autosomal dominant 
inheritance, early onset of hyperglycemia, and impairment of insulin secretion [85].  Diabetes 
has also been related to certain specific genetic syndromes such as Down syndrome, Kleinfelter 
syndrome and Turner syndrome [87].  Certain viral infections such as congenital rubella, 
cytomegalovirus and coxsackie have been implicated in the destruction of pancreatic islets.  
Finally, in some cases certain drugs including nicotinic acid, glucocorticoids, thyroid hormone, 
thiazides and beta blockers have been associated with development of diabetes [85]. 
 
2.2 TYPE 2 DIABETES 
2.2.1 Epidemiology 
While there are several types of diabetes, the lion’s share is attributable to T2D [6].  With a 
prevalence rate in 2005 of about 9.6% and affecting over 20 million adults age 20 and older in 
the United States, diabetes represents a significant health concern for our nation [3].  Worldwide 
prevalence of diabetes continues to increase as well; the prevalence of diabetes for all age groups 
was estimated at 2.8% in 2000 and predicted to rise to 4.4% in 2030 [36].  These increases are 
attributable to several factors including the aging population, increased survival rates, 
urbanization, sedentary lifestyles and continued and increasing rates of obesity.  In the US, 
prevalence of diabetes is projected to increase to 14.5% in 2031 with 37.7 million adults having 
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diagnosed or undiagnosed diabetes [88].   As previously noted, T2D accounts for approximately 
90-95% of all diabetes, thus is the major contributing factor driving these increasing numbers 
[6]. 
Prevalence varies with race and ethnicity; in the US, non-Hispanic whites exhibit the 
lowest prevalence of diabetes (8.7%).  Individuals of Hispanic descent have higher rates of 
diabetes prevalence; Mexican Americans, the largest Hispanic/Latino subgroup in the US, are 
1.7 times more likely to have diabetes as non-Hispanic whites [3].  It has been predicted that the 
prevalence of diabetes in this particular population could be potentially overwhelming in the 
future [36].   Adult non-Hispanic blacks are estimated to have a prevalence of 13.3%, affecting 
about 3.2 million people and are 1.8 times more likely to have diabetes than non-Hispanic whites 
[3].  Data is not available for the total prevalence of diagnosed and undiagnosed diabetes for 
Asian Americans or Pacific Islanders. However, in California, Asians were 1.5 times more likely 
to have diagnosed diabetes than non-Hispanic whites, while in Hawaii, Asians, Native Hawaiians 
and other Pacific Islanders age 20 and older were 2 times more likely to have diagnosed diabetes 
[3].  Finally, American Indians and Alaska Natives are estimated to have the highest prevalence 
of diabetes with a prevalence rate of approximately 15.1% and are 2.2 times more likely to have 
T2D than non-Hispanic whites [89].   Prevalence increases with age, with those in the oldest age 
groups having the highest rates [90].   Approximately 10.3 million people, (20.9%) aged 60 and 
older have diabetes  [3].  In addition, in the US diabetes is somewhat more prevalent in men than 
women, affecting approximately 10% of all men age 20 and older compared to 8% of women in 
the same age group [3], however worldwide estimates for 2003 and 2025 show a higher rate for 
females of about 10% [1].  
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Approximately 1.5 million new cases of T2D were diagnosed in adults aged 20 years and 
older in the year 2005; these numbers are expected to climb as problems with obesity increase 
[3].  This number has risen considerably from National Health Interview Survey data from 1990-
92 which estimated approximately 625,000 new cases of diabetes each year [90].  Although T2D 
often affects middle-aged individuals, thus was previously known as adult-onset diabetes, more 
recently it has been diagnosed in adolescents and even children [84].  In 2002, diabetes was the 
sixth leading cause of death reported on death certificates in the U.S. According to death 
certificate reports, diabetes contributed to a total of 224,092 deaths [3]. Overall, individuals with 
diabetes have twice the risk for death as people of similar age without diabetes. 
Very often symptoms are not present until T2D has progressed considerably and half or 
more may only be diagnosed concurrently with the initial presentation of a complication of the 
disease.  In fact it is estimated that about 20% of patients with T2D have evidence of diabetic 
retinopathy at diagnosis with diabetes due to the long pre-clinical period often observed prior to 
diagnosis [90].  When present, symptoms of T2D may include a lack of energy, increased 
hunger, weight loss, polyuria and polydipsia, blurred vision, irritation and damage to the nerves 
causing pain, infections and/or slow healing of wounds.  Other symptoms may include sexual 
function problems such as impotence in men or decreased vaginal lubrication with painful 
intercourse in women, and mood changes [83].  Over time, chronic hyperglycemia causes long-
term damage to the organs of the body.  Organs affected include the heart, eyes, kidneys, nerves 
and blood vessels [6].  The majority of complications arising from diabetes are due to the 
damage which occurs to blood vessels and are classified as macrovascular or microvascular in 
nature.  Macrovascular complications are related generally to accelerated atherosclerosis 
affecting the coronary, carotid and femoral arteries, while microvascular complications are 
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associated with the retina, kidney and nervous system [91].  Macrovascular complications 
account for the majority of morbidity and mortality associated with T2D (add Diabetes in 
America references), while microvascular complications may lead to blindness, renal failure and 
neuropathy. 
2.2.2 Etiology 
T2D is a condition causing hyperglycemia due to insulin resistance and/or insulin deficiency 
which may be absolute or only partial.  The underlying mechanism may be due to an islet defect 
associated with increased peripheral resistance to the action of insulin which results in decreased 
peripheral glucose uptake, or may be due to increased hepatic glucose output [81].  In many 
populations T2D is characterized not only by insulin resistance but also by insulinopenia (loss of 
β-cell function) [91]; over time the production of insulin is decreased eventually causing 
uncontrolled hyperglycemia.  In general, T2D onset is usually insidious occurring slowly and 
without symptoms over a long period of time, however in certain cases it has been known to 
progress fairly rapidly.  As discussed previously, CVD risk factors often develop during this long 
period of asymptomatic hyperglycemia while other complications such as retinopathy may also 
be occurring in early but harmful stages of progression [92] .   
There is no single cause of T2D and it is apparent that demographic, genetic, and 
behavioral and lifestyle risk factors are all part of the complexity of the individual development 
of T2D [6].   Demographic risk factors include age, ethnicity and gender.  Development of T2D 
in the past before age 30 was rare, however, it was estimated that for 1999-2000 approximately 
7% of adolescents had impaired fasting glucose [93] and diagnosis with T2D  is now beginning 
to be seen more frequently in this age group [84].  Risk for development of T2D continues to 
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increase rapidly with age and is highly prevalent in the oldest age populations in the US [94].   
As mentioned above, rates of diabetes development between ethnicities vary considerably 
between certain groups; in the US, T2D is more prevalent in minority populations.  Risk for 
development of T2D is similar for both genders, however in adolescents, the prevalence of IFG 
was found to be higher in boys than in girls (10% vs. 4%) [93] and in the most recent analysis of 
NHANES data, a significant increase in diagnosed diabetes was seen for men but not for women 
[94]. 
As noted, T2D is a heterogeneous disorder and thus not easily explained by one 
pathophysiological pathway or mechanism.  Due to considerable variations in prevalence in 
different areas around the world the question concerning nature versus nurture has arisen, i.e. is 
the primary cause of T2D related to genetic influences, environmental factors, or both?  Genetic 
or familial contributions have been noted in several populations including the North Dakota and 
Pima Indians [95]; other family studies have been conducted which have shown genetic as well 
as environmental influences.  One study of twins in which one had T2D and the other did not 
found the concordance for abnormal glucose tolerance to be significantly different between 
monozygotic and dizygotic twin pairs, thus concluding that genetic predisposition is important in 
the development of abnormal glucose tolerance but that non-genetic factors might play a 
significant role in determining whether a genetically predisposed subject will progress to overt 
T2D [96].   Similarly, several other twin studies have suggested a genetic predisposition for 
glucose abnormality, however the importance of environmental factors is also stressed [97-100].  
Genes which have been shown to be associated with T2D include Gc genotype gene located on 
chromosome 4, HLA gene on chromosome 6, lipoprotein antigen gene on chromosome 6, insulin 
gene polymorphism on chromosome 11, apo-lipoprotein genes on chromosomes 2 and 11, 
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glucose transporter genes on chromosomes 1 and 12, haptoglobulin gene on chromosome 16, and 
insulin receptor gene on chromosome 19 [101].   Although these genes have been found in 
various populations and are most likely essential components for development of T2D, their 
existence does not fully explain the onset of the disease.  The appearance of the disease is 
probably due to a combination of environmental effects which activate a certain genetic 
predisposition. 
One theory that has attracted attention over the years is that of a “thrifty gene”.  The 
hypothesis is that in the past when humans were hunters and gatherers they exhibited a “thrifty” 
metabolism which made possible efficient storage of fat during so-called “feast” periods, and 
provided storage, or an energy buffer during periods of famine which was mediated by a “quick 
insulin trigger” [102].  This mechanism was beneficial for survival, however, as lifestyles have 
changed over time, has now become detrimental in a continual “feast” environment, leading to 
obesity and increased diabetes.  There have been some investigations of birth weight and 
subsequent development of T2D which some have suggested support this theory [103-107].  
These studies found a relationship between low birth weight and increased risk for T2D.  
Because low birth weight is highly associated with increased rates of mortality, these results 
could suggest that those with a genetic predisposition for diabetes have this “survival” or 
“thrifty” gene.  Another theory put forth involves a ‘thrifty phenotype” (Barker-Hales 
hypothesis) which proposes that a fetus develops alterations in the growth and function of tissues 
when in an adverse intrauterine environment by optimizing the use of a reduced nutrient supply 
to ensure survival.  [108].  This under-nutrition in-utero is hypothesized to cause insulin-
resistance and subsequent T2D later in life.  Some studies have also found a relationship between 
high-birth weight, and both high and low birth weight and risk for T2D later in life [105, 109, 
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110].  In a very recent large meta-analysis of birth weight and risk for T2D, Harder, et al., 
determined that both high and low birth weight was associated with increased risk for T2D [111].   
The authors suggested that the increased risk for high birth weight may be due to perinatal 
exposure to un-diagnosed and non-treated maternal hyperglycemia during pregnancy, as well as 
maternal overweight during pregnancy.  They also postulated that for low birth weight, instead of 
a “thrifty gene” or “thrifty phenotype” being responsible for increased risk later in life, the 
relationship may be due to neonatal over-feeding and over-nutrition of low birth weight babies 
thus causing rapid neonatal weight gain.  It has been suggested that over-nutrition during critical 
periods of life may lead to overweight and obesity later in life, which has been supported in at 
least one animal model [112].  These theories will require further research and investigation. 
As noted above, both high and low birth weight appears to be related to development of 
T2D later in life, and in fact, overweight and obesity are widely recognized as the strongest 
environmental risk factors for T2D development.  Defined as a BMI >30kg/m2 [113] obesity has 
been shown to be very positively associated with the development of T2D in many studies [114-
120].  Conversely and possibly related to the genetic factors discussed above, T2D  has also been 
diagnosed in people who are not overweight and does not always develop in all who are obese 
[90], however in analyses carried out for World Health Report 2002, approximately 58% of 
diabetes and 21% of ischemic heart disease globally were attributable to a BMI above 21 kg/m2 
[113].  The World Health Organization estimates that there are approximately 1.6 billion 
overweight individuals worldwide (age 15 and older) with at least 400 million considered to be 
obese.  WHO further projects that the number of overweight adults worldwide will increase to 
approximately 2.3 billion by 2014 and more than 700 million will be obese.  Of considerable 
concern, WHO estimates that there were at least 20 million children under the age of five years 
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old that were overweight globally in 2005 [113].  There does not appear to be any indication that 
the prevalence of overweight and obesity is decreasing; NHANES data showed that for children 
in the US aged 6 through 19 years in 1999-2002, 31% were at risk for overweight, while 16% 
were actually overweight [121]. Longitudinal data from the National Heart, Lung and Blood 
Institute Growth and Health Study (NGHS) demonstrate that rates of overweight in Caucasian 
girls increased through adolescence from 7% to 10% and from 17% to 24% in African-American 
girls [122].   
As weight gain has also been associated with the development of diabetes, the above 
trend is particularly alarming.  Prospective data from the Nurses Health Study confirmed the 
relationship between obesity and increased risk for development of T2D but also demonstrated 
that a weight gain of 7.0-10.9 kg after age 18 was associated with a twofold increase in the risk 
for diabetes [123].  In 1997, long-term patterns of weight change over about a 10 year period 
were examined in relation to incidence of diabetes in a national cohort of 8,545 adults in the U.S. 
from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study.  
The results demonstrated increased risk with increased weight gain when compared to a stable 
weight; the authors found no evidence that the results differed by age, sex, or race and estimated 
that the population attributable risk was 27% for weight increases of 5 kg or more [124]. 
Additional results published in 2004 from the Health Professionals Follow-up Study also found a 
similar relationship. In this study, changes in body weight and body fat distribution and the 
subsequent risk of diabetes among 22,171 men over time was examined.  The authors found that 
for every kilogram of weight gained, risk for diabetes increased by 7.3%, and that over 50% of 
the cases of diabetes in this group could be credited to a weight gain greater than 7kg  [125].  
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In addition to general obesity, body fat distribution is another very important factor in the 
development of T2D as it is apparent that those with increased abdominal fat are at higher risk 
for T2D.   Several studies have confirmed the association between increased central adiposity, 
including waist circumference, waist hip ratio and T2D development in both men and women 
[126-132].  One recent prospective study compared the ability of BMI, waist circumference 
(WC) and waist to hip ratio (WHR) to predict T2D development.  The authors found both overall 
obesity and WC strongly and independently predicted T2D and determined that WC was a better 
predictor than WHR [133].  As has been shown for weight gain, changes in waist circumference 
are also related to increased risk.  In the Health Professionals Follow-up Study mentioned above, 
in addition to confirming the relationship between weight gain and increased risk for T2D, an 
increased change in WC was also shown to be highly related to increased risk.  When men who 
had increased WC by 14.6 cm or more were compared with men who had a stable WC, those 
with increased WC had 1.7 (95% confidence interval: 1.0, 2.8) times the risk of diabetes after 
controlling for weight gain [125].  Although some debate has arisen concerning waist measure 
cut-points, particularly in areas of ethnic differences, central adiposity is clearly an important 
component of T2D development and insulin resistance. 
Another important environmental factor associated with T2D development is lack of 
physical activity.  Physical activity has generally decreased in many populations in recent years 
due to advances in technology and lifestyle changes.  Much research has suggested a relationship 
exists between sedentary lifestyle and risk for T2D, and vice versa [134-139].  One notable study 
examined the longitudinal relationship between physical activity, BMI and the development of 
type 2 diabetes in a high-risk Gila River Indian community from 1987 to 2000 [140].   A 
physical activity questionnaire that assessed past year leisure and occupation activity was 
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administered to 1,728 non-diabetic Pima individuals age 15-59.  Using the OGTT to determine 
diabetes diagnosis, over an average follow-up period of six years, the authors found that total 
activity was related to the development of T2D in both men and women, with women 
demonstrating a significant relationship between diabetes development and physical activity 
(p<0.05).  Furthermore, the incidence of diabetes remained lower in the more active individuals 
across most categories of BMI for both men and women in this study.  Another example is the  
Honolulu Heart Program, which prospectively followed 6,815 Japanese-American non-diabetic 
men age 45-68 years over a six-year period and found that increased activity was inversely 
related to decreased risk for T2D even when other mediating risk factors were adjusted for [141].  
In another more recent investigation, 2,017 Finnish men and 2,352 Finnish women age 45-64 
years with no previous history of diabetes were followed prospectively for 9.4 years.  After 
adjusting for other risk factors such as age, study year, gender, blood pressure, smoking and 
education, level of physical activity was found to be inversely associated with risk for T2D.  This 
relationship was persistent in those with both obesity and impaired glucose regulation, either 
obesity or impaired glucose regulation or with normal BMI and glucose regulation [142].   
Another prospective study of middle-aged non-diabetic British men over a mean of 9.8 years 
found that men engaged in moderate levels of physical activity had a substantially reduced risk of 
diabetes, when compared to the physically inactive men, after adjustment for age and BMI.  This 
association persisted in full multivariate analysis [143].  Another study using Nurses Health 
Study data, the “dose” of activity required for beneficial risk reductions was examined.  The 
results suggested that more vigorous activity resulted in an increased risk reduction, but also 
confirmed that more moderate activities such as walking provided a reduction in risk as well 
[144].  Low levels of physical activity and increased risk for T2D have been shown in the elderly 
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population as well.  Residents of East Boston age 65 years and older who were participating in 
the East Boston Health Project (one of four components of the National Institute on Aging-
sponsored Established Populations for the Epidemiologic Study of the Elderly) were followed 
prospectively over two 3-year time periods.  High BMI (>26kg/m2) and low physical activity 
level were found to be significant predictors of T2D in a multiple regression model adjusting for 
age, gender, and blood pressure [145].   
Although not as well studied, this relationship has been found in children and adolescents 
as well.  One very recent small study examined 54 obese and lean children age 9-11.5.  The 
results of the study suggested that elevated central adiposity and low levels of daily physical 
activity were the main predictors of insulin resistance in this population [146].  Thus, the 
important relationship between physical activity and risk for T2D exists across gender as well as 
various age groups and ethnicities; however, it does not appear that levels of physical activity are 
increasing.  Using the Medical Expenditure Panel Survey, a nationally representative survey of 
the U.S. population, physical activity in those with diabetes and at risk for diabetes was 
examined for the year 2003.  A total of 39% of adults with diabetes were physically active versus 
58% of adults without diabetes [147].   
One other obvious component of lifestyle risk includes diet.  While the possibility that 
diet is involved in the development of T2D has been recognized for quite some time, the specific 
dietary components and processes involved have not been wholly identified.  The theory that 
high-fat diets may contribute to the development of insulin-resistance and T2D has evolved from 
observations of increased risk for T2D in populations that have “Westernized” their diets, i.e. 
changed from diets rich in multiple fruits and vegetables, which were usually high in complex 
carbohydrate and fiber, to diets which are much higher in fat and lower in complex carbohydrate.  
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In many instances, later generations who have migrated to the U.S. or other western cultures 
have seen marked increases in rates of T2D.  Studies comparing later generation migrated 
populations to those who remain in their  homeland have found higher amounts of dietary fat in 
those who have migrated [148, 149].  Other research, both cross-sectional and prospective, has 
supported the concept of a high-fat diet, or high-fat low-carbohydrate diet being associated with 
the development of T2D [150, 151].  Additional evidence exists to suggest that it is not just the 
quantity but the quality of fat intake which is important in the development of T2D, with higher 
intakes of saturated fat and trans-fat potentially having an adverse effect on glucose metabolism 
[152].   
Carbohydrates and fiber have also been identified as possibly playing a role in the 
development of T2D.  There has been some evidence that high-complex carbohydrate, high-fiber 
diets may improve insulin sensitivity [153]; furthermore the quality of carbohydrate has received 
considerable attention lately as this may influence the rate of digestion and subsequent glucose 
response.  The concept of glycemic index (GI) was developed in 1981 in an effort to quantify the 
glycemic responses induced by carbohydrates in different foods [154] and continues to be a 
nutritional tool as well as a viable hypothesis under continued investigation [155].  Research has 
supported the concept of a relationship between high glycemic load foods, low cereal fiber and 
increased risk for T2D [156-158]  In a review of existing literature, Hu et al., concluded that a 
diet consisting of low GI carbohydrates and high in fiber could potentially reduce risk, while 
diets containing large amounts of higher GI foods may increase risk for T2D [152].  The authors 
admitted that the concept of GI has been controversial, but that GI may be useful when data 
bases are further developed and refined.   The relationship between glycemic index, glycemic 
load and dietary fiber intake and the risk of T2D was examined prospectively over 8 years in a 
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large cohort of young women.  Glycemic index was significantly associated with increased risk 
for T2D after adjustment for age, BMI, family history of diabetes, as well as other potential 
confounders, while cereal fiber intake was associated with a decreased risk of diabetes.  
Glycemic load was not significantly associated with risk for T2D.  The authors concluded that a 
diet with high glycemic index foods and low fiber cereal was associated with increased risk for 
T2D [159]. 
In summary, it is apparent that a variety of components are involved in the development 
of T2D, and in fact all must be addressed in the reduction of risk for T2D.   Findings from a large 
prospective study of 84,941 female nurses followed over a 16-year period from 1980 to 1996 
exemplify the importance of considering all components of risk for T2D.  All participants were 
free of diagnosed CVD, diabetes or cancer at baseline assessment; 3300 new cases of type 2 
diabetes were found during the study time period.  The authors found that overweight or obesity 
was the single most important predictor of T2D; after adjusting for BMI, other factors attributed 
to a significantly increased risk of diabetes were lack of exercise, a poor diet, current smoking, 
and abstinence from alcohol.  The authors concluded that in this large cohort of middle-aged 
women, “a combination of several lifestyle factors, including maintaining a body-mass index of 
25 or lower, eating a diet high in cereal fiber and polyunsaturated fat and low in saturated and 
trans fats and glycemic load, exercising regularly, abstaining from smoking, and consuming 
alcohol moderately, was associated with an incidence of type 2 diabetes that was approximately 
90 percent lower than that found among women without these factors. These results suggest that 
in this population the majority of cases of type 2 diabetes could be avoided by behavior 
modification.” [160]. 
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2.3 CARDIOVASCULAR DISEASE 
2.3.1 Epidemiology 
Cardiovascular disease, which consists of hypertension, coronary heart disease (CDH), heart 
failure, stroke and congenital cardiovascular defects, remains the number one cause of death in 
the U.S., accounting for 36.3% of deaths in 2004, or 1 in every 2.8 deaths in the U.S.  CHD 
accounts for over 50% of CVD mortality, followed by stroke at 17%.  It is estimated that 1 in 3 
adults in the U.S. have some form of CVD, with over half age 65 and older [161].   Data from 
the Framingham Research Study indicate that the lifetime risk for CVD is 2 in 3 for men and 
more than 1 in 2 for women at age 40 [161].  In the U.S., CVD prevalence in 2004 was highest in 
black females (49.0%) and black males (44.6%), followed by white males and females (37.2% 
and 35% respectively).  Mexican American males and females had the lowest rates of CVD at 
31.6% and 34.4% respectively.  
The cost of cardiovascular diseases and stroke for 2007 has been estimated at $431.8 
billion.  This included direct costs such as cost of physicians and other professionals, hospital 
and other healthcare facility services, medications, home health care, etc., as well as indirect 
costs such as lost productivity resulting from illness or death [161].  Costs for CHD contribute 
the highest amount at 151.6 billion, followed by hypertensive disease, stroke, and heart failure 
[162]. 
Although rates of death from CVD have declined considerably for the majority of the 
population in the U.S. [163], mortality rates from CVD for those with diabetes have not 
decreased to the same extent [164, 165].  Macrovascular disease including myocardial infarction 
(MI), stroke and peripheral artery disease (PAD) accounts for the major cause of morbidity and 
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mortality for those with diabetes [90]. Diabetic patients with MI also have a poorer clinical 
outcome than those without as well as higher rates of re-infarction and heart failure [166].  
Research has also shown that individuals with impaired glucose metabolism prior to diagnosis 
are at risk for CVD problems as well [167, 168], particularly those with impaired glucose 
tolerance [15, 169, 170].  In addition, there has been some evidence that women with 
hyperglycemia may have higher risk for CVD than those without [171].   
Because T2D and CVD are so intertwined, it will become more and more important that 
care be directed to both.  Recently the European Society of Cardiology (ESC) and the European 
Association for the Study of Diabetes (EASD) recognizing that T2D and CVD are “two sides of 
a coin”, came together to form a task force to publish guidelines for the diagnosis and 
management of care for the vast number of individuals that have both cardiovascular and 
metabolic diseases in common [172].  Of late the American Diabetes Association has begun 
using the term “cardiometabolic risk” to identify those with risk factors for CVD [173].  
Recently the American Diabetes Association and the American Heart Association issued a joint 
statement to attempt to summarize the evidence supporting lifestyle and medical interventions 
that will prevent the development of CVD in people with diabetes [174].  The report highlighted 
their similarities and differences in prevention and treatment recommendations, but concluded in 
jointly supporting the aggressive use of lifestyle modifications to try to reduce or delay the need 
for medical intervention.  
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2.3.2 Etiology 
Individuals with T2D, as well as those with impaired glycemic function are clearly at increased 
risk for development of complications related to CVD.  There have been several suggestions 
concerning the mechanisms responsible for the early and aggressive development of 
atherosclerosis as well as the poor CVD outcomes seen in those with impaired glucose 
homeostasis including early development of an abnormal endothelial function, platelet 
hyperactivity, enhanced cellular and matrix proliferation following arterial injury, propensity for 
adverse arterial remodeling and impaired fibrinolysis with a tendency for thrombosis and 
inflammation [175].   
As described previously, components of the metabolic syndrome using various 
definitions have been strongly related to the development of CVD [168, 176-179].   Although 
there has been debate concerning the existence of a metabolic syndrome or other similarly 
described conditions [25, 180], evidence exists to support the concept of this syndrome as a valid 
predictor of risk for CVD and that the clustering of these risk factors is more than a coincidence 
[181-183].  The components of the metabolic syndrome are primarily related to development of 
CVD in those with glycemic impairment.  In a recent study, investigators examined the risk for 
CVD in the San Antonio Heart Study using National Cholesterol Education Program (NCEP)-
Adult Treatment Panel III (ATPIII), International Diabetes Federation, and World Health 
Organization definitions of the metabolic syndrome and concluded that the metabolic syndrome 
is associated with a significantly increased risk for CVD, particularly for men age aged 45 years 
of age and women 55 years. In addition, all three of the metabolic syndrome definitions 
demonstrated similar risk for CVD [184]. 
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The two major underlying components of the metabolic syndrome are related to obesity 
and insulin resistance [185].  Similarly to risk for T2D, increased BMI and weight have been 
associated with risk for CVD [186-189].  Results from the Nurses Health Study published in 
1995 found that even within the “normal” range of weight for women, higher levels of body 
weight, as well as moderate weight gain after age 18, appeared to increase risk for CHD in 
middle-aged women [190].   In a further follow-up of the Nurses Health Study, women without 
CVD at baseline were followed prospectively for 20 years; the study found that overweight and 
obesity were significantly related to increased risk of coronary heart disease (CHD) [191].  
Those with BMI > 40.0 kg had 5-fold increased risk of CHD when compared with women with 
BMI 18.5 and 22.9.  Furthermore, similar to the results found for diabetes risk, a modest weight 
gain during adulthood (4.0-10.0 kg) was associated with increased risk for CHD when compared 
to women with a stable weight after adjusting for other CVD risk factors and physical activity 
(RR=1.27; 95% CI, 1.12 to 1.45).  For those with 40.0 kg weight gain or more, risk of 
developing CHD increased considerably (RR=3.86; 95% CI, 3.02 to 4.94). CVD risk has also 
been examined in overweight and obese children and adolescents with alarming results.  Data 
from the National Heart, Lung and Blood Institute Growth and Health Study (NGHS) found that 
childhood overweight was significantly associated with increased unhealthful systolic and 
diastolic blood pressure (defined at or above the sex- and age-specific 95th percentile for systolic 
and diastolic blood pressure and also considering height), high-density lipoprotein cholesterol, 
and triglyceride levels in Caucasian and African American girls [122].  Other studies have found 
increased CVD risk in adulthood to be related to overweight in childhood or adolescence [192, 
193]. 
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Insulin resistance, defined as the inability of the body to use insulin efficiently, is 
comprised of abnormalities in glucose and insulin levels.  Insulin resistance is often found in 
conjunction with obesity; one recent article suggested that varying levels of insulin resistance 
and sensitivity may be the mechanism responsible for adverse clinical outcomes in those who are 
obese, rather than obesity in and of itself [194].  Nonetheless, it is known that insulin resistance 
plays a significant role in the development of type 2 diabetes [195].  As a core component of the 
metabolic syndrome, recognition that disturbances in glycemic control may also play a 
significant role in the development of CVD is growing [196].    Research has shown a 
progressive relationship between non-diabetic glucose levels and CVD risk [167]; this 
relationship has been shown in various populations.  The Study of Health Assessment and Risk 
in Ethnic groups (SHARE) measured glucose tolerance and risk factors for CVD in 985 
individuals of South Asian, Chinese, and European origin living in Canada for greater than 5 
years [197].  The results of this large multi-ethnic study found glucose intolerance to be strongly 
associated with other risk factors for CVD, including age, abdominal obesity, 
hypertriglyceridemia, high free fatty acids, reduced insulin secretion, and increased insulin 
resistance.  More recently, data from the Heart Outcomes Prevention Evaluation (HOPE) trial, a 
large international trial which showed that the ACE inhibitor ramipril reduced risk for CV events 
in diabetic and high-risk non-diabetic subjects, found that glycohemoglobin level was an 
independent risk factor for a broad range of outcomes, including CV events, heart failure, death 
and overt nephropathy [198]. A very similar relationship between fasting plasma glucose and 
outcomes was also noted in the group that included both diabetic and non-diabetic individuals. 
The relationship between fasting plasma glucose and cardiovascular events was maintained in 
this group after accounting for the presence or absence of diabetes. Some research has shown 
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IGT to be a better predictor of CVD and mortality than IFG [199].  Hyperinsulinemia has been 
found to be an independent predictor of CVD [200-202], however in a recent meta-analysis of 
studies of circulating levels of three insulin markers (fasting insulin, non-fasting insulin, and pro-
insulin) and their relation to CHD risk, the authors concluded that associations between CHD 
risk and fasting or non-fasting insulin levels may not be as strong as reported previously and that 
pro-insulin levels may be more strongly associated with CHD risk than are insulin levels [203].  
Insulin resistance is also positively correlated with waist circumference and subcutaneous 
adiposity [204] which are strong predictors of CVD. 
Another major component in the development of CVD is dyslipidemia.  The 
INTERHEART study, a case-control study of acute myocardial infarction with 27,098 
participants representing several major ethnic groups examined risk factors for CVD in 52 
countries and concluded that worldwide, abnormal lipid levels are one of the two most important 
modifiable risk factors for CVD, with the other being smoking [205].  Total cholesterol, low 
density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol have long 
been associated with the development of coronary heart disease (CHD) [206-209], with serum 
cholesterol showing a continuously graded effect on risk for CHD [210] as well as CVD and all-
cause mortality [211].  Furthermore, lower cholesterol levels have been associated with longevity 
and decreased risk for CVD [212, 213].  The inverse relationship between HDL levels and 
development of CHD has also been well documented [20, 214, 215].  Evidence in the past 
regarding elevated triglycerides, a specific component of the metabolic syndrome, as a predictor 
of CHD has been somewhat controversial [216, 217], however, considerable data supporting the 
measure in predicting risk for CHD does exist [218-220].  The level for triglycerides at which 
risk increases has been examined; one retrospective cohort study that evaluated 740 consecutive 
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patients subsequently diagnosed with coronary artery disease examined so-called “normal” levels 
of triglycerides and found that the mean triglyceride level was higher (160 vs. 137 mg/dl; 
p=0.03) in case patients than in control patients.  After adjusting for age, gender and beta-
adrenergic blocking agent use, multiple logistic regression analyses revealed triglycerides to be 
an independent predictor of CAD events with a relative risk of 1.5 (95% CI 1.1%-2.1%).  For 
patients with baseline triglyceride levels > to 100 mg/dl, Kaplan-Meier analyses revealed 
significantly reduced survival from CAD events compared with those with triglyceride levels 
<100 mg/dl (p=0.008).  The authors concluded that triglyceride levels which were previously 
considered to be in the “normal” range were actually predictive of new CAD events [221].  The 
NCEP guidelines for the cut-point for determination of risk related to triglycerides were 
subsequently lowered from 200 mg/dl to 150 mg/dl [20] .  
Evidence has shown that dietary fat intake, particularly saturated and trans-fat is 
associated with the development of dyslipidemia and subsequently CVD [222, 223] .  One study 
conducted in an Italian population looked at consumption of various fats such as butter, olive oil 
and vegetable oil and risk for CHD in a sample of 4,903 Italian men and women 20 to 59 years 
of age.  The authors found that after adjustment for confounding factors, consumption of olive 
oil and vegetable oil was inversely associated with serum cholesterol, glucose levels and systolic 
blood pressure in both sexes leading the authors to conclude that consumption of butter 
(saturated fat)  may detrimentally affect coronary risk factors, while polyunsaturated and 
monounsaturated fats may be associated with lower coronary risk [224].  A high intake of trans-
fat has been implicated as a key component for adverse effects upon lipid profiles [225-228] both 
increasing LDL and decreasing HDL cholesterol levels; further supporting data has been 
collected from the Nurses Health Study which has yielded abundant information about diet and 
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CVD risk. In a study published in 2005 after 20 years of follow-up, intake of trans-fat was 
related to increased risk for coronary heart disease (RR = 1.33, 95% CI: 1.07, 1.66; ptrend = 0.01), 
while intake of poly-unsaturated fat was inversely related to CHD risk [229].   
This relationship was confirmed for men in a cohort of 21,930 men aged 50-69 years who 
smoked but were free initially of diagnosed cardiovascular disease.  The study found after 6.1 
years of follow up that men in the top quintile of trans-fatty acid intake had a multivariate 
relative risk of coronary death of 1.39 (95% CI = 1.09-1.78, p for trend = 0.004) when compared 
with men in the lowest quintile of trans-fatty intake [230]. Conversely, intake of foods higher in 
fiber such as whole grains, fruits, and vegetables has been shown to provide a somewhat 
protective effect upon risk [231, 232].   Other results published regarding the study above found 
that a diet which included a greater intake of foods rich in fiber was found to greatly reduce the 
risk for CHD, particularly death [233].  Additional research has supported a high fiber diet as 
protective against the development of CHD [234-236]. 
However one large study, the Women’s Health Initiative, found that a dietary 
intervention which reduced total fat intake and increased intake of vegetables, fruits and grains 
did not significantly reduce the risk of CHD, stroke or CVD  in postmenopausal women and 
achieved only a modest effect for CVD risk factors.  The authors concluded that a more specific 
diet and interventions may be necessary to improve risk factors for, as well as reduce CVD risk 
[237]. 
In addition to dietary fat contributing to dyslipidemia, high fat intake is related to one of 
the most CVD predictive components of the metabolic syndrome, abdominal obesity.  
Abdominal obesity, particularly waist circumference, has been strongly associated with 
development of CVD in both men and women [191, 238-240] and some have found WC to be a 
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better predictor of CVD risk than BMI [241].  Results from the INTERHEART study 
demonstrated that both waist and hip measures were highly significant after adjustment for BMI 
[242].  Because abdominal adiposity is such an important risk factor for cardiometabolic risk, it 
would seem that physicians and the general public should be aware of the use of this primarily 
simple measure; however, published results from a recent survey indicate quite the opposite.  
The ‘Shape of the Nations’ survey was administered to approximately 100 physicians, 400 
members of the general population and 100 individuals at risk for CVD in 27 countries.   
Interestingly, while 58% of physicians recognized abdominal obesity as an important risk factor 
for CVD, 45% reported never having measured waist circumference and more than half 
overestimated the waist circumference that puts their patients at risk.  Only 42% of the general 
population were aware of the association between increased waist circumference and increased 
risk and more than half of the at-risk group had not been told by their PCP about the relationship 
between abdominal waist circumference and heart disease [243].                   
Like risk for diabetes, risk for CVD has been associated with lack of physical activity.  
Risk factors for CVD such as dyslipidemia, hypertension and insulin resistance have been related 
to lack of physical activity [138, 244, 245], as has the development of CVD [191].  Increased 
physical activity has been shown to reduce risk for CVD [246-248].  One study prospectively 
examined the role of walking as compared with vigorous exercise in the prevention of CHD.  
Total physical activity (walking and vigorous exercise), were examined among 72,488 female 
nurses who were age 40-65 in 1968.   Results showed a strong, graded inverse association 
between physical activity and the risk for coronary events.  Women in increasing quintile groups 
for energy expenditure had age-adjusted relative risks of 0.77, 0.65, 0.54, and 0.46 for coronary 
events (P for trend <0.001).  This relationship remained strong after adjusting for other risk 
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factors.  Walking was also found to be inversely related with the risk for coronary events, with 
those in the highest quintile group showing a greater reduction in risk when compared to those 
who walked infrequently.  Regular vigorous exercise was related with similar risk reductions of 
about 30-40%.  The study also found that women who were sedentary and became active in 
middle adulthood or later had a lower risk of coronary disease than those who remained 
sedentary [249].  Trends in physical activity are of particular concern in children and adolescents 
as the latest data from 2005 show that nationwide, only 35.8% of students had been physically 
active doing any kind of physical activity that increased their heart rate and made them breathe 
hard some of the time for a total of at least 60 minutes/day on > 5 of the 7 days preceding the 
survey; 43.8% of males and 27.8% of females met current recommendations for physical 
activity.  Furthermore almost 10% had not participated in any vigorous or moderate physical 
activity during the 7 days preceding the survey [250]. 
Increased blood pressure, another component of the metabolic syndrome, has also been 
shown repeatedly to be related to development of CVD including stroke and coronary heart 
disease in middle-aged as well as younger populations [251, 252].  For those older than 50 year 
of age, elevated systolic blood pressure is a more significant risk factor for CVD than diastolic 
[253].  Similar to cholesterol levels, blood pressure has been shown to show a continuous and 
graded relationship to risk for CVD, with each increment of 20/10 mm Hg doubling the risk of 
CVD [253].  In 2003 the Joint National Commission on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC) released its latest report (JNC 7) with a new category 
for blood pressure known as “pre-hypertension” with systolic and diastolic ranges of 120-139 
mm Hg and 80-89 mm Hg respectively [253].  The JNC7 also described the optimal range for 
blood pressure to be <120/80 mm Hg.  Research has shown that similar to pre-diabetes, blood 
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pressure in the “high-normal” or prehypertension range is associated with CVD risk [254, 255] 
and thus is an extremely important modifiable risk factor leading the authors of JNC7 to state “a 
great potential exists for improved health and increased longevity through control of the blood 
pressure problem” [253] . 
Finally, tobacco use is well-known as one of the strongest modifiable risk factors for 
CVD [256-259].  In addition, more recent studies have shown a relationship between passive or 
second hand smoke and development of CVD [260-263].  One recent investigation attempted to 
assess the risks associated with tobacco use (both smoking and smokeless), as well as second 
hand smoke, worldwide.  Using a standardized case-control study of acute myocardial infarction 
(AMI) with 27,089 participants in 52 countries (12,461 cases, 14,637 controls), the authors found 
that when compared with those who never smoked, current smoking was associated with a 
greater risk for non-fatal AMI (OR= 2.95, 95% CI 2.77-4.14, p<0.0001) [264].  Chewing tobacco 
was also associated with elevated risk, and risk was highest for those who smoked and used 
chewing tobacco (OR=4.09, 2.98-5.61).  Second hand smoke was associated with a graded 
increase in risk.  In 1960, over 40% of the U.S. population smoked [265]; the prevalence rates 
for adults age 18 and older have declined steadily since 1966 to about 21%  [266].  While 
smoking rates for adults have decreased, for high school students in grades 9-12 in 2005, the 
prevalence for current smoking was 23%, with white females showing the highest prevalence 
(27%) and black females showing the lowest (11.9%) [250].  Thus, tobacco use remains an issue 
of considerable concern demonstrating the importance of continuing efforts to reducing tobacco 
consumption, both actively and passively in all populations.   
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2.4 PREVENTION IN PRIMARY CARE 
2.4.1 Current Recommendations for Screening 
2.4.1.1 Diabetes 
 
At the present time, the American Diabetes Association (ADA) recommends screening to 
detect pre-diabetes and diabetes for individuals who are 45 years of age and older, particularly in 
those with a BMI ≥ 25 kg/m2 [87].  The ADA also recommends that screening should be 
considered for people who are less than 45 years old and who are overweight if they have 
another risk factor for diabetes.  Risk factors include: habitual physical inactivity, having a first 
degree relative with diabetes, being a member of a high risk ethnic group, having hypertension, 
low HDL or high triglyceride level, previous diagnosis with IFG or IGT, or having other clinical 
conditions associated with diabetes.  Additional risk factors for women include delivery of a 
baby weighing more than 9 pounds, diagnosis with gestational diabetes or diagnosis with poly-
cystic ovary syndrome.  Repeat testing should be completed at 3-year intervals.   
For several reasons the ADA recommends that screening should be carried out within the 
health care setting, using either the fasting glucose test or the two-hour OGTT.  The ADA 
considers that community screening outside of the health care setting may be less effective due 
to the failure of people with a positive screening test obtaining appropriate follow-up testing and 
care.  There is also the concern that those who screen negative may not receive appropriate 
repeat testing in the future.  The ADA also states that community screening may fail to reach the 
groups most at risk and inappropriately test those at low risk. 
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Like the ADA, the International Diabetes Federation (IDF) does not recommend 
universal screening for those without symptoms, but recommends screening within a health care 
setting for those determined to have risk factors; for those who screen negative, a repeat 
assessment should be conducted within 3-5 years [267].  The IDF also recommends the fasting 
plasma glucose test for screening and cites the low sensitivity but high specificity of using urine 
glucose for screening, thus indicating that this may be appropriate in very low resource settings 
where other methods of testing are not available. 
The European Association for the Study of Diabetes (EASD) takes a slightly different 
approach in that it recommends the use of a non-invasive risk score subsequently combined with 
an OGTT for screening and diagnosis rather than just the fasting plasma glucose alone [268].  
This is due to concern regarding the possibility of false negatives occurring with the use of the 
fasting plasma glucose test only.  The EASD acknowledges that the OGTT may not be as 
feasible or practical at a population level, however maintains that it is essential since this is the 
only way to diagnose IGT which is more strongly associated with the development of CVD. 
The United States Preventive Services Task Force (USPSTF) does not recommend for or 
against routinely screening asymptomatic adults for type 2 diabetes, impaired glucose tolerance, 
or impaired fasting glucose, however, it does recommend screening for type 2 diabetes for those 
individuals with hypertension or hyperlipidemia [269].  
2.4.1.2 Hypertension 
The Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC-7) was published in 2003 by the 
National Institutes of Health National Heart, Lung and Blood Institute [253].  Although 
screening interval was not mentioned specifically in that report, the Sixth Report (JNC-6) 
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recommended all adults 18 and older should have a blood pressure assessment: those with blood 
pressure <130/85 should be checked at least every two years and those with readings at 130/85 
and higher should be checked more frequently [270].  Diagnosis should be based on the average 
of two readings measured on two different occasions.  The JNC-7 report classifies normal blood 
pressure as being < 120 and < 80 mm/Hg and introduces the concept of “pre-hypertension” 
considered to be in the range of 120-139 mm/Hg for systolic blood pressure and 80-89 mm/Hg 
for diastolic.  JNC-7 further divides blood pressure into two stages: Stage 1 Hypertension (140-
159 mm/Hg systolic or 90-99mm/Hg diastolic) and Stage 2 Hypertension (≥ 160 mm/Hg or ≥ 
100mm/Hg).  
Health-promoting lifestyle measures are the recommended first line of intervention for 
those diagnosed with pre-hypertension and are subsequently integrated with pharmaceutical 
therapy throughout the spectrum.  Thiazide diuretics are recommended as the first line treatment 
for those with uncomplicated hypertension and no other compelling indication.  JNC-7 also 
indicates that most individuals with hypertension will require two or more antihypertensive 
agents to reach a goal of < 140/90 mm/Hg and < 130/80mm/Hg for those with diabetes or 
chronic kidney disease.  This report also presents the methodology for measurement of blood 
pressure at each physical examination and stresses the importance of controlling systolic 
hypertension in those over age 50.   
The USPSTF recommends that physicians screen adults age 18 and older for high blood 
pressure, but currently finds insufficient evidence to recommend or not recommend screening for 
children and adolescents [271].  Like JNC-7 they recommend that diagnosis be made only after 
completion of two readings on two separate visits.   
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The American Heart Association/American Stroke Association recommends regular 
screening for hypertension at least every two years in most adults and more frequently in 
minority populations and the elderly [272].  The AHA/ASA guidelines further follow those of 
JNC-7. 
The European Society of Hypertension/European Society of Cardiology also have 
published guidelines concerning hypertension [273].  The guidelines are somewhat similar to the 
JNC-7 guidelines; however differ on a few key points which are highlighted in an article by 
Mancia and Grassi published in 2005 [274].  The authors cite general differences including the 
main focus of the two sets of guidelines, which they feel to be mainly prescriptive in JNC-7 
while the ESH/ESC guidelines appear to be more informative and educational.  Another 
difference in the guidelines is the complexity: while the JNC-7 guidelines appear fairly straight 
forward, the ESH/ESC guidelines are more detailed and somewhat more complicated.  Other 
differences include those in the classification of blood pressure, with the ESH/ESC guidelines 
suggesting like the JNC-7 that optimal range should be <120mmHg and <80mm/Hg.  The 
ESH/ESC guidelines however do not have a pre-hypertension category, rather include the range 
of 120-129 mm/Hg and 80-84 mm/Hg as “normal” and 130-139 mm/Hg and 85-89 mm/Hg as 
“high normal”.  Hypertension is further categorized as Grade 1 Mild (140-159 mm/Hg or 90-99 
mm/Hg), Grade 2 Moderate (160-179 mmHg or 100-109 mm/Hg) and Grade 3 Severe (≥ 180 
mmHg or ≥ 110 mm/Hg).   ESH/ESC guidelines stress the importance of establishing potential 
target organ damage in the determination of overall cardiovascular risk and subsequent 
treatment.  Like JNC-7, target blood pressure goals are the same for non-diabetics as well as for 
those with diabetes and ESH/ESC recommends healthy lifestyle behaviors as the first 
intervention and that it be subsequently interwoven into pharmaceutical treatment.   Mono-
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therapy is recommended with subsequent addition of medication as necessary; however, no 
specific drug per se is recommended. 
2.4.1.3 Hyperlipidemia 
The National Cholesterol Education Program (NCEP) published it’s most recent 
recommendations and guidelines, Adult Treatment Panel III (ATPIII) in 2001 [20], with updates 
in 2004 [275].  The NCEP recommends that everyone age 20 and older should have a cholesterol 
screening completed at least every 5 years, with testing more often as required.  Further, the 
NCEP recommends that testing should include a complete fasting lipid profile (total cholesterol 
(TC), low density lipoprotein cholesterol  (LDLC), high density lipoprotein cholesterol (HDLC) 
and triglyceride level) completed after a 9-12 hour fast, however, if not possible, then only TC 
and HDLC cholesterol should be collected.  If the TC is ≥ 200 mg/dl or the HDLC is < 40mg/dl 
then a fasting lipid profile should be collected.  Treatment is based on the LDL cholesterol level 
with < 100mg/dl considered to be optimal.  The updates in 2004 were related to treatment levels 
in which those at greatest risk, i.e. individuals with diabetes or existing cardiovascular disease, 
should have a goal of < 70 mg/dl for LDL treatment.  Treatment of elevated triglycerides and 
low HDL are secondary goals after reaching the desired LDL treatment level. 
The USPSTF recommends routine screening for men aged 35 years and older and women 
aged 45 and older for lipid disorders [276].  Routine screening is recommended for men aged 20-
35 and women aged 20-45 if they have other risk factors for coronary heart disease.  These risk 
factors include having diabetes, an immediate family history of CVD in men < 50 years old and 
women < 60 years old, a family history that is suggestive of familial hyperlipidemia, or multiple 
coronary heart disease risk factors e.g. tobacco use, hypertension, etc.  The USPSTF states that 
the optimal interval for screening is uncertain, but based on expert opinions mandates every 5 
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years with shorter intervals for those who have lipid levels close to those warranting therapy.  
The USPSTF does not recommend an age to stop screening, but recognizes that repeated 
screening in those who have been screened previously and are older than 65 may not be 
necessary.   Screening should at least include measuring TC and HDLC; the USPSTF does not 
find evidence to recommend or not recommend routine testing including triglycerides. The 
USPSTF recommends that counseling concerning the benefits of a diet low in saturated fat and 
high in fruits and vegetables, regular physical activity, avoiding tobacco use and maintaining a 
health weight should be provided to all individuals regardless of their lipid levels. 
2.4.2 Current Prevention Practices 
While the Healthy People 2010 report emphasizes the importance of improvement in prevention 
[277], the provision of preventive services continues to be suboptimal.  Because primary care 
physicians’ (PCPs’) delivery of patient care is more broad-based than other specialties, they are a 
logical choice for provision of preventive services to patients at risk, however effective 
prevention programs are lacking.  Results from a  national survey of U.S. PCPs were published 
in 1999; the purpose of the data collection was to overcome the shortage of information about 
prevention practices, as well as to ascertain the relationship between physician demographics and 
the delivery of preventive care [278].  The Primary Care Providers Survey was created by the 
Office of Disease Prevention and Health Promotion and 5 primary care professional associations 
representing family practitioners, pediatricians, internists, OB-GYNs and nurse practitioners.  Of 
the total initial sample of 9,079 physicians, 5400 responded, with 3,881 meeting the study 
criterion of spending at least 50% of their time in primary care.  The survey requested 
information regarding how often PCPs provided preventive services to their patients, which 
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included most preventive services that should be given in an office visit such as review of 
tobacco use, nutrition, exercise and alcohol and drug abuse.  The survey also addressed CVD and 
cancer screening tests, seat belt use, family planning and immunization practices.  Adequate 
provision of services was defined as being delivered >80% of the time.  The survey revealed that 
most PCPs across all disciplines and demographics were not providing adequate preventive 
services to the patients they serve, with services relevant to this review such as addressing 
exercise and nutrition found to occur less than 20% and approximately 27% of the time 
respectively.  Only 37.2% of the responding physicians reported acting more than 80% of the 
time to providing assistance to help their smoking patients stop, while approximately 60% 
performed a cholesterol test.  Blood pressure was the most frequently performed test, with 
responding physicians indicating that this measure was completed adequately over 87% of the 
time.  Women physicians demonstrated higher rates of provision of prevention services, as did 
those physicians < age 50, while a progressive decrease was seen in the provision of adequate 
preventive services corresponding to the change from large metropolitan areas to more rural 
areas. 
Unfortunately, the results of this survey are not unique; there is considerable evidence 
confirming the lack of provision of preventive services in primary care practice.  Data from 
2001–2004 National Ambulatory Medical Care Survey, an annual survey of outpatient visits, 
showed that overall, 32% of patient charts did not include information about tobacco use, 81% of 
smokers did not receive any assistance with stopping and less than 2% were given a prescription 
for pharmacotherapy [279].  Another study examined basic preventive care services in elderly 
patients using the Community Tracking Study Physician Survey which was linked to claims data 
on Medicare beneficiaries they had treated.  Six preventive services were examined:  diabetic 
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monitoring with hemoglobin A1C measurement or eye examinations, screening for colon or 
breast cancer, and vaccination for influenza or pneumococcus.   This study found that overall, the 
proportion of beneficiaries receiving preventive services was below national standards, leading 
the authors to conclude that delivery of routine preventive services for Medicare beneficiaries is 
suboptimal  [280].   Other research has confirmed the lack of preventive services available 
including one study where research nurses directly observed consecutive patient visits in the 
offices of 138 family physicians to determine rates of provision of preventive service.  Medical 
record review was conducted to determine patient eligibility for services recommended by the 
U.S. Preventive Services Task Force.  The investigators found rates of delivery of prevention 
services to be low, determining that patients were up to date on only 55% of screening 
preventive services, 24% of immunizations, and only 9% of health habit counseling services 
[281].   
Patient surveys have also been conducted to determine perception of preventive services 
being rendered.  One such survey sent to 7,997 randomly selected patients from 44 primary care 
practices (6,830 respondents) found that on average, about two-thirds of the patients in each 
practice reported that they were up-to-date on preventive services before their clinic visit, 
however less than 30% of those not up-to-date were offered service if the clinic visit was for a 
reason other than a checkup or physical examination, with the exception of blood pressure and 
smoking cessation advice.  For those patients who were scheduled to see their physician for a 
checkup or physical examination, the only prevention service provided more than 50% of the 
time was Papanicolaou smear [282].   
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2.4.3 Barriers to Prevention 
It is important to recognize the barriers to provision of prevention services.  It has been 
suggested that physicians may not appreciate the value of providing preventive services [278] or 
that they may have ambivalence regarding their ability to promote adherence and behavior 
change [283]. PCPs also believe that prevention is important but consider the lack of 
reimbursement by insurance to be a barrier to provision of services [284].  Competing demands 
for the PCP during a patient encounter such as acute care, patient requests, chronic illnesses, 
psychosocial problems, screening for asymptomatic disease, counseling for behavior change, 
other preventive services, and administration and management of care have all been suggested as 
major barriers to the provision of specific preventive services to patients [285].  Encouragingly, 
one survey found that 9 out of 10 primary care physicians felt that it was "definitely" their 
responsibility to educate patients about health-related risk factors and the majority also felt 
prepared to provide advice about smoking, alcohol use and exercise, however less than half felt 
prepared to provide advice on diet, illicit-drug use, depression, or stress [286].  Another barrier 
to preventive care is related to the provision of services at a “sick” visit versus a visit that has 
been scheduled specifically for a check-up or physical examination; research has shown that 
physicians provide more preventive services during a regularly scheduled visit [287].  One direct 
observational study found that preventive services were delivered in 32% of 3,547 illness visits 
[288].  The authors suggested that perhaps the “sick” visit should be viewed as an opportunity to 
provide preventive services, however information delivered during this possibly stressful time 
may not be well-received.   
Time constraints may also present a barrier to prevention; one study examined the factors 
associated with physician patient volume and looked for differences in selected clinical outcomes 
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and time use during patient visits in the offices of 108 community family physicians.  The rate of 
preventive services delivery, patient satisfaction, and time used during patient visits was 
compared between high, medium and low patient volume practices.   The study found that 
physicians in high volume practices had visits that were 30% shorter and scheduled one-third 
fewer patients for well care.  The study also found that patients in high volume practices had 
lower up-to-date rates of prevention services and also scored lower on patient satisfaction 
measures.  The authors concluded that although the high volume practices were more efficient in 
time management, this came at the cost of decreased preventive services and lower patient 
satisfaction [289].  Other barriers to prevention implementation include lack of awareness or 
familiarity with guidelines and disagreement with guidelines [290] or lack of trust in the 
guideline source [291].  Finally, one of the most important barriers to sub-optimal provision of 
prevention is the lack of organized and effective systems for delivery of prevention services 
[292, 293]. 
2.4.4 Primary Care Prevention Strategies 
It is obvious that much attention has been paid to prevention and the delivery of prevention 
services, however, even basic prevention services continue to be provided on a less than optimal 
level.  Well-organized office systems are necessary for efficient and effective delivery of 
prevention services.  A survey study was completed to examine the presence and 
comprehensiveness of organized processes and systems in a sample of primary care clinics 
which had been shown previously to have a wide variation in rates of providing preventive 
services [294].  The survey examined the following 10 components: 1) sex-specific guidelines 
which included minimum age and frequency for specific preventive services to be provided, 2) a 
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routine screening system for staff to identify which, if any, preventive services are required, 3)  a 
status summary of preventive services on a patient’s chart, 4) reminders to bring routine 
prevention services to the attention of the PCP during a normal visit, 5) resources for patient 
education, 6) patient follow-up for patient to obtain test results, 7) outreach to include patient 
relatives to assist in obtaining the preventive service for an identified risk factor, 8) counseling 
for patients provided by a clinic employee other than the PCP, 9) the scheduling of prevention 
visits and 10) methods to help patients recognize the need for preventive services and to take 
action to obtain them.  The survey responses documented how infrequently the participating 
clinics had functioning, organized processes.  The three processes that would have most potential 
to enhance the likelihood of identification of those at risk and providing appropriate counsel 
(screening systems, status summaries and reminders) were reported to be present in only about 
one-fourth of the practices.  Variation across clinics was seen as well.   
The implementation of an organized system need not always be complex; one recent 
study examined a simple tool, a single checklist reminder form, and the delivery of preventive 
health services at adult health check-up visits in a family practice setting. The investigators 
performed a prospective cluster randomized controlled trial at four urban family practice clinics 
among 38 primary care physicians affiliated with the University of Toronto. The checklist 
reminder forms (Preventive Care Checklist Forms©) were created to be used by family 
physicians at adult health check-ups.  The forms incorporated sex-specific guidelines for 
preventive health services as well as a space for documentation of routine procedures such as 
physical examinations.  The study found that the percentage of up-to-date preventive health 
services delivered per patient at the end of the intervention was 48.9% in the control group and 
71.7% in the intervention group, which represented an overall 22.8% absolute increase (p = 
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0.0001) [295].  The authors concluded that the addition of a simple reminder and documentation 
checklist could be beneficial in improving delivery of prevention services in other practices. 
Another attempt at improving provision of preventive services through facilitation 
intervention specific to individual practices to increase rates of delivery of a broad range of 
evidence-based preventive services was evaluated.  A nurse facilitator met with the participating 
practices and helped them identify both successes and missed opportunities created by the 
practice’s current approach to prevention.  The nurse facilitator helped practices choose from a 
menu of tools and approaches to help enhance preventive service delivery, as well as to create a 
plan for change and identify a practice leader for the intervention.  The study found a significant 
increase in global preventive service delivery rates at the 1-year follow-up in the intervention 
group (31% to 42%) compared to the control group (35% to 37%).   An increase in rates 
specifically for health habit counseling (p=0.007) and screening services (p=0.048) was seen, but 
not for immunizations [296].  The authors concluded that a prevention approach which is 
designed to meet particular practice needs may increase the delivery of global prevention.   
In conjunction with provision of preventive services is the action required to achieve risk 
reduction, in other words a “prescription” for prevention, i.e. provision of preventive intervention 
for risk reduction.  Again, primary care practices are well positioned to provide this care for their 
patients, however while advice regarding prevention and risk reduction may be provided, 
assistance and follow-up may be lacking.  In a cross-sectional direct observation study of 300 
family medicine outpatient visits, the content of each discussion of exercise, diet, and weight loss 
was documented by an observer.  The investigators found that in 56% of observed visits 
discussion of exercise, diet, or weight loss occurred, however, advice rarely included the offer of 
assistance or any type of plan for follow-up.  The authors concluded that while physicians 
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provide exercise, diet, and weight loss advice to obese patients and those with chronic 
conditions, the content of the advice rarely included specific components that could increase 
healthy behavior change [295].   
Although there are not many examples of intervention provision in primary care practice, 
some research has been done.  One study assessed the provision of counseling for overweight 
and obese patients in a primary care practice setting and found that those who received 
counseling from the PCP had significantly higher weight loss and more favorable behavior to 
control weight than those who received no counseling [297].  While it may be effective for PCPs 
to provide counseling, due to some of the barriers mentioned above, particularly time constraints, 
additional strategies for intervention should be employed.  In a study examining nutritional 
counseling in primary health care for patients at high risk of ischemic heart disease, two 
strategies of nutritional counseling were evaluated [298].  Sixty general practitioners (GPs) were 
cluster randomized to either provide nutrition education themselves, or to refer to a dietician.  
The study found that while weight loss was larger in the dietician group, increase of HDL-
cholesterol was larger in the GP group and the reduction of the cardiovascular risk score was 
significantly larger in the GP group (p<0.001).  The authors concluded that while the nutritional 
education provided by the GP was significantly important in reducing risk, a long-term lifestyle 
intervention delivered by even these highly motivated GPs was difficult to implement in a 
practice setting.  Another randomized study examined a year long lifestyle intervention for 
reduction of CVD risk in Sweden for efficacy and feasibility.  A physiotherapist, a dietician, a 
physician were responsible for the intervention; other members of the team were additional 
physiotherapists, a laboratory nurse and two assistants.  The intervention consisted of supervised 
physical activity, counseling for diet and follow-up meetings.  The authors found that the 
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intervention significantly reduced some parameters of risk for CVD and was feasible to provide 
in a primary health care setting using existing staff members [299].   
2.4.5 Summary of Prevention in Primary Care Practice 
The USPSTF was reconvened in 1998 by the Agency for Healthcare Research and Quality 
(AHRQ) to update the guidelines for preventive services.  At that time the importance of 
prevention of chronic diseases such as diabetes and CVD was emphasized.  Since then, despite 
an abundance of published research documenting the efficacy and cost-effectiveness of diabetes 
prevention and CVD risk reduction, progress regarding these issues has been limited.  For many 
reasons, the primary care practice setting provides a unique opportunity for prevention.  Data 
from the U.S. Center for National Statistics published in 1998 showed that on average, patients 
of all ages attended a physician visit 2.8 times per year; for those over age 25, visit rates varied 
between 2.2 and 6.3 times per year [300]; thus patient visits occur frequently in this setting, and 
individuals may often interact with the same healthcare staff.   In general,  patients expect to 
receive advice and guidance from their health care providers [301] and as mentioned above, 
health care providers also perceive this to be a part of their role [286].  The primary care practice 
setting is an integral component of the entire medical system and thus could become the basis for 
prevention screening as well as provision of behavioral change interventions for risk reduction in 
the U.S.   
While it is apparent that there are obviously many barriers to providing prevention 
services in a primary care practice setting, as discussed earlier, research has suggested that it is 
feasible.  The challenge thus becomes to determine the most effective and efficient methods for 
identifying those at risk and delivering preventive interventions in the primary care practice 
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setting.  It is also important to begin to understand certain factors, e.g. a patient’s perception for 
disease risk that may influence potential for patient success in such prevention intervention 
programs.  The utilization of combined, organized systematic approaches, which include 
available staff members as well as the PCP, may be an effective method for delivery of 
preventive risk identification screening services as well as prevention intervention for diabetes 
and CVD risk reduction. 
2.5 CONCLUSION 
While the literature supports the rationale for diabetes prevention from both a scientific and cost-
effective perspective, implementation of diabetes prevention in a ‘real-world’ setting is 
challenging and certainly many barriers exist.  Translational research to examine these issues, as 
well as the effectiveness and feasibility of “real-world” diabetes prevention is lacking.  For many 
reasons the primary care practice venue provides an ideal environment for prevention 
management on a permanent basis.  This project will address these prevention translation issues 
through 1) assessment of a screening program for identification of those at risk, 2) evaluation of 
a modified DPP lifestyle intervention delivered in a primary care practice setting for individuals 
identified to be at risk and 3) evaluation of a potential motivator for lifestyle change, risk 
perception and performance in a lifestyle change program.  Due to the lack of translational 
research related to diabetes prevention and CVD risk reduction, it is anticipated that this project 
will make a significant contribution to the existing literature. 
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3.0  METHODS 
3.1 BRIEF OVERVIEW OF THE STEP UP PROJECT 
STEP UP was a one-group, prospective study which examined a structured screening program 
for identification of those at risk for T2D and CVD and also evaluated the delivery of a modified 
DPP lifestyle intervention in four primary care practices in Western Pennsylvania.  Patients who 
were registered with the four practices and who were between the ages of 25-74 were invited for 
prevention screening using a computer driven recruitment and screening program.  Individuals 
without previously reported diagnosis of diabetes, with BMI > 25kg/m2 and at least three of the 
five components of the metabolic syndrome (based on National Cholesterol Education Program 
Adult Treatment Panel III) [20] were eligible for the Group Lifestyle Balance (GLB) program, 
an adaptation of the individual lifestyle intervention utilized in the DPP.   A total of 2,786 
prevention screening letters were sent with 350 individuals attending screening and 97 
determined to be eligible for the intervention; subsequently 51 subjects were enrolled in the 
intervention component of the project.  Outcome measures included the collection of blood for 
the pre and post lipid profile and glucose (at least 2 hour fast requested), resting blood pressure, 
waist circumference and BMI; global risk was also assessed pre and post intervention.  In 
addition, two surveys were administered before and after the intervention: the mRPS-DD and the 
CDC’s 14-Item Health Related Quality of Life [68].  A third component of the project was the 
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completion of a chart review of those subjects in the targeted screening group as well as another 
group who were not targeted for comparison to determine whether identification of risk states 
had improved as a result of the screening. 
3.2 PROJECT DEVELOPMENT 
3.2.1 Primary Care Practice and Preventionist Selection 
Four primary care practices, two urban and two rural, were identified in the Western 
Pennsylvania area.   The practices were approached initially about participation and agreed to 
implement the screening and lifestyle intervention in their practices.  Meetings were held with 
the medical directors of each practice as well as other available physicians and staff members to 
review the plan for translation and to elicit their input into how the study protocol would best 
work in their setting.   
Each practice was asked to identify a “preventionist” to oversee the prevention screening 
program, including screening, recruitment and delivery of a lifestyle change intervention 
program.  The preventionists were required to have a healthcare background; four were nurses 
and two were health educators (in one practice the position was split and in one practice the 
preventionist was replaced when she left the position).  In two practices, the preventionists were 
identified from within the practice; in the other two practices the preventionists were brought in 
specifically for the position.  The preventionists completed clinical measurement certification 
through the project STEP UP Coordinating Center for the measures that were collected including 
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blood pressure, height, weight, and waist circumference, as well as training regarding prevention 
screening and use of the computer driven program.   
3.2.2 Group Lifestyle Balance Program 
The original DPP Individual Intensive Lifestyle Intervention was developed at the University of 
Pittsburgh by the DPP Lifestyle Resource Core; the details of the intervention have been 
documented previously [302].   Members of the original DPP lifestyle team collaborated to adapt 
the individual intervention to a group-based program and to condense the program from 16 
individual sessions delivered over 24 weeks to 12 group sessions delivered over 12-14 weeks.  
Other modifications included concentrating on healthy food choices rather than specifically the 
food pyramid, a focus on calorie as well as fat intake from the beginning of the intervention and 
more emphasis on the pedometer.  As in the original DPP lifestyle program, the goals of the 
GLB intervention were to achieve and maintain a 7% weight loss, and to safely and 
progressively increase physical activity to 150 minutes per week of moderately intense physical 
activity similar to a brisk walk. 
The GLB curriculum was administered by the trained preventionist(s) in each practice at 
the primary care practice locations.  Initially, training guidelines for delivery of the GLB 
program were developed and a training workshop was held for the preventionists involved in this 
project, as well as approximately 40 other healthcare professionals from the local area. Each 
participant received a copy of the GLB participant handouts, Fat and Calorie Counter, self-
monitoring books for keeping track of food and physical activity, a pedometer with instructions, 
a set of measuring cups and spoons, and a chart for self-monitoring weekly weights over the 
course of the program.  Participants who did not own a scale were given one.  All subjects were 
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asked to self-monitor weight, food intake and physical activity and were given feedback 
concerning progress.   
3.2.3 Screening Guidelines 
Because the guidelines for prevention screening often come from different sources and can be 
confusing and disjointed at times, a concise, “user-friendly” document summarizing current 
prevention screening guidelines for diabetes and cardiovascular disease was compiled based on 
the recommendations for prevention screening regarding diabetes, hypertension, dyslipidemia, 
and obesity [20, 253, 275, 303, 304].  The goal was to organize the current guidelines for ease of 
use, including recommended tests and time schedules to eliminate these barriers in providing 
prevention services in primary care practices. 
3.2.4 Computer Driven Screening Program and Database Development 
The members of this project contracted with Flipside Media, Inc. to work with them to create a 
questionnaire and data collection system to be used in the identified primary care practices.  
Laptops running the custom software application were used to track, screen and report on 
targeted patients within the practices.  Additionally this system included a study recruitment tool 
that integrated with the office's existing patient database.   The program allowed the 
preventionist to send invitation letters to eligible patients and then track their progress through 
the program.  The system was designed to assess and evaluate all of the data collected at the 
screening, as well as to create a patient-specific report.  The data were stored locally on the 
laptops and once a week were synchronized with a central server.  This sync process transferred 
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the collected data to the central database, generated and emailed status reports to the researchers, 
and updated the software on the laptop to any newer versions. 
The system is based on Flipside's ScoreMD screening and data collection platform. 
Embracing open source tools due to their standardization and interoperability, the ScoreMD is 
built upon a Unix-based operating system, Apache web server, MySQL database, the PHP 
scripting language, PDF-based reporting, secure web services for data transfer, and is usable 
through standard web browsers (like Internet Explorer, Firefox/Mozilla, Safari, and Opera). 
Initially, each practice was assisted in preparing a data set that included all practice 
patients age 25-74 in 2005 that had been seen by a practice physician within the past three years.     
In planning for this project and from discussions with the practices, it was assumed by all 
involved that existing patient data sets could be utilized for this project.  However, while two of 
the practices had an existing database that was converted relatively easily to the platform 
required by the computer program, the others needed more extensive assistance.  The two that 
had existing databases were actually part of a patient billing system already in place that 
included all of the information required for recruitment for the screening.  In the other two 
practices, the outside company that handled billing had to be contracted to provide the patient 
data in a usable format.   Even with the data supplied, in one practice there were still several 
patients that had to be entered by hand.  The entire dataset development was very time 
consuming and created an unforeseen delay in beginning the project.  Once all of the datasets 
were in place, all patients were assigned a random 8-digit ID number with the link to the 
patient’s identifying information kept in a secure location on site.   
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3.3 ELIGIBILITY AND RECRUITMENT 
3.3.1 Screening 
Within each practice, one quarter of the year (a consecutive 13-week period of time) was 
identified; all patients age 25-74 who were registered as patients at the participating primary care 
practices and had birthdates within the 13-week window were eligible for a prevention screening 
invitation.  Using the computer program, invitations were sent near the time of the patient’s 
birthday.  The invitations, which encouraged the recipient to call the preventionist to set up an 
appointment were generated automatically by the program and sent out weekly by the 
preventionists.  A subsequent follow-up telephone call was made if no response was received 
within one month.  Preventionists were asked to make three such attempts at reaching the patient, 
calling at different times and days of the week, including weekends and evenings.  De-identified 
information concerning invitation mailing and subsequent contact was tracked by the 
Coordinating Center, with appropriate reminders for follow up contact sent to the preventionists 
as necessary.   
This prevention screening and chart review project received approval by the University of 
Pittsburgh Medical Center Quality Assurance Council.   
3.3.2 Group Lifestyle Balance Intervention 
All participants in the GLB program were patients of the participating practices who had 
attended screening or had been referred by one of the participating physicians.  Inclusion criteria 
consisted of males and females without previously reported diagnosis of diabetes, age 25-74 
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years in 2005 with BMI > 25kg/m2 and at least three of five components of the metabolic 
syndrome (based on National Cholesterol Education Program Adult Treatment Panel III) [20] 
identified at screening.  At the time of study, the NCEP had not yet changed its glucose criterion, 
although the American Diabetes Association had lowered its criterion for pre-diabetes from a 
fasting glucose of 110 mg/dl to 100 mg/dl [305].  Therefore patients who met the above criteria 
with only 2 components of the metabolic syndrome with a fasting glucose between 100 mg/dl 
and 109 mg/dl were also included at their primary care physician’s discretion.  Exclusion criteria 
included previously reported diabetes, pregnancy, lack of physician approval and inability to sign 
informed consent.  Participants meeting eligibility criteria were invited to take part in the 
intervention program. A total of 51 individuals enrolled in the intervention component of the 
study; 43 were enrolled from the screening and 8 were enrolled via direct physician referral.  
This research project was approved by the University of Pittsburgh Institutional Review Board 
and the University of Pittsburgh Medical Center Quality Assurance Council, as well as the 
Surgeon General’s Office of Review.  Eligible and interested patients signed informed consent 
prior to beginning the study. 
3.4 OUTCOME MEASURES 
3.4.1 Screening 
Patients attended a brief 30 minute screening visit which was conducted at the primary care 
practice, completing a short interview that included questions about medical, social and family 
history.  The preventionist reviewed the chart for pre-existing blood glucose and lipid profiles 
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and other clinical measures, i.e., blood pressure, height, weight, and waist circumference.  This 
information was subsequently entered into the computer program which determined if and when 
screening measures were necessary according to the guidelines.  After completion of the required 
testing the program determined the prevention follow up schedule and provided a written 
summary for the patient, preventionist and physician.   All measures were completed by the 
certified preventionists from the practices. 
3.4.2 Group Lifestyle Balance Intervention 
Enrolled participants were asked to attend an assessment to obtain clinical measures prior to 
beginning and again at the conclusion of the intervention.  All clinical measures were obtained 
by a certified preventionist and/or certified STEP UP Center staff member.  Blood pressure was 
measured in a sitting position in the right arm after resting for five minutes.  First appearance and 
last heard (phase V) Korotkoff's sounds were used to define the pressure readings; the measures 
were repeated three times with a thirty second wait between each reading [306].  An average of 
the 2nd and 3rd readings was computed.  Height and weight were measured twice without shoes 
with the average computed; BMI was calculated as average weight divided by average height 
squared (kg/m2).  Waist circumference was measured at the midpoint between the lower rib 
margin and the iliac crest; the measurement was repeated twice and the average computed.    
Total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol and 
glucose were measured after at least a two-hour fast using the Cholestech LDX System by a 
certified laboratory assistant.   Global CVD risk assessment [307] was estimated and medication 
use was assessed via participant interview.  In addition, weight was recorded weekly at each 
session. 
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Two surveys were collected at the pre and post intervention assessment visits; the mRPS-
DD and CDC’s 14-Item Health Related Quality of Life survey.  The mRPS-DD responses were 
evaluated for the third part of this project and the survey is discussed further below. 
3.4.3 Modified Risk Perception Survey for Developing Diabetes  
The Risk Perception Survey for Developing Diabetes (RPS-DD) developed by Walker, et al.,  is 
designed for assessment of multiple dimensions of perceived risk for developing diabetes [308].  
During the initial survey development, all items of the survey were reviewed for content and face 
validity by a panel of clinical diabetes experts, risk perception experts, and health psychologists. 
A pilot study was conducted with 74 nondiabetic, overweight, middle-aged individuals [309], 
after which the survey was revised slightly to enhance validity, reliability and ease of use.  The 
original RPS-DD included 53 items and four subscales as well as other individual items to assess 
various aspects of risk perception.  Internal consistency reliability for the four subscales was 
assessed using Cronbach α coefficients, both in a physician population as well as in an ancillary 
study population in the DPP [310, 311].   
The survey was modified by the authors for this study; specifically it was shortened to 
include only the 32 items pertaining to the subscales, as well as the 3 items regarding lifestyle 
behavior.  In addition, 5 questions pertaining to risk for diabetes development in relation to 
lifestyle changes were added, for a total of 40 items.  The self-administered mRPS-DD was 
completed by enrolled participants at the baseline and post-intervention assessments.  The 
Personal Control subscale (4 items [alpha] = 0.67, physician population, 0.68, DPP population) 
reflects perceived control over developing diabetes with a higher score indicating greater 
perceived control.  The Comparative Disease Risk subscale assesses perceived risk for 
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development of 15 diseases and conditions on a scale ranging from 1 (“almost no risk”) to 4 
(“high risk”) with a higher score indicating a greater perceived risk ([alpha] = 0.86 physician 
population, 0.83 DPP population).  The Comparative Environmental Risk subscale uses the same 
scale and measures 9 perceived environmental risks, such as driving accidents, air pollution and 
extreme weather ([alpha] = 0.83 physician population, 0.81 DPP population).   Finally, the 
Optimistic Bias subscale (2 items [alpha] = 0.64 physician population, 0.71 DPP population) 
reflects an individual’s perception for risk for developing diabetes as compared to others of the 
same gender and age, with a lower score indicating less perceived risk and more optimistic bias.  
The survey also includes 2 items which assess worry about developing diabetes (Worry Sum) 
and a Composite Risk Score which includes all 32 items; a higher score indicates higher overall 
perceived risk.    
3.5 CHART REVIEW 
In addition to the collection of patient screening data, a chart review was conducted to examine 
the efficacy of the prevention screening.  The computer driven chart review program was 
developed with Flipside Media and incorporated all aspects of the screening measures.  Similar 
to the prevention screening program, the chart review program was designed to automatically 
perform calculations such as BMI and determination of diabetes and CVD risk based on the 
information entered, as well as appropriate follow up for identified risk states.  Development of 
the chart review program took several months, with ongoing internal testing of individual 
questions and calculations conducted throughout the process.  The completed chart review 
system was subsequently tested using “dummy” charts which were reviewed by the principal 
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investigator and program coordinator for this project to determine reliability and accuracy.  
Correct responses were corroborated for training for the chart reviewers. 
Chart reviews were conducted by trained staff members that were independent of the 
research component of the project.  All of the chart reviewers were healthcare professionals (2 
registered nurses and 1 health educator) with prior experience conducting chart reviews.  The 
chart reviewer training was conducted by the program coordinator again using “dummy” charts; 
comparisons were made between the previously determined correct responses and the chart 
reviewers’ responses.  All discrepancies were addressed and corrected.  Ongoing quality 
assurance was completed by the chart reviewers; 5% of the charts were randomly assigned to be 
repeated for review by a different chart reviewer and were completed on an on-going basis 
throughout the project to determine and resolve any potential problems.   
A ‘pre’ screening (primary) chart review which covered the 13 months immediately prior 
to the 13-week screening period was conducted for those who had the prevention invitation 
letters sent.  Similarly a ‘post’ invitation (secondary) chart review was conducted for the 13 
month period forward from the date of the invitation letter.  A comparison group consisting of 
those with birthdates in another quarter of the year and not invited for screening was similarly 
examined by chart review.  All data collected was de-identified by the chart reviewers and 
uploaded to the STEP UP Coordinating Center.   
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4.1 ABSTRACT 
 OBJECTIVE: To evaluate a structured prevention screening program incorporating national 
guidelines for type 2 diabetes (T2D) and cardiovascular disease (CVD) risk identification and 
management in primary care practice. METHODS:  The program was implemented in 4 primary 
care practices in Western Pennsylvania; screening invitations were sent to patients aged 25-74 
whose birthdates feel within a selected quarter of the year. Chart review was conducted for two 
13-month periods preceding and following the screening invitation for those invited for 
screening (n=3,610). A comparison group consisting of those with birthdates in another quarter 
of the year and therefore not invited for screening was similarly examined (n=3,506). Measures 
assessed included the prevalence of elevated LDL cholesterol, fasting blood glucose, blood 
pressure and BMI. RESULTS: Of the 1,963 eligible patients, 350 (17.8%) attended screening, 
776 (39.5%) were unable to be reached and 837 (42.6%) refused. A total of 224 patients (64%) 
had at least one risk factor meriting further medical evaluation; after chart review, 142 patients 
(41% of those screened) were confirmed to have a potentially new risk state found at screening. 
The target group demonstrated a significantly greater increase from the pre to the post-screening 
review in prevalence of diagnosed hyperlipidemia (4.1% vs. 2.1%, p<0.001), pre-diabetes (1.7% 
vs. 0.7%, p<0,007) and obesity (3.8% vs. 1.4%, p<0.001) than the comparison group.  
CONCLUSION: Although response to the screening invitation was modest, these results 
support the importance of prevention screening in identifying those at risk. 
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4.2 INTRODUCTION   
Often referred to as a “touch of sugar” and frequently perceived by the general population as 
nothing more than a nuisance requiring a pill, type 2 diabetes  has continued to hide behind a 
wall of ignorance and denial, with the truth often revealed only after an individual is diagnosed 
with the disease.   Currently over 20 million people or about 7% of the US population are 
estimated to have diabetes, with one-third unaware (1).  With rates increasing steadily around the 
world (2), diabetes is clearly one of the most important public health concerns of our time. 
A major complication of diabetes, cardiovascular disease (CVD) is the leading cause of 
death for those with diabetes in the U.S.  Individuals with diabetes are 2-4 times more likely to 
have heart disease or suffer a stroke than those without diabetes (3).  CVD is the most costly 
complication of diabetes, accounting for more than $17 billion of the $91.8 billion in annual 
direct medical costs for diabetes in 2002 in the U.S. (4).    
CVD risk factors are often present in the interim stages prior to diagnosis with T2D and 
predict its development (5-14).  The clustering of these conditions of risk including insulin 
resistance, dyslipidemia, obesity and hypertension has been referred to as syndrome X, insulin 
resistance syndrome and more recently the metabolic syndrome. While definitions of and criteria 
for inclusion in this disorder have varied (15-20) and even its very existence as a syndrome has 
been debated (21; 22), research has supported the conclusion that the grouping of these risk 
factors generally places an individual at increased risk for both type 2 diabetes and CVD (23-28). 
 It seems appropriate therefore, that prevention be directed toward both type 2 diabetes and 
CVD, a position consistent with the recent American Diabetes Association cardiometabolic 
initiative and joint statements form both the U.S. and European diabetes and cardiology 
associations (21). 
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Current estimates from the Center for Disease Control indicate that over 54 million 
people in the US have pre-diabetes (1).  In addition, using NCEP ATP III diagnostic criteria, the 
estimated unadjusted prevalence of the metabolic syndrome in the U.S. was approximately 23% 
based on NHANES data from 1988-1994  (29), while data from NHANES 1999-2000 showed a 
significant increase in prevalence to 26.7% (30).  The current target group for joint 
diabetes/CVD prevention thus likely exceeds a quarter of the adult population. 
Fortunately proven strategies exist for the prevention or delay of type 2 diabetes and for 
the reduction of CVD risk (31-35) in those at risk for diabetes by virtue of impaired glucose 
tolerance. While most physicians practice some form of prevention screening, many are falling 
short of recommended prevention guidelines (36-38).  When prevention screening does occur it 
may often be combined with a “sick” visit where other acute medical conditions require attention 
or the patient may be ill thus rendering risk assessment and counseling difficult. Other reasons 
for lack of routine prevention assessment may be attributable to multiple and confusing 
prevention guidelines (39), physician and patient time constraints, patient ignorance concerning 
screening requirements, cost of testing and both physician and patient attitude and personal 
characteristics (40).    
For these reasons, a systematic birthday-based prevention screening program 
incorporating national guidelines designed for type 2 diabetes and CVD risk assessment for 
patients in a primary care practice setting was developed and evaluated.  The screening program 
was devised to address some of the above barriers to prevention screening and risk identification, 
specifically a lack of organized prevention screening for risk identification, as well as 
simplification of prevention guidelines for easier implementation, provision of patient education 
information regarding individual risk and alleviating time constraints. 
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4.3 METHODS 
Initially, a concise, “user-friendly” document summarizing current guidelines was compiled 
based on the recommendations for prevention screening regarding diabetes, hypertension, 
dyslipidemia, and obesity (41-45).  In addition, a computer driven screening program was 
developed to facilitate the collection of screening information and to provide immediate 
feedback regarding risk and necessary follow-up.   
4.3.1 Practice and Preventionist Identification 
Four primary care practices, two urban and two rural, were identified in the Western 
Pennsylvania area.   Each practice was asked to identify a “preventionist” to oversee the 
prevention screening program, including screening, recruitment and delivery of a lifestyle 
change intervention program.  The preventionists were required to have a healthcare background; 
four were nurses and two were health educators (in one practice the position was split and in one 
practice the preventionist was replaced when she left the position).  In two practices, the 
preventionists were identified from within the practice; in the other two practices the 
preventionists were brought in specifically for the position.  The preventionists completed 
clinical measurement certification through the Diabetes Prevention Support Center (DPSC) for 
the measures that were collected including blood pressure, height, weight, and waist 
circumference, as well as training regarding prevention screening and use of the computer 
program.   
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4.3.2 Computer Driven Screening Program  
In collaboration with Flipside Media, Inc. a lap top driven questionnaire and data collection 
system was developed to track, screen and report on targeted patients within the practices.  The 
system included a study recruitment tool, integrated with the office's existing patient database, 
which facilitated sending invitation letters to eligible patients and tracking their progress.  The 
system also generated a patient-specific report.  The data were synchronized weekly with a 
central server, through which progress reports (indicating who needed to be contacted) were 
generated and emailed to the researchers weekly.  The system is based on Flipside's “ScoreMD” 
screening and data collection platform which is built upon a Unix-based operating system, 
Apache web server, MySQL database, the PHP scripting language, PDF-based reporting, secure 
web services for data transfer, and is usable through standard web browsers (like Internet 
Explorer, Firefox/Mozilla, Safari, and Opera). 
4.3.3 Eligibility and Recruitment 
Initially, each practice was assisted in preparing a data set which included all practice patients 
age 25-74 in 2005 that had been seen by a practice physician within the past three years.   All 
patients were assigned a random 8-digit ID number with the link to the patient’s identifying 
information kept in a secure location on site.  Within each practice, all patients with birthdates 
within one quarter of the year (a consecutive 13-week period of time) were identified as eligible 
for a prevention screening invitation and were sent computer generated invitation letters near 
their specific birthday.  The invitations, which encouraged the recipient to call the preventionist 
to set up an appointment, were sent out weekly by the preventionists.  Up to three subsequent 
 74 
  
follow-up telephone calls at different time and days of the week were made if no response was 
received within one month. This prevention screening and chart review project received approval 
by the University of Pittsburgh Medical Center Quality Assurance Council.   
4.3.4 Screening and Data Collection  
Patients attended a brief 30 minute screening visit which was conducted at the primary care 
practice, completing a short interview concerning medical, social and family history.  The 
preventionist reviewed the chart for pre-existing blood glucose and lipid profiles, blood pressure, 
height, weight, and waist circumference.  This information was subsequently entered into the 
computer program which determined if and when screening measures needed to be performed 
according to the guidelines.  After completion of the required testing the program also 
determined the prevention follow up schedule and provided a written summary for the patient, 
preventionist and physician. The prevention screening was provided at no cost to the patients, 
however any follow-up lab tests or care that was required as a result of the screening were billed 
for in the usual manner.   
4.3.5 Chart Review 
In addition to the collection of patient screening data, a chart review was conducted to examine 
the efficacy of the prevention screening.  Chart reviews were conducted by trained staff members 
that were independent of the research component of the project.  A ‘pre’ screening (primary) 
chart review which covered the 13 months immediately prior to the 13-week screening period 
was conducted for those who had the prevention invitation letters sent.  Similarly a ‘post’ 
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invitation (secondary) chart review was conducted for the 13 month period forward from the date 
of the invitation letter.  A comparison group consisting of those with birthdates in another quarter 
of the year and not invited for screening was similarly examined by chart review.  All data 
collected was de-identified by the chart reviewers and uploaded to the STEP UP Coordinating 
Center.   
4.3.6  Outcome Measures 
All clinical measures were obtained by a certified preventionist.  Blood pressure was measured 
in a sitting position in the right arm after resting for five minutes.  First appearance and last heard 
(phase V) Korotkoff's sounds were used to define the pressure readings; the measures were 
repeated twice with a thirty second wait between each reading.  An average of the 2nd and 3rd 
readings was computed.  Height and weight were measured twice without shoes with the average 
computed; BMI was calculated as average weight divided by average height squared (kg/m2).  
Waist circumference was measured at the midpoint between the lower rib margin and the iliac 
crest; the measurement was repeated twice and the average computed.    
Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and glucose were 
recorded from the patient chart or when necessary, were completed by the practice or referred 
lab.  Type 2 diabetes and global CVD risk assessment (46) was completed automatically by the 
program, as well as determination of follow-up scheduling. 
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4.3.7 Statistical Analysis 
The efficacy of the computer-assisted screening program was evaluated by documenting the 
proportion of individuals responding to screening invitation by age and gender, the reasons for 
declining the screening invitation and the proportion of cases identified that were contacted after 
a reminder from the central DPSC, using the chi-square test as appropriate.   
The proportion of patients within the selected quarter that were 1) evaluated for 
diabetes/CVD risk according to national guidelines, 2) newly identified to be at risk and 3) newly 
identified to be at risk and received appropriate action were also documented from the chart 
review.  For the purposes of this evaluation, appropriate action was defined as the reasonable 
response that would be expected to occur upon the identification and documentation of a risk 
factor state, i.e., scheduling a repeat test or follow-up visit, beginning a new treatment or 
changing treatment type or dose, or referral to a specialist.  Situations where the time interval 
following detection of a new risk factor was not sufficient for action within the chart review 
period were not counted as lack of action.  Patient attendance or compliance with 
recommendations was not required for the action to be considered appropriate; for example if it 
was documented that a repeat visit was to occur but the patient did not attend, the clinic action in 
attempting to schedule the appointment was still considered to be appropriate.  The chi-square 
test was utilized to examine appropriate action for those who attended screening versus those 
who did not.  
In addition, the change in prevalence of diagnosed risk conditions including diabetes, pre-
diabetes, hypercholesterolemia, hypertension and obesity between primary and secondary 
reviews was examined in both the target and comparison groups using the non-parametric 
McNemar’s test for related categorical data.  The target and comparison group’s change in 
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prevalence was subsequently compared using the chi-square test.  The study sample size was 
based on the ability to detect with 80% power, a 20% increase in the prevalence of known 
hyperlipidemia and hypertension between pre and post.  One of the rural practices was sold prior 
to the secondary chart review phase for the target group and thus could not provide complete 
reviews.  The chart review data from this practice was excluded from the analysis of prevalence 
of diagnosed conditions. 
  
4.4 RESULTS 
4.4.1 Recruitment 
Three of the primary care practices reported a similar number of registered patients (range 2,150-
2,659); however the fourth, urban, center was a larger practice with 5,539 patients.  Figure 1 
shows the planning and recruitment scheme for this project.  A total of 2,786 letters were sent 
out across all practices; those found to have moved away from the area permanently, to have a 
different primary care physician outside the practice, or found to be deceased were subsequently 
excluded (n=823).  Of the remaining 1,963 patients, 776 (39.5%) were not able to be reached 
with three phone calls and 837 (42.6%) refused screening.  Among refusals, most common 
known reasons were illness/medical condition (23.1%), scheduling issues (lack of time or out of 
area-21.9%), felt screening was not necessary (18.8%) and lack of insurance (11.6%).  A 
significantly higher proportion of males than females refused the screening invitation (69.1% vs. 
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58.1%, p<0.01).  Three hundred and fifty (17.8%) of those invited attended a screening 
assessment. 
Of the 350 individuals that attended a screening visit, 216 (61.7%) self-responded after 
receiving the invitation.   Of the remaining group, 45 individuals (12.9%) required one follow-up 
telephone call to schedule a visit, 49 (14%) and 40 (11.4%) scheduled a visit on the second and 
third follow-up calls respectively.  A significantly higher proportion of those who attended the 
screening and self-responded to the invitation were male (69.7% vs. 58.6%, p=0.05).  There were 
no differences noted for age and self-response. 
Screening attendance rates varied by clinic with a high of 34.2% and a low of 7.0% 
(p<0.01).  The two rural clinics, both of whom used internally assigned preventionists had 
significantly higher rates of screening attendance than the urban clinics with externally identified 
preventionists (27.9% vs. 10.9%, p<0.01).    
 
4.4.2 Screening Results  
The median age of those screened was 49 years old; 26.3% were less than age 40, 60% were age 
40-64, 13.7% were 65 and older (Figure 2).  Seventy-two percent of those screened were women.  
A total of 68 patients (19.4%) were from minority ethnic groups (African American (17.2%) and 
other (2.2%)).  The two urban practices were significantly more ethnically diverse with 51.2% 
non-white participants compared to 1.4% non-white participants in the rural practices (p<0.01); 
these racial proportions reflect the local community structure.  
Of the 350 individuals that attended screening, 277 (79.1%) were found to have a body 
mass index (BMI) > 25kg/m2, of whom 97 (27.7% of those screened) had no reported history of 
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diabetes and met criteria for the metabolic syndrome (based on National Cholesterol Education 
Program Adult Treatment Panel III) (42), thus were eligible to participate in a lifestyle change 
program.  A total of 43 patients (45.3%) enrolled in the prevention program, representing a yield 
of 2.2% from the attempted invitation of 1,963 patients.   
4.4.3 Identification of Risk Factors at Screening 
Overall, regardless of previous diagnosis, 224 patients (64% of those screened) had at least one 
risk factor meriting further medical evaluation (405 total risk factor states noted) (Table 1).  New 
potential risk factor states were identified by examining elevated levels and assessing patient 
report of previous diagnosis at screening; 21 patients (6%) attending screening were found to 
have elevated blood pressure (SBP ≥ 140 and/or DBP ≥ 90) without reporting a previous 
diagnosis, while elevations in glucose at the diabetes and pre-diabetes levels were seen in 9 
(2.6%) and 56 (16%) respectively.  Elevated total cholesterol (≥ 200mg/dl) was identified in 78 
(22.3%) and elevated triglycerides (≥150 mg/dl) in 72 (20.6%) individuals without previously 
reported dyslipidemia.  Thus a total of 236 potentially new risk states were identified at 
screening.  Furthermore, almost one-half (n=66, 44.9%) of 147 patients who reported no 
previous diagnosis with any of the above conditions had at least one risk factor which warranted 
further follow-up.   
4.4.4 Chart Review for Potential New Risk Factors 
Results of the chart review are further shown in Table 1 and revealed that of the 21 individuals 
with new potential hypertension, 2 (9.5%) had a previous diagnosis of hypertension recorded on 
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the patient chart (2 did not have a chart review completed).  Similarly, of the 56 with glucose in 
the pre-diabetes range, 3 (5.4%) had a diagnosis noted in the chart (2 had not had a chart review 
completed), while for the 72 with elevated triglycerides, 7 (9.7%) had this noted previously in 
the chart.  No previous diagnoses of diabetes was noted for 8 of those with glucose levels in the 
diabetes range; however one did not have a chart review completed.  Of the 78 with cholesterol 
levels greater than or equal to 200mg/dl, 7 (9%) had a diagnosis noted on the chart (6 had no 
chart review completed).  Thus excluding those without chart review, 206 potential cases of new 
hypertension, diabetes, pre-diabetes or hypercholesterolemia were identified at screening, with 
only 19 (9.2%) of those conditions being already noted in the chart.  This translates to 142 
patients (41% of those screened) being identified through screening to have one or more 
potentially new risk states. 
4.4.5 Chart Review 
A total of 7,116 chart reviews were completed with 3,765 (2,011 target and 1,754 
comparison) completed prior to the screening period (primary review) and 3,351 (1,599 target 
and 1,752 comparison) completed post-screening (secondary review).  The results of the chart 
review for diagnosis detection are presented in Table 2.  Changes in the prevalence of diagnosed 
conditions in the target group increased significantly from the primary review to the secondary 
review for hyperlipidemia (20.1% vs. 23.1%, p<0.01), for pre-diabetes (2.0% vs. 3.2%, 
p=0.005), for diabetes (10.1% vs. 10.8%, p=0.004), for obesity (15.5% vs. 16.9%, p=0.03), and 
for hypertension (30.4% vs. 31.5%, p<0.05).  Similar results were found for each condition 
within the comparison group, with the exception of pre-diabetes which showed only a marginal 
increase in diagnosis (3.7% vs. 4.3%, p=0.06).   Rates of diagnosis detection from the primary to 
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the secondary review were compared between the target and comparison groups.  The target 
group demonstrated a significantly greater increase from the primary to the secondary review in 
prevalence of diagnosed hyperlipidemia (4.1% vs. 2.1%, p<0.001), pre-diabetes (1.7% vs. 0.7%, 
p=0.007) and obesity (3.8% vs. 1.4%, p<0.001) than the comparison group; a greater increase in 
prevalence of both diagnosed hypertension and diabetes was also noted but was not significant. 
Overall appropriate follow-up action was examined for each risk factor identified in all 
charts included in the chart review with primary and secondary reviews (Table 3).  A risk factor 
was counted if it was recorded at least once during the chart review period; patients were 
assumed to be fasting when not specifically noted in the chart as non-fasting.  Including the 
target and comparison groups for both primary and secondary review, a total of 189 charts were 
noted to have glucose levels above 125 mg/dl and 682 within the pre-diabetes range of 
100mg/dl-125mg/dl (those with previous diagnosis of diabetes were excluded for both groups); 
appropriate follow-up action was noted for 95 (50.3%) and 151 (22.1%) charts respectively.  A 
total of 1,823 charts were noted to have an elevated blood pressure recorded (≥140 and/or ≥ 90 
mmHG); appropriate action was noted for 620 (34%), while 728 were noted to have elevated 
LDL cholesterol (based on risk), with appropriate action noted for 330 (45.3%).  Elevated 
triglycerides were noted on 901 charts with appropriate action noted for 479 (53%).   Obesity 
(BMI >30kg/m2) was also examined; 1,816 charts were noted to have obesity with appropriate 
follow-up noted for 541(29.9%).  Overall appropriate action for abnormal risk factors noted in 
the chart was 36%. 
The same risk factors and appropriate action were examined for charts of individuals who 
attended screening and had a post-screening (secondary) review completed (n=185 individuals) 
as well as for those with a secondary chart review who were not screened (n=3,065).  These 
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results are shown in Table 4.  A significant difference was noted between those who completed 
the screening versus those who did not for appropriate action for pre-diabetes (39% vs. 15.1%, 
p<0.01) and obesity (41% vs. 30.9%, p=0.03); no significant differences were noted for 
appropriate action for diabetes, hypertension, elevated LDL or triglycerides.  Overall results for 
appropriate action were higher in the screened versus non-screened group (41% vs. 36%); 
however, this difference was not significant. 
4.5 DISCUSSION 
The results of this evaluation demonstrate that prevention screening for risk identification for 
type 2 diabetes and cardiovascular disease is feasible in a primary care practice setting and can 
be successful in identifying many at risk so that appropriate action and follow up may occur.  It 
is interesting to note that over 60% of the individuals that attended a screening visit responded to 
the invitation letter and scheduled a visit without further recruitment contact.  This suggests that 
letter mailing may be a reasonable method to contact patients for prevention screening as well as 
being time-saving and fairly inexpensive.  Although no formal cost-effectiveness evaluation was 
performed, based on feedback from the preventionists, the authors estimate that on average 
approximately 5 minutes per individual was spent during the recruitment process.  For this 
project this would translate to about to about 164 hours of time per clinic or about 32% of a full-
time employee’s annual hours.  Much of the time initially was spent in the identification of 
patients that were actually eligible to be contacted, i.e., alive, still living in the area and listing 
that primary care physician as their provider.  Once a practice has developed and subsequently 
maintains a database, future time spent on contacting patients would be minimized.   
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As noted, recruitment rates varied significantly across the clinics (34.2% versus 7%) , 
with the two rural clinics who used internally assigned preventionists demonstrating significantly 
higher recruitment rates than the two urban clinics with preventionists brought in specifically for 
the position.  These results suggest that recruitment for screening may be higher when done by 
someone the patients already are familiar with and trust, i.e. the internally assigned preventionist.  
However, other reasons for this discrepancy could certainly exist, for example, both of the 
externally assigned preventionist clinics were in an urban area with a significantly higher non-
white population attending screening.  Because these proportions reflect the racial makeup of the 
communities it is conceivable that certain racial barriers related to screening may exist.  There 
may also be some inherent differences between urban and rural responses to health care.  It will 
be important to further evaluate these issues in order to develop appropriate recruitment methods 
for different settings. 
Several key themes emerged from the data concerning refusal of prevention screening: 
medical illness/health condition, lack of time/out of the area, felt screening was not necessary 
and lack of insurance were the top rated known reasons for refusal.  Medical problems (47) and 
lack of time/inconvenience are reasons that are often cited for non-participation (48; 49).  Further 
investigation revealed that of those who felt that prevention screening was not necessary, over 
half (57%) were missing at least one risk assessment measure including weight, glucose, blood 
pressure or LDL measure within the 13 month primary review period prior to screening. It is 
interesting to note that lack of insurance was a common reason for refusal even though there was 
no charge for the screening visit.  There were also a fair number of individuals that cited “other” 
unknown reasons for non-participation.  Research has suggested that those who do not 
participate in health-related research may be at higher risk than those who do (50).  Similarly 
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individuals who do not take part in preventive practices may also be at higher risk; thus it is 
important to further evaluate reasons for refusal in order to reach out to patients that may not 
initiate a “healthy” visit with their physician.   
Of the 350 individuals that attended a screening assessment visit, 224 (64%) had at least 
one risk factor warranting further medical follow-up (405 elevated risk factors), with 206 risk 
factors subsequently determined to not have been previously diagnosed through patient self-
report at screening and chart review.  This translates to 142 patients (41% of those screened) 
with potentially new risk states.  Thus the importance of screening is once again substantiated, 
and may be a consideration when planning for financial support for a prevention screening 
program as all of the risk factors identified are potentially billable in the future as follow up 
services provided by the practices.  The authors estimate based on preventionist feedback that 
each screening visit took about 30 minutes to complete; when considering a preventionist salary 
of approximately $50,000, each visit cost approximately $12 in staff time (excluding fringe).  It 
is anticipated that the screening program and process could be streamlined in the future to permit 
the patient to complete a large portion of the information prior to or at the visit, which would 
allow for a significant reduction in staff time.  It is also conceivable that using a program such as 
this could actually save cost by decreasing physician time spent in reviewing old results, 
determining risk manually and evaluating the prevention schedule as all of these components 
would be completed prior to the actual encounter with the patient. 
While more than half of those screened were identified as having at least one elevated 
risk state warranting further follow-up, it is somewhat disturbing to note that overall, for the 
entire group with chart reviews completed, only 36% of elevated risk factors noted in the charts 
received appropriate follow-up.  The screened group exhibited slightly better follow-up with 
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41% of elevated risk factors receiving appropriate action in the chart review conducted post-
screening.  Appropriate action for pre-diabetes and obesity was significantly higher in the 
screened group when compared to the non-screened group.  Overall , elevated LDL-C, glucose in 
the diabetes range (>125mg/dl), and triglycerides seemed to receive appropriate action most 
often, while blood pressure received appropriate action in one-third or less of both the screened 
and non-screened groups.  While the lack of appropriate follow up for blood pressure is 
surprising, it is possible that the focus on diabetes prevention for this project influenced the 
significant increase in appropriate action for pre-diabetes and obesity.  When performing the 
chart review, along with other actions considered appropriate, a follow-up visit scheduled for a 
patient was counted even if the patient did not actually attend.  Because patient non-compliance 
with return visits is a well-known problem, the actual number receiving appropriate follow-up 
action may thus be even lower than these results indicate.   
A greater increase in the prevalence of all diagnosed conditions was found from the 
primary to the secondary review for the target group versus the comparison group, with 
significantly greater increases noted in prevalence of diagnosed hyperlipidemia, pre-diabetes, 
and obesity.  These results mirror those found concerning appropriate action above and again 
support the effectiveness of prevention screening.   
Although widely recognized as being essential for prevention of many chronic diseases, 
organized screening programs for risk factors leading to these conditions are lacking; little 
progress has been made toward making prevention part of our health care system (51).  While 
other stimuli for preventive services have been examined such as patient satisfaction as a 
mechanism to prompt physicians to refer for prevention (52) it is generally agreed that in order 
for preventive service use to increase, prevention must become an integral part of the health care 
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system (40).  The results of this project validate the need for prevention screening and describe a 
means for implementation in a health care system.  A computer driven prevention screening 
program such as described could certainly be integrated into the usual routine of a primary care 
practice.  The program has several advantages:  1)  reminder invitation letters may be set up to be 
sent out on a regular schedule automatically with little time and effort on the part of the primary 
care staff;  2) the program provides a print-out of the screening information for the patient and 
physician thus providing an excellent opportunity for patient education about risk, 3) the results, 
risk assessment and time schedule for prevention measures are completed and available to the 
physician at the time of visit,  thus potentially facilitating better time management for the 
physician and 4) ongoing screening would be provided on a regular basis with built-in follow-up 
guidelines, thus making the entire process somewhat less daunting but more effective for 
practices.   
There are some limitations to this project including 1) a smaller than desired sample size 
responding to and attending screening, thus possibly limiting the observed results and 2) a lack 
of a formal cost analysis which would be very beneficial in further understanding financial 
implementation of prevention screening in the health care system.   
There will certainly be challenges to implementing a program such as this including a 
general lack of the existence of patient databases within primary care practices, thus 
necessitating that this step be completed first, as well as getting physicians and staff “on-board” 
with the idea of prevention screening. Ensuring that follow-up action after risk states are 
identified is completed is another challenge, although this seems to be better when risk factors 
are discovered as part of a structured program as shown here. 
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Future areas of study should include examination of potential barriers to recruitment for 
preventive services, including racial, cultural and financial concerns, research to continue to 
follow post-screening action taken for risk states that are identified and comprehensive cost 
analysis to help clinicians determine how best to make prevention work in their setting. 
While prevention has become the “buzz” word of this century, very few concrete 
measures have been taken toward one of the most key components of prevention: identification 
of those at risk.  The information provided here offers an overview of the importance of 
prevention screening as well as present a roadmap for prevention screening implementation 
which is rooted in the health care system. 
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Figure 4-1 Screening Program Development and Recruitment 
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Table 4-1 Potential New Risk Factors Identified at Screening 
n=350 
 Elevated Risk Factors Identified 
at Screening 
 
 
n=224 patients  
(64% of those screened) 
Potential New Risk States  at 
Screening 
(Excluding those w/previously 
reported diagnosis) 
Potential New Risk States Based 
on Chart Review 
(Excluding those w/previous 
diagnosis on chart review) 
n=142 patients 
(41% of those screened) 
TC ≥ 200mg/dl 
 
 
139 78 
5 
7 w/previous diagnosis 
6 w/o chart review 
Trig ≥ 150mg/dl 
 
 
114 72 
5 
7 w/previous diagnosis 
SBP ≥ 140 mmHg 
and/or DBP ≥ 90 
mmHg 
66 21 
7 
2 w/previous diagnosis 
2 w/o chart review 
FBG ≥ 126 mg/dl 
 
 
23 9 
8 
1 w/o chart review 
FBG ≥ 100 mg/dl 
& ≤ 126 mg/dl 
 
63* 56 
1 
3 w/previous diagnosis 
2 w/o chart review 
Total Risk Factors 
 
 
405 236 206  
* Those with previously reported diabetes excluded 
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Table 4-2 Prevalence of Diagnosed Conditions between Primary and Secondary Review 
 
 Hyperlipidemia Hypertension Diabetes Pre-diabetes Obesity 
 Primary 
Review 
 
Second 
Review 
 
Primary 
Review 
 
Second 
Review 
 
Primary 
Review 
 
Second 
Review 
 
Primary 
Review 
 
Second 
Review 
 
Primary 
Review 
 
Second 
Review 
 
Target 
n=1,600 
321 
(20.1%) 
 
370 
(23.1%) 
 
p<0.01 
487 
(30.4%) 
504 
(31.5%) 
 
p=0.05 
162 
(10.1%) 
179 
(10.8%) 
 
p=0.004 
33 
(2.0%) 
51 
(3.2%) 
 
p=0.005 
248 
(15.5%) 
271 
(16.9%) 
 
p=0.03 
Comparison 
n=1,650 
345 
(20.9%) 
 
 
377 
(22.8%) 
 
p<0.01 
491 
(30.0%) 
524 
(31.8%) 
 
p<0.01 
162 
(9.8%) 
173 
(10.5%) 
 
p=0.007 
61 
(3.7%) 
71 
(4.3%) 
 
p=0.06 
271 
(16.4%) 
289 
(17.5%) 
 
p<0.01 
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Table 4-3 Elevated Risk Factors and Appropriate Action for Whole Group 
 Whole Group Primary and Secondary 
Chart Review 
(n=7,116) 
 Elevated Result 
 
Appropriate Action 
Glucose  
> 125mg/dl 
189 95 
(50.3%) 
Glucose 
100-125 mg/dl 
682 151 
(22.2%) 
BP  
>=140 or 90 mm/Hg 
1,823 620 
(34.0%) 
LDL (based on risk) 728 330 
(45.3%) 
Triglycerides  
>= 150 mg/dl 
901 479 
(53.2%) 
Obesity BMI  
>30 kg/m2
1,816 541 
(29.8%) 
Total 
 
6,139 2,216 
(36.1%) 
 
 
 
 
Table 4-4 Secondary Chart Review for Screened vs. Non-Screened 
 Screened Group Secondary  
Chart Review 
(n=185) 
Non-Screened Group 
Secondary Chart Review 
(n=3,065) 
 Elevated Result Appropriate Action Elevated Result Appropriate Action 
Glucose  
> 125mg/dl 
11 6 
(55.5%) 
67 30 
(44.8%) 
Glucose 
100-125 mg/dl 
41 16 
(39.0%) 
245 37 
(15.1%)* 
BP  
>=140 or 90 mm/Hg 
73 20 
(27.4%) 
636 214 
(33.6%) 
LDL (based on risk) 49 23 
(46.9%) 
247 117 
(47.3%) 
Triglycerides  
>= 150 mg/dl 
46 24 
(52.2%) 
300 179 
(59.7%) 
Obesity BMI  
>=30 kg/m2
117 48 
(41.0%) 
625 193 
(30.9%)** 
 
 
337 137 
(41%) 
2,120 770 
(36%) 
*p<0.01   **p=0.03 
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5.1 ABSTRACT 
Objective: To assess the effectiveness and feasibility of a modified version of a proven lifestyle 
intervention program delivered in a primary care practice setting.  Research Design and 
Methods: Four primary care practices were invited to participate in a lifestyle intervention 
effort; 51 participants (42 female) without prior history of diabetes with a body mass index 
(BMI) >25kg/m2 and metabolic syndrome (NCEP ATPIII definition) were enrolled in the 12-
session Group Lifestyle Balance (GLB) program which was adapted from the intensive lifestyle 
intervention utilized in the Diabetes Prevention Program.  The GLB program closely followed 
the DPP protocol with minor adaptations; weight loss and physical activity goals remained at 7% 
and 150 min/week respectively.  Anthropometric measures were collected before and after the 
intervention. Results: Using last observation carried forward methodology for participants who 
did not complete the intervention, average weight loss, comparing the pre and post-intervention 
assessments, was 4.6 lbs. (2.2% relative loss, p<0.001). An average 0.5 pound weight loss per 
week was estimated (p<0.001) after adjusting for starting weight and clinic. Waist 
circumference, BMI and fasting blood glucose decreased an average of 0.69 in. (1.6%, p=0.003), 
0.82 kg/m2 (2.3%, p<0.001) and 4.63mg/dl (3.7%, p=0.02) respectively. A positive correlation 
was noted between total activity minutes and total pounds lost (Spearman’s r=0.36, p=0.01). 
Conclusion: The results of this translational research suggest that the GLB program was 
successful in reducing some parameters of risk for diabetes and cardiovascular disease in this 
group of individuals with metabolic syndrome.  The DPP lifestyle intervention can be adapted 
for use in the “real-world” and is feasible to conduct in a primary care practice setting.   
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5.2 INTRODUCTION  
In 2001, the Diabetes Prevention Program (DPP) ended prematurely due to significant results 
indicating that the intensive lifestyle intervention utilized in the program was highly successful 
in reducing risk for type 2 diabetes in all groups regardless of ethnicity, age or gender (1).  Other 
studies have also demonstrated the efficacy of lifestyle intervention and reduction in risk for type 
2 diabetes (2-5). In addition, the DPP lifestyle intervention was found to be effective in reducing 
risk factors for cardiovascular disease (CVD) (6) and components of the metabolic syndrome (7).  
While it is apparent that type 2 diabetes and CVD risk can be lowered with lifestyle intervention, 
the translation of these intervention programs in a real-world setting presents a number of 
challenges. 
Some of these challenges include lack of trained personnel, patient recruitment and 
retention, coordination of care, and availability of quality programs (8).  Primary care practices 
provide an ideal venue for institutional delivery and reinforcement of prevention intervention, 
long-term, for several reasons.  They employ individuals who have the knowledge and 
background to be trained to deliver a lifestyle intervention.  Patients are familiar with their 
primary care practice staff, routine, and location, which could facilitate participation and 
retention.  Finally, since one of the most important aspects of prevention intervention is 
continued monitoring regarding lifestyle change, primary care practices are well placed to 
provide ongoing follow-up care.  For these reasons, translation of a modified DPP Group 
Lifestyle Balance (GLB) intervention for patients with the metabolic syndrome was assessed for 
effectiveness and feasibility in a variety of moderately low income and ethnically diverse 
primary care settings.   
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5.3 RESEARCH DESIGN AND METHODS 
This prospective study used a one-group design to deliver intervention, incorporating pre and 
post intervention testing of subjects in four diverse primary care practices in the Western 
Pennsylvania area (two urban and two rural practices).   The two rural practices were 
approximately 1-2 hours from Pittsburgh, while the urban practices were within close proximity 
to the city.  Each of the participating practices was asked to identify a “preventionist” to be 
responsible for implementation of the GLB program.  The identified preventionists included 
nurses, a health educator and an exercise physiologist.  One practice shared the responsibilities 
between two nurses. Preventionists were required to attend a two-day training workshop which 
addressed all aspects of the intervention and was conducted by faculty at the study STEP UP 
Coordinating Center.  Additionally, preventionists took part in a pilot GLB intervention 
themselves where they completed all of the components of the program as well as clinical 
outcomes measurement certification through the Coordinating Center.   
5.3.1 Participant Inclusion and Exclusion Criteria 
Inclusion criteria consisted of males and females without previously reported diagnosis of 
diabetes, age 25-74 years in 2005 with body mass index (BMI) > 25kg/m2 and at least three of 
five components of the metabolic syndrome (based on National Cholesterol Education Program 
Adult Treatment Panel III) (9) identified at screening.  At the time of study, the NCEP had not 
yet changed its glucose criterion, although the American Diabetes Association had lowered its 
criterion for pre-diabetes from a fasting glucose of 110 mg/dl to 100 mg/dl (10).  Therefore 
patients who met the above criteria with only 2 components of the metabolic syndrome with a 
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fasting glucose between 100 mg/dl and 109 mg/dl were also included at their primary care 
physician’s discretion.  Exclusion criteria included previously reported diabetes, pregnancy, lack 
of physician approval and inability to sign informed consent.   
5.3.2 Recruitment and Study Population 
In order to facilitate screening for diabetes and CVD risk, a computer driven screening program 
was developed which provided immediate feedback regarding the patient’s risk and determined 
eligibility for the GLB program.  Invitations for prevention screening were sent to all practice 
patients age 25-74 with birthdays within a specific quarter of the year.  The screening assessment 
included collection of medical and family history, fasting lipid and glucose and clinical measures 
consisting of blood pressure, height, weight, and waist circumference.  A total of 350 patients 
attended the screenings, with 97 (27.7%) found to meet eligibility criteria for the intervention.    
Eligible patients were invited to take part in the study which included attendance at the 
12-session GLB program, as well as pre and post intervention assessments.  Of the 97 eligible 
individuals, 54 declined participation, yielding a study population of 43.  Specific reasons for 
non-participation are not available as the screening component was not part of the research 
evaluation.  An additional 8 participants who met the eligibility criteria were directly referred by 
the practice physicians to the program.  This research project was approved by the University of 
Pittsburgh Institutional Review Board and the University of Pittsburgh Medical Center Quality 
Assurance Council, as well as the Surgeon General’s Office of Review.  Eligible and interested 
patients signed informed consent prior to beginning the study. 
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5.3.3 Procedures and Outcome Measures 
Enrolled participants were asked to attend an assessment to obtain clinical measures prior to 
beginning and again at the conclusion of the intervention.  All clinical measures were obtained 
by a certified preventionist and/or certified STEP UP staff member.  Blood pressure was 
measured in a sitting position in the right arm after resting for five minutes.  First appearance and 
last heard (phase V) Korotkoff's sounds were used to define the pressure readings; the measures 
were repeated three times with a thirty second wait between each reading (11).  An average of 
the 2nd and 3rd readings was computed.  Height and weight were measured twice without shoes 
with the average computed; BMI was calculated as average weight divided by average height 
squared (kg/m2).  Waist circumference was measured at the midpoint between the lower rib 
margin and the iliac crest; the measurement was repeated twice and the average computed.    
Total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol (total 
cholesterol - HDL cholesterol) and glucose were measured after at least a two-hour fast using the 
Cholestech LDX System by a certified laboratory assistant.   Global CVD risk assessment (12) 
was estimated and medication use was assessed via participant interview.  In addition, weight 
was recorded weekly at each session. 
5.3.4 Intervention 
The original DPP Individual Intensive Lifestyle Intervention was developed at the University of 
Pittsburgh by the DPP Lifestyle Resource Core and has been described in detail elsewhere (13).   
Members of the original DPP lifestyle team collaborated to adapt the individual intervention to a 
group-based program and to condense the program from 16 individual sessions delivered over 24 
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weeks to 12 group sessions delivered over 12-14 weeks.  Other modifications included 
concentrating on healthy food choices rather than specifically the food pyramid, a focus on 
calorie as well as fat intake from the beginning of the intervention and more emphasis on the 
pedometer.  As in the original DPP lifestyle program, the goals of the GLB intervention were to 
achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity 
to 150 minutes per week of moderately intense physical activity similar to a brisk walk. 
The GLB curriculum was administered by the trained preventionist(s) in each practice at 
the primary care practice location.  Groups were conducted during the daytime as well as in the 
evening with the participants selecting the time that best fit their schedule.  Each participant 
received a copy of the GLB participant handouts, Fat and Calorie Counter, self-monitoring books 
for keeping track of food and physical activity, a pedometer with instructions, a set of measuring 
cups and spoons, and a chart for self-monitoring weekly weights over the course of the program.  
Participants who did not own a scale were given one.  All subjects were asked to self-monitor 
their daily weight, food intake and physical activity and were given feedback concerning 
progress.   
5.3.5 Sample Size Estimation and Statistical Analysis 
Based on the local DPP weight loss experience and using this variance estimate, we estimated 
that 21 subjects were needed to detect a 7% weight loss (as per the DPP goal) with α=0.05 and 
90% power. The DPP achieved a 7% mean weight loss in the intensive lifestyle (ILS) group after 
6 months. In translation to a real-world setting, we assumed the new intervention might achieve 
only half the DPP goal by 3 months, i.e. a 3.5% mean weight loss, requiring 78 subjects.   
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Analyses were carried out using the SAS statistical package (version 9.1, SAS Institute, 
Cary North Carolina, USA).  The mean change between pre and post intervention measures was 
analyzed using the Paired Student’s t-test when change data was normally distributed (weight, 
waist circumference and BMI); however, for most measures the non-parametric Wilcoxon 
Matched-Pairs Signed Rank test was used.  Mixed models were used to examine weight change 
over time (repeated measures per participant) adjusting for weight at study entry and clustering 
of participants within clinical site; individual participant and clinical sites were random effects in 
this model.  Correlations were calculated using Pearson’s or Spearman’s correlation coefficient r.  
Primary analyses were conducted on an intention to treat basis; to handle missing data we used 
last observation carried forward methodology for participants who did not attend the post 
assessment visit (n=51).  Subjects with changes in medication during the course of the 
intervention for the condition being evaluated were excluded from the analyses (4 were excluded 
from lipid analysis and 6 were excluded from hypertension analysis); in addition 8 participants 
whose glucose results were affected by a laboratory error were excluded from glucose analysis.  
Secondary (per protocol) analyses were also performed for the group (completers) that attended 
at least 50% of the intervention sessions and the pre and post intervention assessments (n=28).   
5.4 RESULTS 
The mean age of the participants in this study was 52.9 years; the majority (82%) of participants 
were female (n=42/51) and approximately 25% of the participants were non-white.  Baseline 
clinical measures for the total group are shown in Table 1.  There were no notable differences in 
baseline measures between gender with the expected exception of a higher HDL cholesterol for 
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females (43.8 mg/dL v. 31.4 mg/dL, p<0.05).  Average BMI for the group was greater than 
30kg/m2. 
A total of 31 participants (61%) attended 6 or more of the 12 intervention sessions, with 
81% of those (25 participants) attending 8 or more sessions.  Retention (defined as attending at 
least half of the sessions) varied between the clinics with a range of 38.5% - 81.8% (p<0.05) 
(Figure 1).   Attendance at fifty percent or more of the sessions was associated with achieving 
3.5% weight loss (p=0.002) and reaching the 150 minutes/ week physical activity goal 
(p=0.003).   
Table 2 shows the results of the pre and post intervention measure comparisons for the 
total group (n=51) and those who completed the intervention and the post assessment visit 
(n=28).  Overall weight loss for the total group was significant with an average weight loss of 4.6 
pounds (2.2%, p<0.001).  Using mixed models, participant weight loss was estimated as an 
average of 0.5 pound per week (p<0.001) after adjusting for starting weight and clinic.  A 
significant decrease from pre to post intervention was also found for waist circumference (-0.69 
inches, 1.6%, p=0.003), BMI (-0.82 kg/m2, 2.3%, p<0.001) and glucose (-4.63 mg/dl, 3.7%, 
p=0.02).   No significant changes were noted for systolic or diastolic blood pressure or total, non-
HDL or HDL cholesterol. There is no suggestion of heterogeneity between the clinics for any of 
the measures with the exception of waist circumference, where one center had an increase in 
contrast to all other centers. 
 A sub-analysis of “completers” (those who attended at least 50% of the intervention 
sessions as well as the pre and post assessments, n=28) was also conducted.   Significant results 
were seen in the same variables as for the total population, although mean weight loss was 
greater in this group (7.22 pounds, 3.5%, p<0.001), and a marginally significant decrease in 
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diastolic blood pressure (-2.55 mm/Hg, 2.5%, p=0.09) was noted. The change results comparing 
pre and post intervention measurements were not impacted by age or by gender.    
Attainment of the program goals was examined for both the total and “completer” groups 
(Figure 2). In the total group of 51 participants, four participants reached the weight loss goal of 
7% (7.8%), while 11 (21.6%) reached 5% or greater and 17 participants (33.3%) had 3.5% or 
more weight loss.  Of those participants who recorded physical activity minutes (n=21), 12 
(57.1%) were successful in reaching the physical activity goal (average of > 150 minutes/week) 
with an overall mean of 242.5 (sd=398.6, range=0-1,914) activity minutes per week observed.  
For those who recorded both initial and later activity (n=16), a non-significant mean increase of 
46.1 (sd=139.6, 28.3%, p=0.11) in activity minutes was noted. 
Within the “completers” group, 4 of 28 participants reached the 7% weight loss goal 
(14.3%), while 10 (35.7%) and 15 (53.6%) achieved weight loss of at least 5% and 3.5% 
respectively.  Of the 18 “completers” who recorded physical activity minutes, 12 (66.7%) met 
the physical activity goal, with an overall mean of 274.88 (sd=423.0) activity minutes per week.  
Of those completers who recorded activity level for both initial and later weeks (n=15), a 
significant increase in mean physical activity minutes of 51.13 (sd=142.99, 31.8%, p=0.04) was 
noted.   
Overall, a positive correlation was observed between total activity minutes and total 
pounds lost (Spearman’s r=0.36, p=0.01).  Furthermore, a significant association between 
attainment of the activity and weight loss goals was noted; 25% of those who attained activity 
goal (n=12) vs. 2.5% of those who did not (n=39) were successful in reaching the weight loss 
goal (p=0.03).   
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5.5 DISCUSSION 
The current project is one of the first attempts to take the successful intervention utilized in the 
DPP, modify it for real-world implementation and evaluate its effectiveness in a primary care 
setting.  The results suggest that the current GLB adaptation of the DPP lifestyle intervention can 
be successfully delivered by trained healthcare providers in diverse primary care practices, with 
comparable weight loss to that achieved in DPP itself.  As is well known, translation from 
research to the “real-world” presents a number of challenges, which make the current findings 
particularly encouraging.   
One notable difference between research studies such as the DPP and the real world is the 
population being examined.  Unlike volunteer research, the current program targeted all primary 
care practice patients found to be at risk, rather than the more selective recruitment of volunteers 
already willing to participate in a clinical treatment trial.   In a recent analysis of the physical 
activity component of the DPP intervention, investigators found that the level of reported 
physical inactivity in the DPP cohort was less than that reported in the NHANES III subgroup 
with impaired glucose tolerance (14) suggesting that the DPP volunteers were probably healthier 
and more motivated.  Thus it is likely that the participants enrolled in this translation project 
were less likely to be as motivated to be successful in the program both from a recruitment and 
retention perspective.   
Retention of enrollees in an intervention program can be difficult in a research 
environment, however, may be even more challenging in real-world settings operating with 
limited funds and devoid of monetary rewards or incentives.  In the current study, about 60% of 
participants attended at least half of the sessions.  Interestingly, there was a significant difference 
between retention rates in two clinics (81.8% vs. 38.5%, p<0.05) although there were no 
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significant differences in age, gender or ethnic distributions in these clinics and both clinics were 
located in an urban setting.  This finding warrants further investigation to determine what factors 
may contribute to program retention.   
Comparisons for retention to similar translational programs are limited; however, one 
such translational study in a workplace setting exhibited about 95% retention.   Participants were 
encouraged to attend during work hours without loss of pay or personal time and received other 
small incentives (15).   Another lifestyle translation study involving a partnership between a 
university and a local HMO noted a 92% retention rate; patients were charged an initial 
commitment fee which was returned in its entirety if the subject met certain attendance 
requirements (16). These translation attempts suggest that allowing patients to attend sessions 
during work without loss of pay and offering some incentive and/or reimbursement for 
attendance may be beneficial in improving retention.  Since the current project’s evaluation 
indicated a correlation between attendance and weight loss as well as physical activity, attention 
to provision of motivational items for attendance should be an important consideration for future 
translational efforts. 
Likewise, levels of interest for primary care staff working in the real world may be 
dissimilar to those involved in traditional research, with different goals and role expectations.  
One study examining health care provider attitudes toward the detection and management of 
those at risk for diabetes found that many have concerns including lack of resources and 
questionable patient motivation for making lifestyle change (17).  It is important to note that the 
preventionists who were trained to deliver the GLB had no prior experience in behavioral 
modification, or specialist diabetes interest and had varied backgrounds.  One important lesson 
learned from this project concerns the importance of offering prevention education not only for 
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the preventionist involved in delivering prevention, but for other staff members and physicians as 
well.  Staff input and “buy-in” appear to be important components in facilitating success with a 
lifestyle change program in a primary care practice setting.   
The GLB was successful in reducing certain risk factors for diabetes and CVD including 
weight, BMI, waist circumference and glucose.  Weight loss data from the DPP is only available 
for the 6 month follow up visit forward, so we are unable to directly compare weight loss in the 
DPP at 3 months to the GLB weight loss; however, review of the trend in the DPP at 3 months 
shows a mean weight loss of 3.5%, similar to that achieved by over half of the “completer” 
group.  As it is expected that the effectiveness of an intervention may be reduced when being 
translated from research to clinical practice (18), thus these findings are encouraging.    
Strengths of this study include a prospective follow-up design in one of the first efforts to 
translate the DPP lifestyle intervention to a real-world health care setting.  In addition, we were 
able to collect measures of change in risk parameters for subjects in both rural and urban primary 
care settings.  Data were analyzed according to the principle “intention to treat” as well as for 
those that actually completed the program and follow-up assessment. 
Limitations of this study include: 1) a lower number of participants enrolled than 
originally anticipated, thus not permitting practice specific comparison analyses, 2) the number 
of men enrolled in the program limited gender comparisons for success in the program, however, 
that less men than women took part in the program is not an unusual finding, 3) the attrition of 
participants and subsequent lack of evaluation of those who did not complete the intervention, 
and 4) the limited period of study (3 months) due to funding considerations  
We have successfully adapted the individual lifestyle intervention utilized in the DPP for 
group implementation in a “real-world” setting while maintaining the fundamental aspects of the 
 111 
  
original intervention.  The current project is an important step in moving from efficacy to 
effectiveness in diabetes prevention translation.  The results suggest that the GLB program, 
delivered by trained health professionals, was feasible and effective in reducing some parameters 
of risk for type 2 diabetes and CVD in this group of individuals with the metabolic syndrome.  It 
will be important to evaluate the GLB program in larger populations and other venues over time.  
Additional future areas of study should address methods of delivery of GLB versus standard 
care, as well as in-depth cost analysis. It will also be important for future evaluations to consider 
longer follow-up.   
 In the “real-world”, patients with risk factors for diabetes and CVD are often told to 
“lose weight and increase activity”.  It is hoped that this, and similar programs will enable 
physicians to write a “prescription” for lifestyle change (and insurers to cover the costs) with the 
assurance that tangible health benefits will ensue.   
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Table 5-1 Baseline Characteristics of Study Population 
 Female (n=42)  
Mean (sd) 
Male (n=9) 
Mean (sd) 
Overall (n=51)  
Mean (sd) 
Weight (pounds) 
 
212.8 (44.7) 231.0 (24.8) 216.0 (42.3) 
Total Cholesterol (mg/dL) 194.5 (31.3) 176.2 (28.7) 191.3 (31.4) 
HDL Cholesterol* (mg/dL) 43.8 (11.1) 31.4 (5.7) 41.6 (11.4) 
Non-HDLC (mg/dL) 150.7 (32.1) 144.8 (28.2) 149.7 (31.2) 
Blood Glucose (mg/dL) 98.4 (18.4) 100.6 (17.6) 98.8 (17.9) 
Systolic Blood Pressure 
(mm Hg) 
122.9 (19.1) 130.1 (19.3) 124.2 (19.1) 
Diastolic Blood Pressure 
(mm Hg) 
77.8 (12.6) 80.4 (8.3) 78.3 (11.9) 
Waist (inches) 
 
42.8 (5.9) 44.8 (3.9) 43.2 (5.6) 
Body Mass Index1 36.9 (7.9) 35.2 (3.9) 36.6 (7.4) 
 Data are means (standard deviation) 
 *p<0.05, statistically significant difference between genders 
 1n=50, height missing for 1 participant 
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Table 5-2 Pre and Post Intervention Comparisons 
 Total Group 
n=51 
Completers 
n=28 
Variable n Pre-
Mean 
(sd) 
Post-
Mean 
(sd) 
Mean 
Change 
(sd) 
Mean % 
Change
p-value Pre-
Mean 
(sd) 
Post-
Mean 
(sd) 
Mean 
Change 
(sd) 
Mean % 
Change
p-value
Weight 
(pounds) 
51 216.0 
(42.3) 
211.4 
(43.0) 
-4.60 
(7.2) 
 
-2.2% <0.001 
8 
213.98 
(46.9) 
206.76 
(47.8) 
-7.22 
(8.1) 
-3.5% <0.001 
Total 
Cholesterol* 
(mg/dL) 
47 190.57 
(31.4) 
190.74 
(32.4) 
0.17 
(23.9) 
0.8% 0.92 
5 
194.0 
(30.2) 
195.52 
(33.1) 
1.52 
(32.0) 
1.96% 0.69 
HDL* 
(mg/dL) 
47 42.11 
(11.5) 
42.77 
(11.7) 
0.66 
(7.1) 
 
2.2% 0.32 
5 
44.56 
(13.1) 
45.48 
(13.2) 
0.92 
(9.63) 
3.45% 0.41 
Non-HDL* 
(mg/dL) 
47 148.47 
(31.2) 
147.98 
(32.8) 
-0.49 
(22.6) 
-0.51% 0.84 
5 
149.44 
(29.9) 
150.04 
(33.7) 
0.6 
(30.0) 
 
1.8% 0.92 
Glucose** 
(mg/dL) 
43 99.09 
(15.7) 
94.46 
(15.5) 
-4.63 
(16.7) 
 
-3.7% 0.02 
1 
102.28 
(16.1) 
95.28 
(18.9) 
-7.0 
(19.4) 
-5.9% 0.03 
SBP* 
(mm Hg) 
45 122.41 
(17.9) 
124.23 
(19.9) 
1.82 
(9.31) 
1.6% 0.29 
2 
124.73 
(16.2) 
126.50 
(20.2) 
1.77 
(12.0) 
 
1.5% 0.71 
DBP* 
(mm Hg) 
45 77.59 
(11.8) 
76.58 
(10.9) 
-1.00 
(5.39) 
-0.08% 0.22 
2 
79.09 
(8.3) 
76.55 
(5.9) 
-2.55 
(7.0) 
 
-2.5% 0.09 
Waist 
(inches) 
51 43.16 
(5.58) 
42.46 
(5.67) 
-0.69 
(1.61) 
-1.6% 0.003 
 
 
8 
42.85 
(5.3) 
41.63 
(5.5) 
-1.21 
(2.0) 
-2.8% 0.003 
BMI 
(kg/m2) 
50 36.55 
(7.35) 
35.74 
(7.45) 
-0.82 
(1.18) 
-2.3% <0.001 
 
 
8 
36.85 
(8.8) 
35.62 
(9.0) 
-1.23 
(1.3) 
-3.53% <0.001 
*Patients with med changes excluded 
**n=43 due to lab error 
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Participant Retention by Clinic (p<0.05)
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Urban 2
 
Figure 5-1 Participant Retention by Clinic 
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Figure 5-2 Weight Loss Attainment for Total Group and Completers 
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6.1 ABSTRACT 
Objective:  Individuals with the metabolic syndrome (MS) are at risk for development of type 2 
diabetes and cardiovascular disease. Prospective data relating perception of health risk and 
achievement of lifestyle changes are lacking.  Methods:  Fifty-one patients with the MS who 
participated in the Group Lifestyle Balance (GLB) program completed a modified Risk 
Perception Survey for Developing Diabetes (mRPS-DD). The GLB, adapted from the Diabetes 
Prevention Program (DPP) included the same intervention goals with minor modifications. 
Participants had no prior history of diabetes, BMI >25 and at least 3 components of MS (NCEP 
ATPIII definition).  The mRPS-DD included questions concerning attitude about lifestyle 
behaviors, health, environmental and individual risk. Results:  Over one-third (37.3%) of this 
high risk group perceived their health risk to be almost none/slight. A greater proportion of those 
who completed the program believed prior to starting that their risk for development of diabetes 
within the next 10 years was moderate/high (64.3% v. 25%, p=0.05).  Risk perception for 
diabetes development decreased significantly between pre and post assessments (p=0.03); no 
difference in clinical outcome was observed between those who perceived a decrease in risk and 
those who did not. Conclusion:  Over one-third of this high risk group did not correctly perceive 
their risk.  Risk perception for diabetes decreased after participation in the GLB; however, no 
differences in clinical outcomes were noted between those who perceived a risk reduction and 
those who did not.  Results of this evaluation underscore the importance of incorporating 
diabetes risk communications into lifestyle change programs.  
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6.2 INTRODUCTION 
Diabetes, specifically type 2 diabetes which accounts for 90-95% of all diabetes cases [1], has 
become one of the largest public health challenges of our time.  In the US, over 12 million 
people have diabetes and an additional 8 million are undiagnosed [2]. The seriousness of the 
disease is well-known as it is the sixth leading cause of death in the United States [3].  Diabetes 
is strongly related to cardiovascular disease [4] and is the leading cause of new blindness and 
kidney failure in those age 20-74 years old and a major cause of lower limb amputation [2].  
Diabetes costs in the US in 2002 exceeded $132 billion and are expected to worsen over time [5].    
Even more frightening is the fact that an estimated 54 million Americans have pre-diabetes, thus 
are at increased risk for developing type 2 diabetes, as well as heart disease and stroke [6].   
The metabolic syndrome, a clustering of risk factors including insulin resistance, 
dyslipidemia, obesity and hypertension has also been associated with increased risk for both type 
2 diabetes and cardiovascular disease [7-11].  In 2002, the overall prevalence of the metabolic 
syndrome in adults in the US over age 20 years was 24%, with a considerable increase with age: 
the prevalence in 50-year-old subjects was >30%, while over 40% of subjects age 60 years had 
the metabolic syndrome [12].  
Recent results from prevention studies demonstrated that type 2 diabetes can be 
successfully prevented or delayed through lifestyle intervention [13-15].  Furthermore, the 
Diabetes Prevention Program (DPP) also demonstrated the efficacy of an intensive lifestyle 
intervention for diabetes prevention [16], as well as effectiveness in reducing risk for metabolic 
syndrome [17] and cardiovascular risk factors [18].  With the advent of these important results, 
understanding the factors that contribute to an individual’s performance in programs which 
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facilitate the lifestyle changes necessary for beneficial health outcomes becomes of primary 
concern. 
One component of many theories of health behavior is that an individual with a high 
perceived risk of harm would be motivated to take action to reduce his or her risk ([19-21].  
While some research supports the relationship between perceived risk and protective action [21-
24], studies that prospectively examine risk perception for diabetes development and reduction 
of risk through lifestyle change are lacking.  Several studies, however, have examined cross-
sectional data for perceived risk of developing diabetes; Walker et al., collected data on 
physician’s personal risk perception for developing diabetes [25] as well as perception of risk for 
developing diabetes in participants in the DPP, who were at high risk with impaired glucose 
tolerance [26].   The first study found that physicians who were at higher risk (based on self-
reported risk factor categories) had significantly greater comparative risk perception scores and 
greater perception of diabetes risk than those with lower risk.  Similarly, nearly 80% of the 
participants in the DPP sub-study examining personal risk for diabetes development ranked 
diabetes as a moderate/high risk.  In another study, the predictive effects of health beliefs on 
weight loss in subjects at high risk for type 2 diabetes who were participating in a weight loss 
intervention were examined.  No relationship was found between health beliefs and subsequent 
behavior including attendance, weight loss, dietary intake or fasting glucose [27].  Although this 
was a prospective study, results were reported for the baseline risk survey responses only and did 
not address results post-intervention.  In addition, single items of belief were measured rather 
than the use of a survey with composite scores.  We are not aware of any other prospective 
studies examining risk perception for development of diabetes and performance in a lifestyle 
change program.   
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Lifestyle change has been shown to be effective in reducing risk for development of type 
2 diabetes; however, prospective data concerning risk perception and performance in a lifestyle 
change program are lacking.  Thus, the current project investigated prospectively patient 
perception of risk for developing diabetes and performance outcomes in Group Lifestyle Balance 
(GLB) program, a lifestyle change program adapted from the Diabetes Prevention Program’s 
highly successful intensive individual lifestyle intervention.  Specifically, baseline mRPS-DD 
responses were examined, as well as the correlation with clinical outcomes and measures of 
success in the program.  In addition, changes in response after completion of the program were 
assessed.   
6.3 RESEARCH DESIGN AND METHODS 
6.3.1 Subjects 
The study participants were identified through screenings held in four primary care practices in 
the Western Pennsylvania area; two were urban practices and two were rural.  The Diabetes 
Prevention Support Center of the University of Pittsburgh (DPSC), was responsible for oversight 
of the program in these four primary care practices.  Participants aged 25-74 years with BMI ≥ 
25 kg/m2 and no previous history of diagnosed diabetes were eligible for the GLB program if 
they had at least three of the components of the metabolic syndrome as per the NCEP ATP III 
guidelines [28].  A total of 51 participants were enrolled in the program.  Exclusion criteria 
included: self-report of previously diagnosed diabetes, pregnancy, lack of physician approval and 
inability to sign informed consent.   
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6.3.2 Intervention 
The original DPP Individual Intensive Lifestyle Intervention was developed at the University of 
Pittsburgh by the DPP Lifestyle Resource Core and has been described in detail elsewhere [29].   
Members of the original DPP lifestyle team collaborated to adapt the individual intervention to a 
group-based program and to condense the program from 16 individual sessions delivered over 24 
weeks to 12 group sessions delivered over 12-14 weeks.  Other modifications included 
concentrating on healthy food choices rather than specifically the food pyramid, a focus on 
calorie as well as fat intake from the beginning of the intervention and more emphasis on the 
pedometer.  As in the original DPP lifestyle program, the goals of the GLB intervention were to 
achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity 
to 150 minutes per week of moderately intense physical activity similar to a brisk walk. 
6.3.3 Procedures and Outcomes Measures 
This prospective study used a one-group design incorporating pre and post intervention testing of 
subjects.  Enrolled participants were asked to attend an assessment to obtain clinical measures 
prior to beginning and again at the conclusion of the intervention.  All clinical measures were 
obtained by a certified preventionist and/or certified DPSC staff member.  Blood pressure was 
measured in a sitting position in the right arm after resting for five minutes.  First appearance and 
last heard (phase V) Korotkoff's sounds were used to define the pressure readings; the measures 
were repeated three times with a thirty second wait between each reading [30].  An average of 
the 2nd and 3rd readings was computed.  Height and weight were measured twice without shoes 
with the average computed; BMI was calculated as average weight divided by average height 
 123 
  
squared (kg/m2).  Waist circumference was measured at the midpoint between the lower rib 
margin and the iliac crest; the measurement was repeated twice and the average computed.    
Total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol and 
glucose were measured after at least a two-hour fast using the Cholestech LDX System by a 
certified laboratory assistant.   Global CVD risk assessment [31] was estimated and medication 
use was assessed via participant interview.  In addition, weight and physical activity minutes 
were recorded weekly at each session. 
6.3.4 Modified Risk Perception Survey for Developing Diabetes  
The Risk Perception Survey for Developing Diabetes (RPS-DD) developed by Walker, et al., is 
designed for assessment of multiple dimensions of perceived risk for developing diabetes [32]. 
During the initial survey development, all items of the survey were reviewed for content and face 
validity by a panel of clinical diabetes experts, risk perception experts, and health psychologists. 
A pilot study was conducted with 74 nondiabetic, overweight, middle-aged community 
individuals, after which the survey was revised slightly to enhance validity, reliability and ease 
of use.  The original RPS-DD included 53 items and four subscales as well as other individual 
items to assess various aspects of risk perception.  Internal consistency reliability for the four 
subscales was found to be acceptable using Cronbach α coefficients.   
The survey was modified by the authors for this study; specifically it was shortened to 
include only the 32 items pertaining to the subscales, as well as the 3 items regarding lifestyle 
behavior.  In addition, 5 questions pertaining to risk for diabetes development in relation to 
lifestyle changes were added, for a total of 40 items.  The self-administered mRPS-DD was 
completed by enrolled participants at the baseline and post-intervention assessments.  The 
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Personal Control subscale (4 items) reflects perceived control over developing diabetes with a 
higher score indicating greater perceived control.  The Comparative Disease Risk subscale 
assesses perceived risk for development of 15 diseases and conditions on a scale ranging from 1 
(“almost no risk”) to 4 (“high risk”) with a higher score indicating a greater perceived risk.  The 
Comparative Environmental Risk subscale uses the same scale and measures 9 perceived 
environmental risks, such as driving accidents, air pollution and extreme weather.   Finally, the 
Optimistic Bias subscale reflects an individual’s perception for risk for developing diabetes as 
compared to others of the same gender and age, with a lower score indicating less perceived risk 
and more optimistic bias.  The survey also includes 2 items which assess worry about developing 
diabetes (Worry Sum) and a Composite Risk Score which includes all 32 items; a higher score 
indicates higher overall perceived risk.    
6.3.5 Statistical Analysis 
Analyses were carried out using the SPSS Statistical package (Version 15.0).  The first set of 
analyses examined cross-sectional data for baseline measures; differences between gender, age 
and race for all 51 participants were examined using t-tests for equality of means or the non-
parametric equivalent Mann-Whitney for Independent Samples and Pearson chi-square.  
Correlations between the subscales and measures of success in the program including weight 
loss, total activity minutes and attendance were evaluated using Spearman’s correlation 
coefficient r.  Pearson chi-square test was used to explore associations among perceived risk for 
diabetes and performance in the GLB program.  Performance measures included achievement of 
program goals and adherence (attendance at 50% or more of the sessions and the last assessment 
visit).   The mean change between pre and post survey responses was analyzed for those who 
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completed both a baseline and post-intervention survey (n=34) using the non-parametric 
Wilcoxon Matched-Pairs Signed Rank test.  The Mann-Whitney test for Independent Samples 
was utilized to examine differences in changes in risk between groups.  Significance for all 
results was set at 0.05.  This study was approved by the University of Pittsburgh Institutional 
Review Board. 
6.4 RESULTS 
All 51 participants completed baseline mRPS-DD surveys, while 34 (27 female, 7 male, 26 
Caucasian, 7 African American, 1 Hispanic, age range 30-74) provided post intervention 
surveys.  There were no significant differences in age or pre-intervention weight between those 
who completed both the pre and post mRPS-DD surveys and those who did not.  
6.4.1 Baseline Results 
Mean baseline values for the subscales were evaluated by gender, race and age for differences 
(Table 1).  Women showed a higher mean Personal Control subscale value (3.1 vs. 2.6, p<0.01) 
indicating greater feelings of personal control over health.  A borderline higher mean Worry Sum 
score was also noted for men (3.1 vs. 2.6, p=0.08) indicating greater worry about diabetes.  No 
significant differences were noted between Caucasian and African American baseline responses 
for the subscales.  Both Comparative and Personal Disease risk sores (p=0.04 and 0.02 
respectively) were higher in those 50 years and older demonstrating higher perceived risk for 
 126 
  
disease.   A borderline higher mean Composite Risk score was also noted in those over age 50 
(2.3 vs. 2.1, p=0.08).  
Table 2 shows the 15 diseases or conditions which comprise the Comparative Disease 
Risk score ranked by mean score; those who indicated they already have the disease or condition 
were removed from the analysis.  Risk for high blood pressure had the highest mean score, with 
diabetes ranked second; diabetes demonstrated the greatest proportion of high perceived risk 
(29.4%) and moderate/high risk (62.7%) responses when compared to the other 
diseases/conditions.  When individuals were asked about their risk perception for diabetes 
development, if they did not make any changes in their current lifestyle, the number believing 
they were at high risk remained essentially the same for risk of developing diabetes in 10 years at 
33% but for risk of diabetes in 1 year, risk decreased to only 16%.   
6.4.2 Correlation of mRPS-DD and Outcomes 
The next part of the analyses examined whether there was any relationship between risk 
perception and several quantitative measures of behavioral success in the program including 1) 
weight loss, 2) total number of activity minutes achieved, and 3) number of sessions attended.  
The mean weight loss in the program was 4.6 pounds (sd=7.1); total mean activity minutes for 
all participants achieved over the course of the program was 665.6 (sd=2,209) and the mean 
number of sessions attended was 6.6 (sd=4.2), with 31 (61%) attending at least half of the 
sessions.  Correlations are shown in Table 3 and generally show little association between the 
subscales and any of the three outcomes; the only one approaching significance was that between 
Comparative Disease Risk and physical activity minutes (Spearman’s r=0.28, p=0.05).   
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Achievement of the program goals was also examined categorically in respect to baseline 
survey responses.  In terms of weight loss, when collapsing the responses strongly 
disagree/disagree and strongly agree/agree, a marginally significant higher proportion of those 
who achieved a 3% or higher weight loss disagreed/strongly disagreed with the statement “If I 
am going to get diabetes, there is not much I can do about it” (42.9% v.11.1%, p=0.07, Figure 1).  
There were no differences noted for achieving weight loss in overall perception of risk for 
diabetes, or belief that risk was high for developing diabetes in the next one or ten years if no 
changes to lifestyle behaviors were made. 
Attainment of the physical activity goal was also assessed; a marginally higher proportion 
of those who reached the activity goal believed they were at moderate/high risk of developing 
diabetes than those who did not meet the activity goal (91% versus 57.5%, p=0.07).  A higher 
proportion of those who achieved the activity goal also noted a belief at baseline that their risk 
was high for developing diabetes in the next one (64% vs. 35%, ns) or ten years (82% vs. 50%, 
p=0.08)  if no changes to lifestyle behaviors were made. 
Another measure of success in the program is adherence, defined as attending at least half 
of the sessions and the final assessment visit for this project. A total of 28 participants attended at 
least 50% of the sessions and the final assessment visit. A marginally greater proportion of those 
who completed the program believed prior to starting that their risk for development of diabetes 
within the next 10 years was moderate/high (64.3% v. 25%, p=0.06, Figure 2).  There were no 
significant differences in the adherent versus non-adherent group regarding overall perception of 
risk for diabetes or risk of developing diabetes within one year if they did not make any lifestyle 
changes.  
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6.4.3 Changes in mRPS-DD post assessment 
Responses regarding general attitudes about diabetes development were assessed for the 34 
subjects who completed both a pre and post intervention survey.  A significant increase in the 
perceived Personal Control subscale score was noted (p=0.02), while single item questions 
designed to assess belief in personal control over health risks and feelings that personal effort 
may control diabetes risk showed marginally significant increases (p=0.06, 0.07 respectively).  
The only other subscale to demonstrate any change was the Composite Risk score which showed 
a significant decrease (p=0.03) indicating a reduced perception of risk overall.   While neither the 
Personal nor Comparative Disease Risk subscales demonstrated differences between baseline 
and post-intervention, when examined specifically by individual diseases/conditions, the only 
item that showed a significant change in reported risk perception was diabetes, which 
demonstrated a significant decrease in risk perception from the pre assessment survey to the post 
(p=0.03) with the proportion believing they were at moderate/high risk at baseline decreasing 
from 62.7% to 35.3% post-intervention.  Baseline measures for both groups were examined and 
no significant differences were noted.  In addition, each group was stratified by decrease in risk 
perception for diabetes and composite score changes; all groups demonstrated a significant 
decrease in BMI, but the group whose risk perception stayed the same or increased also showed 
significant decreases in glucose and diastolic blood pressure.  Furthermore, there were no 
differences between the groups regarding attainment of weight loss goals.  
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6.5 DISCUSSION 
The results of this study indicate that less than two-thirds of this study population was concerned 
about developing diabetes at baseline with 62.7% rating risk for development of diabetes as 
moderate/high risk.  At post-intervention, there was a significant reduction in perception of risk 
for diabetes with only 35.3% believing themselves to be at moderate/high risk.  These results are 
lower than the responses from the participants in the DPP, where nearly 80% of the sample 
believed themselves to be at moderate/high risk.   These results may reflect their participation in 
a lifestyle program which they may believe decreases their risk. 
That over one-third believed themselves to be at only slight/almost no risk for developing 
diabetes clearly represents a problem in education as subjects were told of their risk before 
starting the GLB program.  Similar findings however have been noted previously with perception 
of risk for developing diabetes [33, 34], as well as for other conditions such as hypertension [35], 
heart attack [36], stroke [37] and AIDS [38].   Thus, education concerning risk may be the first 
step toward diabetes prevention and risk reduction.  This is an important point for educators to 
consider as they approach patients to begin discussions regarding diabetes prevention.    
Measuring the link between the success of a lifestyle change program and perception of 
risk is difficult.  In this analysis we have examined behavioral successes such as weight loss, 
physical activity minutes achieved and number of sessions attended.  For all three of these 
quantitative measures, little association was noted with any of the subscales with the exception 
of Comparative Disease Risk and total physical activity minutes.  Although this relationship was 
not shown to be strongly correlated, it may suggest that concern about developing diseases or 
conditions provided some motivation for physical activity in this group.   
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Regarding attainment of the program goals for weight loss and physical activity, it is 
interesting to note that those who were successful in achieving at least 3% weight loss did not 
feel hopeless about their situation prior to beginning the intervention which was demonstrated by 
their greater disagreement with the statement “if I am going to get diabetes there is not much I 
can do about it”.  Such fatalistic attitudes are common in the “real-world” of diabetes education 
and prevention.  One study that looked at risk perception for developing diabetes through a 
telephone survey found that those with multiple risk factors were less likely than those with 
fewer risk factors to believe that anything could be done to change the course of diabetes 
development [39].  In addition, the same study also found that those with certain risk factors 
including family history, high blood pressure and high cholesterol were less likely to believe that 
they could do anything about developing diabetes.  This relationship was not confirmed in the 
current project. 
It is not clear whether this attitude is due to a lack of knowledge regarding research 
supporting success in the prevention or delay of diabetes, or if in spite of having knowledge, 
these individuals choose to ignore it.  Regardless, ascertainment of an individual’s perception of 
control regarding the development of diabetes, as well as determination of whether a fatalistic 
attitude exists may be important concepts to consider when enrolling a patient in a lifestyle 
change program so that appropriate education can be provided. 
When looking at baseline versus the post-intervention responses for the individuals that 
completed both, two of the risk perception subscales showed significant changes.  The Personal 
Control subscale showed a significant increase indicating an overall feeling of having more 
control over health.  In addition, the Composite Risk score showed a significant decrease 
representing a reduced perception of overall risk.  These results suggest that participation in a 
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lifestyle change program may increase feelings of personal control and responsibility for health 
risk, as well as decreasing feelings of overall risk.  For the individual components of the Personal 
and Comparative Risk scores, it is interesting to note that only risk perception of diabetes 
decreased significantly in the pre and post analysis.   
It is of some concern that although a decrease in perceived risk for both diabetes and the 
overall Composite Risk subscale score was noted, evaluation of clinical outcomes measures 
when stratified by risk perception belief did not show any differences between the groups.  This 
could indicate that the individuals taking part in this program may have had a “false sense of 
security” due to their participation alone, rather than due to any actual reduction in risk.  Thus, it 
may be important in future planning for lifestyle change programs to consider including 
materials that continually address and redirect the focus of the program back to diabetes 
prevention and individual risk. 
Strengths of this study include a prospective study design that allowed for assessment of 
relationships between attitude and subsequent performance in the Group Lifestyle Balance 
program.  This evaluation is one of the first using the mRPS-DD prospectively to evaluate risk 
perception performance.  Other strengths include a fairly diverse study population with 27% 
being non-white. 
The main limitation to this evaluation is the small sample size which limits the power to 
find significant changes where in some cases only trends are noted.  In a post hoc power 
analysis, given the observed weight loss and sample sizes in those perceiving themselves at high 
risk for diabetes versus those who did not, we had 80% power to detect a difference in weight 
loss of 7.4 lbs more than what was observed.  However, this evaluation was primarily a 
feasibility study; because the survey has not been utilized on a large scale, this information will 
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be helpful to others in planning for research studies examining risk and using this survey.  
Another limitation was the fact that there was no control group, thus comparisons between post-
intervention responses were not permitted.   In addition, these results were obtained in a small 
group of individuals in Western Pennsylvania and so may not be generalizable to other 
populations.   
Because concern regarding individual misconception of personal risk has been shown in 
this and other investigations, in moving forward, it will be important to evaluate methods of 
conveying risk effectively both prior to initiation, as well as during the provision of a lifestyle 
change program.  The concept of risk perception for disease and subsequent preventive behavior 
change is still widely unknown, thus future studies should continue to utilize and evaluate the 
survey prospectively in larger groups as intervention programs continue to grow.  As the results 
of this investigation indicated that success in the program, as measured by achieving some 
weight loss, was associated with belief that something can be done to prevent diabetes, other 
areas of study should include examining the fatalistic attitude often observed that nothing can be 
done to prevent diabetes to determine possible interventions to negate this. 
In this small investigation of individuals at high risk for developing diabetes, perception 
of risk subscales were generally not significantly related to performance in the GLB program, 
however, trends observed support the concept of risk perception acting as a motivator for 
lifestyle change.  In addition, the results suggest that success in the program is related not only to 
completion of the program and making lifestyle changes, but also to a positive (or less negative) 
attitude toward the possibility of diabetes prevention.  Due to the increasing diabetes crisis, it 
will become ever more essential to understand what education/ information is helpful for 
increasing an individual’s chances of success in making lifestyle changes; risk perception for 
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diabetes development remains an unstudied concept, thus larger investigations are needed to 
examine this concept further. 
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Figure 6-1 Baseline Perception Regarding Diabetes Prevention by 3% Weight Loss 
p=0.07 
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Figure 6-2 Pre-Intervention Perceived Risk of Diabetes by Completion of GLB 
p=0.06 
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Table 6-1 Baseline Mean Subscale Results  
(n=51) 
 Gender 
 
Race Age 
 Male 
 
(n=9) 
Female 
 
(n=42) 
p Caucasian 
 
(n=37) 
Non-
white 
(n=14) 
p 25-49 
years 
(n=20) 
50-74 
years 
(n=31) 
p 
Personal Control 
 
2.6 3.1 <0.01 3.0 3.0 ns 3.0 3.0 ns 
Optimistic Bias 
 
2.3 2.0 ns 2.0 2.3 ns 2.1 2.1 ns 
Worry Sum 
Score 
3.1 2.6 0.08 2.7 2.6 ns 2.8 2.6 ns 
Comparative 
Disease Risk 
2.1 2.1 ns 2.2 1.9 ns 1.9 2.2 0.04 
Personal Disease 
Risk 
2.3 2.4 ns 2.5 2.2 ns 2.1 2.5 0.02 
Environmental 
Risk 
1.8 1.6 ns 1.7 1.7 ns 1.6 1.7 ns 
Composite Risk 
 
2.3 2.2 ns 2.2 2.1 ns 2.1 2.3 0.08 
 
 
 
Table 6-2 Baseline Perceived Risk of Diseases/Conditions*  
(n=51) 
Comparative Disease 
or Condition Risks 
n Mean Scores Percent 
Responding 
“High Risk” 
Percent 
Responding 
“Moderate” or 
“High Risk” 
High Blood Pressure  25 3.0 40.0 64.0 
Diabetes  51 2.8 29.4 62.7 
Heart Disease  45 2.7 28.9 62.2 
Cancer  46 2.5 17.4 54.4 
Stroke  48 2.4 16.7 43.8 
Arthritis  29 2.4 13.8 51.7 
Impotence (men only) 8 2.0 - 37.5 
Osteoporosis 48 2.0 10.4 27.1 
Hearing Loss 46 1.7 4.3 19.5 
Asthma 48 1.6 4.2 12.5 
Blindness 51 1.6 3.9 15.7 
Infections 47 1.6 2.1 14.9 
Kidney Failure 49 1.5 2.0 16.3 
Foot Amputation 51 1.4 3.9 7.8 
AIDS 51 1.0 - - 
*Those already diagnosed with the disease/condition are excluded 
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Table 6-3 Baseline Subscale Scores and Quantitative Measures of GLB Success  
(n=51) 
 Weight Difference 
 
Physical Activity 
Minutes 
Number of Sessions 
Attended 
 Spearman’s rho 
 
Spearman’s Rho Spearman’s Rho 
Personal Control 
 
0.00 0.06 -0.11 
Optimistic Bias 
 
-0.03 -0.05 -0.13 
Worry Sum Score 
 
-0.02 -0.04 -0.09 
Comparative Disease  Risk 
 
0.16 0.28* 0.17 
Personal Disease Risk 
 
0.17 0.24 0.15 
Environmental Risk 
 
-0.03 0.06 -0.05 
Composite Risk 
 
0.12 0.19 0.09 
* p=0.05 
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7.0  DISCUSSION 
The gap between research and practice has been well documented; it has in fact been suggested 
that it may take one or two decades for original research to be translated to clinical practice 
[312].  The Diabetes Prevention Program announced that intensive lifestyle intervention was 
efficacious in reducing risk for type 2 diabetes by 58% in 2002, thus at the present time, five 
years have already passed.  As noted, there was considerable evidence to support an intervention 
for prevention of diabetes prior to the DPP, and during the five years since publication of the 
DPP results there have been additional supporting results published.  Thus, it seems clear that the 
time has come to begin translating diabetes prevention research to practice.  Because lifestyle 
intervention has been shown to be one of the most efficacious interventions for risk reduction for 
diabetes, with the added bonus of minimal or no side effects, it would appear that translation 
attempts should focus on adapting the lifestyle intervention for real-world application. 
The findings of this project, not only an attempt at translating a modified DPP lifestyle 
intervention but also the development of a screening program to identify those at risk, support 
the concept that a prevention screening and intervention program can be effectively implemented 
in a primary care practice setting.  The primary focus of the prevention screening project was to 
evaluate the effectiveness and achievability of an organized program for prevention screening 
and risk identification.  The recruitment results showed that the majority (61.7%) of individuals 
who attended screening initially responded to a letter sent to explain the importance of 
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prevention and to offer them an opportunity to be screened.  These results suggest that mailing 
an invitation for screening may be a fairly efficient and cost-effective method of recruiting for 
prevention screening.   Another finding regarding recruitment for prevention screening was the 
difference noted between the urban/outside preventionist and rural/internal preventionist 
screening rates (27.9% vs. 10.9%, p<0.01).  Although the difference in screening rates may be 
related to the preventionist specifically, it is important to consider that the clinics with lower 
screening rates also had a higher minority population than the clinics with higher screening 
response, thus there may be contributing racial or other socioeconomic barriers.  Barriers to 
health care and preventive services related to racial and socioeconomic reasons have been well-
documented [313-316] and have also been previously noted to be related to attitudes about 
testing, lack of knowledge and environmental factors such as lack of transportation or lack of 
time [317].  It is also possible that there are inherent differences in people living in rural versus 
urban communities that may contribute to these differences.  While it has been documented that 
rural populations often are actually less likely to receive health screenings, this may due 
primarily to a lack of services being available [318].  Another finding of note is that a 
significantly higher proportion of men refused screening than women, with 71.7% of those 
attending screening being female.  It will be important to examine reasons for the noted 
discrepancies in screening invitation response, as well as participation in future prevention 
screening projects as they may impact how prevention screening is presented in different 
community settings and to a variety of individuals. 
Prevention screening was successful in identifying 206 potentially new risk states which 
translates to 142 patients (41% of those screened) with potentially new conditions of risk 
identified through screening.  Of those screened, 97 individuals without diabetes met the criteria 
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for metabolic syndrome and were eligible for prevention intervention, with 43 taking part in the 
Group Lifestyle Balance program offered at each practice.  Furthermore, regardless of whether 
they were previously diagnosed or not, 224 patients (64%) were found at screening to have at 
least one risk factor meriting further medical evaluation.   
These results strongly support the concept of prevention screening for several reasons.  
First, the identification of over 40% of those screened with newly found risk states could indicate 
previously undetected chronic conditions contributing to increased risk for diabetes and CVD.  
The identification of these conditions should theoretically lead to reduced risk for these 
individuals in the future.  Second, following the previous line of reasoning, when individuals are 
identified as being at risk, in order to reduce that risk, it is imperative that a prevention 
intervention program is readily available and accessible.  This project demonstrated the 
feasibility of identification of those at risk and subsequent enrollment in a prevention program 
offered in the primary care practice setting; however, as the number enrolled were only about 
half of those found to be eligible, it will be important to try to understand the barriers to 
participation in lifestyle change programs when considering future lifestyle program 
implementation.  Finally, as 82 individuals (23.4% of those screened) with at least one elevated 
risk factor warranting further follow up had been previously diagnosed, this project also 
demonstrates the importance of regular, systematic follow up for those already diagnosed with 
chronic diseases/conditions such as the ones discussed here in order to assure that risk states are 
controlled. 
 The results of the subsequent chart review again support the concept of prevention 
screening to identify risk; a greater increase in the prevalence of all diagnosed conditions was 
found from the primary to the secondary review for the target group versus the comparison 
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group, with significantly greater increases noted in prevalence of diagnosed hyperlipidemia, pre-
diabetes, and obesity.   
The chart review also revealed that only 36% of elevated risk parameters noted in the 
chart review for those who did not attend screening and 41% of those who attended screening 
and had a post-intervention review completed received appropriate follow-up.  These are 
important findings showing that in general, not only are screening guidelines not being met, but 
that even when patients are identified as being at risk only a small proportion of them are 
receiving appropriate follow-up.  This underscores the importance of providing easy to use 
guidelines and education for those in practice, as well as the availability of appropriate 
interventions for risk reduction. 
For those identified as being at risk, the Group Lifestyle Balance program proved to be 
effective in reducing some parameters of risk for diabetes including weight, waist measurement 
and glucose.  The program was successfully implemented in each of the four practices by health 
care professionals who were trained to deliver the intervention, as well as to conduct the 
prevention screening.  It is important to note that the preventionists had no prior experience in 
behavioral modification or any specialist diabetes interest and had varied backgrounds.  Thus, a 
large pool of health professionals is potentially eligible to deliver the GLB with appropriate 
training.  This suggests that the provision of trained healthcare professionals delivering group 
lifestyle intervention in primary care practice is feasible and could be a potential sustainable 
model for the “real world”.   
As is well known, translation from research to the “real-world” presents a number of 
challenges, thus it was anticipated that results from the current translation project would be 
somewhat reduced from those seen in the DPP.   As noted, the Group Lifestyle Balance program 
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was successful in significantly reducing some parameters of risk including weight, waist 
circumference, BMI and glucose.  Unfortunately no changes were noted for blood pressure, total 
cholesterol, non-HDL cholesterol, or HDL cholesterol; however one of the limitations of this 
project was the lack of a long-term follow-up period, thus there may have been changes over 
time that were not observed. 
The number of sessions attended was positively correlated with weight loss (p=0.002) 
and physical activity minutes (p=0.003).  Attainment of the program goals was examined for 
both the total and “completer” groups. In the total group of 51 participants, 7.8% reached the 
weight loss goal of 7%, while 21.6% and 33.3% had weight loss of at least 5% and 3.5% 
respectively.  Within the “completers” group, 4 of 28 participants reached the 7% weight loss 
goal (14.3%), while 35.7% and 53.6% achieved weight loss of at least 5% and 3.5% respectively.  
In the DPP, 49% of lifestyle participants reached the 7% goal by the completion of the core 
intervention at the end of six months [319]; in the current project, 33.3% and 53.6% in the total 
and completer groups respectively met a weight loss goal of 3.5% at 3 months, similar to the 
trend for weight loss in the DPP at 3 months.  The Finnish Diabetes Prevention Study (FDPS) 
found that after one year, 43% in the lifestyle intervention group had reached the study goal of 
5% weight loss [320].  Recent results of the Good Ageing in Lahti Region (GOAL) Lifestyle 
Implementation Trial, an effectiveness study examining a program based on the FDPS in a “real-
world” health care setting, demonstrated 12% reaching the goal at the end of one year [321].  It 
will be important to continue to study the implications of these translation efforts over a longer 
period of time. 
The importance of physical activity in reaching weight loss goals for lifestyle change is 
underscored by the results of the intervention.  Overall, a positive correlation was observed 
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between total activity minutes and total pounds lost (Spearman’s r=0.36, p=0.01) and a 
significant association between attainment of the activity and weight loss goals was noted; 25% 
(n=12) of those who attained the activity goal vs. 2.5% (n=39) of those who did not were 
successful in reaching the weight loss goal (p=0.03).    
Because the process of making lifestyle changes is so complex, it is important to consider 
other factors related to success, in particular understanding motivation for change.  The primary 
goal of the third component of this project was to investigate the relationship between perceived 
risk and performance in the GLB program.  The Risk Perception Survey for Developing Diabetes 
(RPS-DD) was modified for use in this population.  Baseline results for the mRPS-DD, 
predictive responses for performance in the GLB program and comparisons between responses at 
baseline and again after intervention for those who completed both assessments were examined. 
In general, it would seem logical that individuals who perceive their risk for diabetes 
development to be high would also be highly motivated to make changes to reduce that risk.  For 
the high-risk individuals participating in this project, risk perception for diabetes development 
was ranked second on the list for mean scores (high blood pressure was ranked first) and 
represented the greatest proportion of high risk (29.4%) and moderate/high risk (62.7%) 
responses when compared to the other diseases/conditions.  However, this represents less than 
two-thirds of the individuals in this high risk group accurately identifying themselves to be at 
risk.   
When examined specifically by individual diseases/conditions, the only item which 
showed a significant change in reported risk perception was diabetes, which demonstrated a 
significant decrease in risk perception from the pre assessment survey to the post (p=0.03) with 
the proportion believing they were at moderate/high risk at baseline decreasing from 64.7% to 
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35.3% post-intervention.  When examining those with a decrease in perceived risk for diabetes 
versus those whose perception of risk did not change or increased, there were no significant 
differences noted between the groups for change in any of  the clinical outcomes measures 
including weight, BMI, glucose, systolic or diastolic blood pressure, total cholesterol, LDL 
cholesterol, non-LDL cholesterol or waist circumference.  Because perception of risk decreased, 
but actual observed changes in risk were not different in those who perceived a decrease and 
those who did not, these results suggest that it is important to consider including materials which 
reinforce the concept of diabetes risk throughout a lifestyle change program, in order to keep the 
individual focused on their actual risk for diabetes development. 
7.1 FUTURE PUBLIC HEALTH IMPLICATIONS 
Quite obviously, prevention and risk reduction cannot occur if those at risk are not identified in 
some manner.  While prevention screening and risk assessment do occur, assessments are often 
haphazard and not rooted in the healthcare system.   Some of the barriers to risk identification 
which have been presented in the introduction include lack of structured screening over time 
resulting in testing being overlooked or repeated unnecessarily, confusing screening guidelines, 
lack of time on the part of the physician and primary care staff, and poor patient understanding of 
risk.  The current project presents a systematic and organized model for prevention screening 
which could be implemented throughout the healthcare system, as well as an effective and 
feasible lifestyle intervention for those identified as being at risk. 
One of the major barriers to prevention screening is the lack of an organized system in 
which individuals can be screened and subsequently followed over time.  The advantage of an 
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automated program is that once a patient is entered into the system, the follow-up schedule is set 
for the patient based on current recommendations, with little effort or configuring on the part of 
physicians or primary care staff.  The results of the current project which indicated that only a 
small proportion of identified risk states receive appropriate follow-up underscore the 
importance of incorporating a structured follow-up plan, with reminders for the patient as well as 
the physician and primary care staff.   
Another potential advantage to a computer driven system is that the information required 
to obtain a risk assessment is entered in the program prior to the actual visit with the physician, 
thus potentially saving time by avoiding manual risk assessment.  The components of the 
computer program would appear to save time for physicians and staff for whom currently all 
such determination must be done manually, however it will be important to study the 
implications of such a program from a cost and time saving perspective.  Because many of the 
guidelines for prevention are somewhat confusing, another advantage to a structured program is 
that the guidelines have been put together in an easy to use format and in this system are actually 
built into the program.  Physicians can enter specific information about the patient and the risk 
assessment is performed automatically.   
The results of the prevention screening component of this project demonstrate that 
prevention screening for risk identification for type 2 diabetes and cardiovascular disease is 
feasible in a primary care practice setting and can be successful in identifying those at risk so 
that appropriate action and follow up may occur.  Prevention screening was effective in 
identifying potentially new risk states that had not been previously noted or diagnosed and also 
demonstrated a significant increase in the prevalence of clinically diagnosed hyperlipidemia and 
pre-diabetes.   
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Mailing of invitation letters for prevention screening was effective in recruiting those 
patients who actually attended screening.  The implications of these findings from a public health 
perspective are important in that a prevention screening program in primary care practice using 
an automated patient recruitment and screening tool could be a model for application on a large 
scale for identifying those at risk within the existing health care system.   It is apparent that more 
work is needed on reaching the large proportion of individuals who decline; for those who do 
respond and are identified with potential risk states, mechanisms for facilitating appropriate 
follow up will be needed. 
While identification of those at risk for diabetes and CVD development is the first step in 
reducing risk, risk identification cannot stand alone.  Comprehensive lifestyle change programs 
delivered in practical and easily accessible settings are an essential partner in disease prevention.  
The current project is one of the first attempts to take the successful intervention utilized in the 
DPP, modify it for real-world implementation and evaluate its effectiveness in a primary care 
setting.  A major component of this project is the development and evaluation of the Group 
Lifestyle Balance program as well as the development of the training guidelines and workshop 
for the program.   All of the preventionists involved were healthcare professionals without 
special backgrounds in diabetes who were able to successfully deliver the intervention in their 
settings.  Thus this work has clearly demonstrated the feasibility of training health care 
professionals within primary care practices to deliver lifestyle intervention on a broad scale. The 
combination of the availability of a group lifestyle change program and established training 
guidelines represent a key implication for public health in providing a model for lifestyle 
intervention translation.  As has been discussed, lifestyle change programs for those at risk are 
lacking, thus even when identifying a patient as being at risk a physician is limited in what he 
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can “prescribe”; generally patients are told to “lose weight and exercise”.  With the availability 
of a successful group intervention for lifestyle change, as well as a mechanism for training 
appropriate individuals in the delivery of the intervention, this project provides an outline for 
delivering intervention for those determined to be at risk on a wide-scale basis. 
With the advent of evidence that type 2 diabetes can be prevented or delayed, as well as 
the increasing availability of evidence-based lifestyle interventions, understanding the behavioral 
factors that may be related to success in lifestyle change programs becomes of primary 
importance.  The current project is one of the first to examine perception of risk for developing 
diabetes using a modified Risk Perception Survey for Developing Diabetes prospectively to 
investigate the relationship between performance in a lifestyle change program and perception of 
risk prospectively.  
The results of this study of a group of individuals with metabolic syndrome participating 
in the Group Lifestyle Balance program indicate that over half of this study population was 
concerned about developing diabetes at baseline.  It is of concern that although the majority of 
this high risk group correctly perceived their risk at baseline, almost 40% perceived their risk to 
be slight or none at all.  These results could have implications for public health in that they 
reflect other studies of perceived risk for various other chronic diseases as well as diabetes [322-
327] in which individuals who are at risk for a disease or condition do not perceive their risk 
accurately.  As we move forward with diabetes prevention efforts, an important initial step will 
be to determine ways to best translate the correct perception of risk to those who are identified as 
being at risk.   
Another important point to consider is that at post-intervention, there was a significant 
reduction in perception of risk for diabetes with only 35.3% believing themselves to be at 
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moderate/high risk.  It is of concern that an actual difference in risk reduction between those who 
perceived a decrease in risk and those who did not was not observed.  Therefore, it may be 
important for those planning lifestyle change programs in the future to consider including 
materials that continue to address and redirect the focus of the program back to the primary 
reason for the program: diabetes prevention and risk reduction. 
No relationship was noted between any of the risk perception subscales and weight loss 
in the GLB program; however, this may likely be due to a lack of power for this component of 
the project (see limitations).  While none of the risk perception subscales were related to weight 
loss in the GLB program, it is interesting to note that those who were successful in achieving at 
least 3% weight loss did not feel hopeless about their situation prior to beginning the intervention 
which was demonstrated by their disagreement with the statement “if I am going to get diabetes 
there is not much I can do about it”.  From a public health perspective, this suggests that it may 
be important to assess an individual’s perception regarding their attitude toward development of 
diabetes prior to entering a lifestyle change program.  It may also be important to determine the 
basis for their attitude and to provide education where needed, as having a negative attitude 
about one’s ability to change the course of diabetes development could potentially prohibit a 
positive outcome. 
Due to the increasing diabetes crisis, it will become ever more essential for those 
involved in translating diabetes prevention to the public on a large scale to understand what 
education/information is helpful for increasing an individual’s chances of success in making 
lifestyle changes.  For the most part, perception of risk for developing diabetes remains an 
unstudied area in which larger studies are needed to evaluate its relationship with success in 
making healthy lifestyle choices. 
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7.2 LIMITATIONS 
While the STEP UP project provided an excellent opportunity to evaluate a prevention screening 
program as well as a first attempt at translating the successful lifestyle intervention utilized in the 
DPP to a “real-world” situation, there are a few limitations that are applicable to all three papers 
and should be noted. 
Study Design The STEP UP project did not include a control group (due to the non-
research priorities of the funding source), thus results for comparison to standard care are not 
available.  Furthermore, the project did not include long-term follow-up of participants, thus only 
pre and post intervention results are available.  This may limit the prognosis for this prevention 
program over time, although long-term maintenance will be a focus of subsequent research. 
Study Population The participants in the STEP UP program were from four primary care 
practices in Western Pennsylvania.  While an effort was made to select both rural and urban 
practices, the results of this project may not be generalizable to individuals in other areas.   
Sample Size The actual number of patients at the participating practices was smaller than 
what was anticipated by the practices, thus yielding a smaller number of individuals screened 
and subsequently lower enrollment in the GLB program and mRPS-DD evaluation.  A larger 
sample size would have provided better power for detecting differences in outcomes measures. 
 The following include the limitations specific to each paper. 
7.2.1 Paper 1 
The lack of a formal cost analysis, which would be very beneficial in further understanding 
financial implementation of prevention screening in the health care system, is a limitation of this 
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component of the project.  A cost analysis of the recruitment procedures for prevention screening 
would provide an assessment of the time and cost involved in recruiting patients to come in for 
screening.  Furthermore, information about the actual cost of the screening itself would be 
helpful for planning purposes.  Finally an in-depth evaluation of the potential revenues to be 
generated for practices in the identification and follow-up of those at risk would be helpful in 
determining how such a program could become self-sustaining. 
7.2.2 Paper 2 
In addition to the small sample size, attrition of participants and subsequent lack of evaluation of 
those who did not complete the intervention was a considerable limitation of the analysis of this 
component of the project.  Number of sessions attended was positively correlated with weight 
loss, thus the importance of engaging and retaining participants cannot be stressed enough.  It 
should be noted that some of the attrition in one of the clinics may be related to the fact that the 
fate of one of the clinics was unclear and patients were uncertain as to whether they would need 
to find another primary care practice.  Another potential limitation was requiring only at least a 
2-hour fast for the blood sample; however, it was felt that because this was not a clinical trial, but 
a translational effort to a real-world situation, it was important to try to make participation as 
“user-friendly” as possible by accommodating subjects’ busy and varied schedules, thus 
encouraging maximum attendance.  These are issues that certainly arise when dealing with “real-
world” situations.  In addition, as mentioned above, the limited period of study (3 months) due to 
funding considerations was also a considerable limitation to this component of the project, in that 
a long-term follow-up for continued change in outcomes measures was not feasible.  
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7.2.3 Paper 3 
In addition to the limitations described that affect all three papers, the main limitation to this 
component of the project was the original small sample size.  Because this survey was not the 
primary focus of this project, it was anticipated that this component of the project was likely 
considerably underpowered to find differences if they did in fact exist.  In a post hoc power 
analysis, given the observed weight loss and sample sizes in those perceiving themselves at high 
risk for diabetes versus those who did not, we had 80% power to detect a difference in weight 
loss of 7.4 lbs more than what was actually seen in the study. Attrition from the program was 
also limiting as the additional post-survey responses from those who did not complete the 
program may have provided some insight into changes in perception of risk that may influence 
decisions to discontinue lifestyle changes.   
7.3 FUTURE RESEARCH 
There are several areas for future research regarding prevention of diabetes and reduction in 
cardiovascular risk to be noted.  Regarding screening for prevention, in order to improve 
screening attendance and subsequently risk identification, it will be important to further evaluate 
reasons for refusal and the barriers that exist concerning recruitment for prevention screening.  
While mailing an invitation to attend prevention screening was an effective method for recruiting 
those that actually attended screening in this project, other methods, such as offering incentives 
or performing screenings within a less clinical environment to engage those who did not attend 
screening should be evaluated in order to increase the overall yield and reach those who may not 
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normally have contact with their primary care practice.   Other areas of future research regarding 
prevention screening include examining ways to improve appropriate follow-up on risk states 
identified through prevention screening.  These could include the evaluation of automated 
programs such the one described in this project specifically directed toward appropriate follow 
up post screening, educational programs regarding guidelines for follow up for physicians and 
staff, or a combination of both.  Finally, one of the most important areas of future research 
concerning prevention screening, will be cost-analysis of 1) recruitment of patients to attend 
screening, 2) the cost of the actual prevention screening visit, 3) the potential revenue brought 
into a practice through identification of billable conditions requiring follow up and 4) an overall, 
long-term evaluation of the cost-effectiveness of identification of risk assuming that appropriate 
action occurs and outcomes are reduced. 
Future research regarding translation of a lifestyle change intervention should include 
longer observation of the intervention to establish if lifestyle changes can be expanded upon 
and/or maintained over time.  This will be important in determining the best ways to provide 
lifestyle intervention and in developing materials to help individuals continue a healthy lifestyle 
over a lifetime.  Other areas of study should address delivery of the lifestyle program in other 
settings such as in a community or worksite setting.  As there is a large potential pool of heath 
care professionals to be trained to become preventionists, investigating other areas for delivery 
will increase the dissemination of information on a wider scale.  Another important area for 
future research should address attrition from the program to determine if this was unique to these 
sites or if this will be a common problem that will occur in the real world of translation.  It will 
be important to try to develop strategies to promote retention, possibly including incentives 
which may be monetary in nature, for example, rebates on costs for health care, reimbursement 
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for attendance, or time off from work to attend sessions.  Finally, other delivery modes of the 
intervention should be explored in the future, for example using multi-media tools such as 
DVD’s or CD’s to deliver the intervention, or via the Internet, television broadcast or long-
distance learning for rural areas. 
Risk perception for developing diabetes is a relatively new concept and could take on an 
important role in the future as prevention becomes more mainstreamed. It will be important to 
understand what motivates individuals to take part in lifestyle change programs and what makes 
them continue and succeed in living more healthfully.  Future areas of research regarding risk 
perception should examine risk perception in a larger group over a longer period of time.  It is 
possible that some of the individuals who initially did not perform well, could become engaged 
in the future, thus it will be important to asses their risk perceptions over time. 
7.4 CONCLUSION 
The need for diabetes prevention in general has been well established; the difficulty now lies in 
trying to translate what is known from research to application in the real world.  This project is 
an important first step in the war on diabetes; however there is still much to be done on many 
levels.  The findings of the current project support the concept of prevention screening as an 
integral part of a comprehensive preventive service; however, controversy regarding screening 
on a broad scale continues.  While the International Diabetes Federation’s recent consensus 
statement on diabetes prevention recommended prevention based on controlling modifiable risk 
factors through screening [328], others have debated the merit of screening, and believe that 
there is still uncertainty over the extent to which the benefits of prevention screening justify the 
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costs and outweigh the potential harms [329].  It has also been suggested that because the main 
population burden of CVD related to hyperglycemia does not generally come from a small 
number of individuals with high levels of glucose, but rather from a large number of people with 
moderately elevated glucose levels, it would be most logical to focus prevention on attempting to 
lower mean glucose levels overall by reducing obesity and increasing physical activity in the 
general population [330].  Others have recommended screening for those with other high risk 
states such as hypertension or dyslipidemia [331] or in noting the significant relationship 
between diabetes and CVD have suggested incorporating diabetes risk assessment with existing 
vascular risk assessments [332].   
It would seem that these ideas do not need to be mutually exclusive; an infrastructure for 
prevention screening could be developed by implementing screening in larger systematic 
controlled environments such as hospitals or health plans, and could continue to be monitored 
and evaluated for effectiveness and cost while moving forward.  Because of the closely 
interwoven relationship between diabetes and CVD, it seems reasonable to asses risk for both 
simultaneously as was the concept in this project in the assessment of the metabolic syndrome.  
Furthermore, those found to be at risk should be provided an evidence-based risk reduction 
program such as the Group Lifestyle Balance program described here.  At the same time, global 
efforts toward reducing obesity and increasing physical activity in the population at large should 
be of primary importance.  Officials and policy makers will need to come on board in order to 
initiate meaningful policy changes at top levels to make prevention a national priority.   
Screening and subsequent risk identification in and of itself may be related to some risk 
factor modification for CVD [333, 334]; however, evidence exists to the contrary.  In one study 
which reported significant changes in behavior after risk screening for cholesterol, the results 
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were based on self-reported lifestyle behavior changes; actual objective measures did not show 
any significant changes [335].  Another recent study examined the impact of conducting a 
targeted stepwise diabetes screening program on health-related lifestyle behaviors (physical 
activity, dietary habits, alcohol use or smoking) in a Danish population aged 40–69 years.  The 
results of this investigation indicated that there were no clinically significant lifestyle changes 
which occurred as a result of being screened [336].  Other research has demonstrated that the 
addition of counseling to screening is more effective than screening alone [337, 338]  Thus, the 
concept of pairing evidence-based intervention with screening appears to be an appropriate 
model for comprehensive prevention.   
The current project found that a modified DPP intervention, the Group Lifestyle Balance 
program, was successful in significantly reducing weight, BMI, waist circumference and glucose 
levels in this group of individuals at high risk for diabetes with metabolic syndrome.  The 
intervention was delivered by health care professionals with no special background in diabetes 
who were trained in the provision of the intervention, thus demonstrating that there is a large 
pool of potential individuals who can be trained to provide prevention intervention.  In order to 
have the largest impact possible, third party reimbursement for intervention delivered by trained 
health care professionals will be necessary, perhaps in conjunction with a nominal fee that 
patients will be reimbursed for when meeting certain goals such as attendance or adherence. 
Medicare would be an obvious place to begin implementing primary prevention of 
diabetes as costs for the population in that age group are considerable and will continue to 
increase as the baby-boomers reach Medicare age.  As Ackerman et al. reported, when compared 
with placebo, providing the lifestyle intervention at age 50 years could prevent 37% of new cases 
of diabetes before age 65 [64].   The authors also noted that offering the DPP lifestyle 
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intervention for eligible people between the ages of 50 and 64 could provide financial return on 
investment for private payers and long-term benefits for Medicare.  In a review examining 
prevention of diabetes in a clinical setting, Burnet, et al. concluded that the cost-effectiveness 
analysis of the DPP provided “a compelling case for increased insurance coverage of nutrition 
and physical activity interventions in persons at high risk for diabetes” [339].  Prevention 
intervention programs could be initiated through system-based referrals based on prevention 
screening results with ongoing efficacy and cost evaluation. 
In summary, the STEP UP project demonstrated the feasibility of a comprehensive 
program for the prevention of diabetes and CVD risk reduction.  The project included 1) a set of 
easy to use guidelines for prevention, 2) a computer driven prevention recruitment tool and 
screening program, 3) a modified DPP lifestyle change intervention, and 4) an established 
training program for instruction in delivery of the intervention.  The results of this project 
suggest that prevention is feasible and effective and can be carried out in a primary care practice 
setting.  Although there will continue to be many barriers to  implementation of prevention 
within our health care system, the described project provides a framework for a model that could 
potentially be implemented throughout the country as well as setting the stage for the 
development of a national prevention service. 
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APPENDIX A:  STEP UP PREVENTION SCREENING GUIDELINES 
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STEP UP General Follow-up Guidelines* 
 
1. All patients with “normal” results should receive general information regarding 
prevention of diabetes, CVD, healthy lifestyle, weight control and regular exercise, as 
well as their future prevention screening schedule.   
 
2. Primary care practices should feel free to supplement the health pamphlets and brochures 
provided by STEP UP. 
 
3. In terms of action based on a screening value, STEP UP generally suggests an abnormal 
value be repeated within three months before initiating therapy, particularly drug therapy. 
 
4. Using the patient tracking system on the laptop, preventionists should review patients 
result forms annually to assess the need for scheduling of a prevention screening 
appointment.  In the case where an office visit is not required, the patient should be sent a 
letter informing them that all is well and that they will be due for a visit the following 
year. 
 
5. Other sources for information: 
 
a. American Diabetes Association:  
i. www.diabetes.org or 1-800-DIABETES 
b. American Heart Association 
i. www.americanheart.org or 1-800-AHA-USA 
c. Centers for Disease Control 
i. www.cdc.gov or 1-800-311-3435 
d. National Cholesterol Education Program 
i. www.nhlbi.nih.gov/about/ncep  or 301 592 8573 
e. National Diabetes Education Program 
i. http://www.ndep.nih.gov/ or 301-496-3583 
f. National High Blood Pressure Education Program 
i. www.nhlbi.gov/guidelines/hypertension      
g. United States Preventive Services Task Force 
i. http://www.ahcpr.gov/clinic/uspstfix.htm 
 
 
 
 
*NOTE:  Group Lifestyle Balance (GLB) was originally called Group Intensive Lifestyle (GILS) 
and is referred to as GILS in this document. 
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STEP UP BMI SCREENING GUIDELINES 
 
1. Overweight and obesity should be assessed in all individuals every two years for those who have 
not been overweight (>25kg/m2)  in the past. 
2. Overweight and obesity should be assessed more frequently for those who have been or are 
overweight or obese. 
BMI < 
18.5kg/m2 
Underweight 
 
Assess weight loss, determine if recent, e.g. 
within 3-6 mos.  If weight loss is >5% and 
unintentional, recommend PCP follow-up. 
BMI = 18.5- 
24.9 
Normal/ 
Optimal:  
Recheck within 
2 years 
Recommend healthy lifestyle changes and 
reinforce appropriate weight goals.  Provide 
weight loss counseling and pamphlets as 
appropriate.   
BMI = 25.0-
29.9 
Overweight:  
Recheck within 
1 year 
No additional action required. 
 
Obese:  
Evaluate and 
refer as soon as 
possible 
BMI > 
30kg/m2 
  
If ineligible or unwilling, provide counseling 
as necessary.  Initiate weight management 
program through caloric restriction and 
increased caloric expenditure as appropriate. 
Goal:  Reduce body weight by 10% in first 
year of therapy. 
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STEP UP WAIST CIRCUMFERENCE SCREENING 
GUIDELINES
 
Women
Waist <32 inches or 
80cm  
Normal, reassess 
within 2 years 
No additional action 
required. 
Waist >32 inches or 
>80cm 
Increased risk, 
reassess within 1 
year 
Provide education on CVD 
risk factors, diet and 
exercise. 
Waist >35 inches or 
>88cm 
Substantially 
increased risk, 
reassess within 6 
months 
May be eligible for GILS.  
If ineligible or unwilling, 
provide education on CVD 
risk factors, diet and exercise 
and pamphlets as 
appropriate 
Men
Waist <37 inches or 
<94cm 
Normal/Optimal, 
reassess within 2 
years 
No additional action 
required. 
Waist >37 inches or 
>94cm 
Increased risk, 
reassess within 1 
year 
Provide education 
on CVD risk factors, 
diet and exercise. 
 
Waist >40 inches 
or >102cm 
Substantially 
increased risk, 
reassess within 6 
months 
 
May be eligible for GILS.  
If ineligible or unwilling, 
provide education on CVD 
risk factors, diet and exercise 
and pamphlets as 
appropriate 
**** If Waist Circumference > 40 inches for MEN or >35 inches for WOMEN may be eligible for 
GILS.  
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STEP UP BLOOD GLUCOS  SCREENING GUIDELINES 
1. General guidelines: 
• All patients should have a diabetes risk assessment every three years (see risk factors 
es Risk Factors: 
E
 
 
listed below). 
i. Diabet
• Age >45 yrs,  
• BMI > 25 kg/m2.  
iabetes (parents, siblings, children),  
panic-American, 
• 
M or baby >9lbs.,  
s diagnosis) 
• Family History of d
• Race/ ethnicity (African-American, Asian-American, His
Native-American & Pacific Islanders),  
IFG or IGT, 
• History of GD
• Hypertension (>140/90 or previou
• HDL cholesterol <35mg/dl or triglycerides >250 mg/dl,  
• FPG should be performed every 3 years for those age >
• Polycystic ovary syndrome,  
• History of vascular disease 
 
 45 years  
d at least two other 
• s (<45 and 0-1 diabetes risk factors) every 
 
2. Patients should fast for at least 2-4 hours but not longer than 14 hours before blood glucose test; 
• FPG should be performed every 3 years for those age <45 years an
diabetes risk factors (see above risk factors) 
Diabetes risk should be assessed for all other
three years 
patients who have fasted less than 2 hours should be scheduled for an appointment for a fasting 
glucose whenever possible.  If it is not possible for the patient to return for a fasting glucose, a 
random glucose should be collected.  Any person with a random glucose of > 200mg/dl should 
strongly encouraged to schedule an appointment for a fasting glucose or see their PCP. 
be 
 
. Clinics may perform a finger stick blood glucose screening check if they prefer.  The finger stick 
h 
 
hole Blood-calibrated Sample 
>
3
should be used as a SCREENING rather than as a diagnostic tool.  It is important for clinics to 
know how their glucose monitoring meter is calibrated (this information should be included wit
the meter information).  For those that are whole blood-calibrated, results will be 10-15% lower 
than a venous plasma sample result.  For those meters that are plasma-calibrated, results may be 
compared directly with a laboratory plasma sample.  Cut-point criteria for finger stick blood 
glucose are as follow: 
W
Fasting 90 
Non-fasting >120 
 
Plasma-calibrated Sample 
>Fasting 100 
Non-fasting >140 
 
ny finger stick sample meeting the above criteria indicates that an appointment should be scheduled A
for a fasting blood glucose.  Finger stick results will not be acceptable for inclusion in GILS. 
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           STEP UP BLOOD GLUCOSE SCREENING GUIDELINES-continued 
 
 
Fasting 
glucose 
<100 
Normal/Optimal 
1. Reassess diabetes risk within 
3 years. 
2. If age >
Provide information regarding risk factors 
for diabetes, identify and discuss any risk 
factors present.  For those with at least one 
risk factor provide diabetes prevention 
pamphlet. 
45 OR age <45 and 
at least two diabetes risk 
factors repeat FPG within 3 
years 
Fasting 
glucose = 
100-109 
Meets ADA criteria for IFG/Pre-
diabetes 
• If patient has 2 other 
components of MS, 
physician may offer OGTT, 
repeat FBS or HbA1c within 
6 wks if being considered for 
GILS. 
• If patient does not have at 
least 2 other risk factors, 
confirm FBG within 6 
weeks.
Based on 2 hr OGTT, repeat FBS or 
HbA1c results (with 2 other components of 
MS) it will be up to the physician to 
determine eligibility for GILS. 
If ineligible and/or unwilling, review FBG 
to confirm or refute IFG diagnosis.   
1. IFG confirmed-Provide counseling 
and pamphlet regarding pre-
diabetes 
2. Not confirmed-reassess within one 
year with counseling and pamphlet 
Meets ADA criteria for IFG/Pre-
diabetes 
• Repeat fasting glucose 
within 6 weeks to confirm. 
 
IFG confirmed:  Determine eligibility for 
GILS and enroll if eligible. 
 
If ineligible and/or unwilling:  Provide 
counseling and pamphlet regarding pre-
diabetes 
 
If IFG NOT confirmed:  Reassess within 
one year, provide counseling and pamphlet 
regarding pre-diabetes 
Meets ADA criteria for diabetes  
• Repeat fasting glucose 
within 6 weeks to confirm. 
 
Fasting 
glucose > 
110 AND 
<126 
Fasting 
glucose >
Diabetes confirmed:  Institute diabetes 
education following ADA guidelines of 
care. 
 
Diabetes NOT confirmed: May consider for 
GILS.  May consider repeating FBG within 
6 weeks. 
 
126 
**** If FBG > 100 and <126 may be eligible for GILS.  
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STEP UP PULSE SCREENING GUIDELINES 
 
1. PULSE:  Monitor pulse for at least 30 seconds to one minute to assess rate and rhythm after five-
minute rest:  
 
 
 
 
 
 
 
STEP UP SMOKING SCREENING GUIDELINES 
 
 
1. G (cigarette, cigar and/or pipe) should be assessed at every clinic visit. 
 
 
 
 
 
 
 
 
 
 
 SMOKIN
 
 
Smoker 
Optimal; reassess at next visit. Non-smoker 
Risk factor for CVD.  Assess patient’s 
interest in smoking cessation.  Provide 
information regarding CVD risk and 
smoking.  Provide smoking cessation 
handout and local smoking cessation 
information when available.  Reassess  
within one year. 
Pulse Rate <50 OR 
>100 OR irregular 
rhythm 
Pulse Rate > Optimal; reassess within two years.  50 and 
<100, and regular 
rhythm 
Abnormal, ECG may be considered to assist 
in treatment considerations for blood 
pressure and/or lipids. 
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STEP UP BLOOD PRESSURE SCREENING GUIDELINES 
Blood pressu1. re should be measured at least every two years. 
2. Blood pressure should be measured after 5 minute rest period sitting in a chair. 
3. Two blood pressure readings should be measured at least one minute apart. (see Manual 
of Operations for complete assessment procedures) 
 
 
Normal/Optimal:  
Blood pressure 
should be re-
assessed within 2 
years. 
Blood 
Pressure = 
120-39 OR 
80-89 
Blood 
Pressure = 
0-99 
140-159 OR 
9
Pre-hypertensive:  
Recheck within 
one year¹ 
 
Stage 1:  Confirm 
within 2 months; if 
(<140/90) recheck 
within one year¹ 
not confirmed 
May be eligible for GILS.  Provide education on 
CVD risk factors, diet and exercise and blood 
propriate 
Mono-drug therapy indicated.  Consider 
addition of additional drug for *“compelling” 
indication
pressure pamphlet as ap
No additional action required.
May be eligible for GILS.  Provide education on 
CVD risk factors, diet and exercise and blood 
pressure pamphlet as appropriate 
Consider drug therapy for *“compelling” 
indication  
Stage 2:  Confirm 
within one week 
and evaluate or 
refer within 1 
month¹ 
May be eligible for GILS.  Provide education on 
CVD risk factors, diet and exercise and blood 
pressure pamphlet as appropriate 
Mono-drug therapy indicated.  Consider 
addition of additional drug for *“compelling” 
indication 
Blood 
Pressure 
>180 OR 
>110  
 
Stage 2 Elevated:  
Evaluate or refer 
immediately or 
within 1 wk¹ 
May be eligible for GILS.  Provide education on 
CVD risk factors, diet and exercise and blood 
pressure pamphlet as appropriate 
Two drug combination for most.  Consider 
addition of additional drug for *“compelling” 
indication
SBP>140 
AND DBP 
<90  
 
Isolated Systolic 
Hypertension: 
Confirm following 
above using 
systolic reading¹ 
May be eligible for GILS.  Treatment 
recommendations for older people with HBP, 
including those who have isolated systolic 
hypertension should follow the same principles 
outlined for the general care of hypertension. In 
many individuals, lower initial drug doses may 
be indicated to avoid symptoms. 
Blood 
Pressure = 
160-179 OR 
100-109 
 
Blood 
Pressure 
<120 and 
<80 
* Compelling indications:  Include heart failure, post MI, high 
coronary disease risk, diabetes, chronic kidney disease, r urrent 
stroke prevention 
¹ Blood pressure 
ec
> 130 or >85 may be eligible for GILS  
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STEP UP LIPID SCREENING GUIDELINES 
 
A complete lipid profile should be measured every five y1. ears for adults >20 years of age. 
 2 years. 
id profile should be completed after a 9-12 hour fast. 
 fasting, collect only total cholesterol and non-HDL cholesterol.  If total cholesterol is >
2. Patients with at least two risk factors for CVD should be checked every
3. Lip
4. If not  
HDL cholesterol is <40mg/dl, fasting lipid profile should be scheduled. 
owering treatment is started a 30-60% reduction in LDL-C should be achieved 
 
CVD Risk Factors:  Assess and determine CVD risk factors: 
 
1. Cigarette Smoking 
2. Hypertension (blood pressure >140 or >90) or on antihypertensive medication 
3. Low HDL cholesterol (<40mg/dl) 
4. Family history of premature CHD (CHD in male first-degree relative <55 yrs. or CHD in female 
first-degree relative <65 yrs.) 
5. Age: 
Men:    >
200mg/dl or 
5. If lipid l
45 years of age 
Women: >55 years of age 
 
Negative Risk Factor:  HDL > 60mg/dl (removes one risk factor) 
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LDL Cholesterol 
0-1 Risk Factors 
 
Reassess within 5 years 
 
 
2+ Risk Factors: 
Reassess within 2 years 
 
 
CHD or CHD Equiv.: 
ear Reassess within 1 y
 
No additional action required. LDL 
<100 
O  
P 
T 2+ Risk Factors:  Discuss individual risk factors.  
Provide pamphlet concerning specific CVD risk 
 
I 
M 
A 
factors. 
L 
 
 
CHD or CHD Equiv**July 2004 NCEP ATPIII 
recommendations suggest serious consideration of a 
goal of LDL <70 for this high-risk group, which may 
necessitate initiation or increased dietary or drug 
therapy. 
LDL = 
100-129 
 
A    O 
L    P 
M   T 
O    I 
S    M 
T    A 
       L 
 
0-1 Risk Factors: 
Reassess within 5 years 
0-1 Risk Factors: Provide CVD risk pamphlet 
 
2+ Risk Factors: 
Reassess within 2 years 
 
 
 
 
2+ Risk Factors: Determine risk based on 
Framingham risk assessment. >20% risk: Institute 
therapeutic lifestyle change (TLC), consider drug 
therapy following NCEP ATPIII guidelines of care.  
<20% risk:  Institute or intensify TLC. 
 
CHD or CHD Risk Eq.: 
Reassess within 3 
months 
CHD or CHD Equiv.: Institute or intensify TLC, 
consider drug therapy following NCEP ATP III 
guidelines of care.  **July 2004 NCEP ATPIII 
recommendations suggest serious consideration of a 
goal of LDL <70 for this high-risk group, which may 
necessitate initiation or increased dietary or drug 
therapy. 
LDL= 
130-159 
 
B 
O 
R 
D 
E 
R 
L 
I 
N 
E 
0-1 Risk Factors:  
Reassess within 2 years 
 
0-1 Risk Factors: Provide CVD risk pamphlet 
 
 
2+ Risk Factors: 
10->20%  
Reassess within 6 wks-
3mos.   
<10% Reassess within 
3 mos. 
 
CHD or CHD Equiv. 
Reassess within 6 wks-
2+ Risk Factors:  Initiate or intensify TLC.  Estimate 
10- year risk based on Framingham risk assessment.  
>20% follow guidelines for CHD, 10-20% Initiate 
TLC, consider drug therapy following NCEP ATP 
III, <10%. initiate TLC 
 
CHD or CHD Equiv: Initiate or intensify TLC and 
drug therapy following NCEP ATPIII. 
 
3 months
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0-1 Risk Factors: 
Reassess within 6 wks-
3 months 
 
2+ Risk Factors: 
Reassess within 6 wks-
3 mos. 
 
 
CHD or CHD Equiv. 
Reassess within 6 wks-
3mos. 
0-1 Risk Factors:  Institute TLC.  Follow NCEP ATP 
III. 
 
 
2+ Risk Factors:  Initiate or intensify TLC.  Estimate 
10- year risk based on Framingham risk assessment.  
10- >20% initiate or intensify TLC and drug therapy.  
<10% Initiate or intensify TCL.  Drug therapy may 
be considered. 
CHD or CHD Equiv.: Initiate or intensify TLC and 
drug therapy following NCEP ATPIII. 
 
LDL= 
160-189 
 
H 
I 
G 
H 
 
LDL= 
>190 
 
H 
I 
G 
H 
 
0-1 Risk Factors: 
Reassess within 6 wks-
3 months 
 
2+ Risk Factors: 
Reassess within 6 wks-
3 mos. 
 
CHD or CHD Equiv. 
Reassess within 6 wks-
3mos. 
 
0-1 Risk Factors:  Institute or intensify TLC and drug 
therapy.  Follow NCEP ATP III. 
 
 
2+ Risk Factors:  Initiate or intensify TLC and drug 
therapy. 
 
 
 
CHD or CHD Equiv.: Initiate or intensify TLC and 
drug therapy following NCEP ATPIII. 
 
LDL Cholesterol-continued 
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Triglycerides and HDL Cholesterol 
 
1. Therapy for these atherogenic dyslipidemic states begins after the LDL goal has been achieved 
and starts with TLC alone or simultaneously with initiation of more intensive LDL-lowering 
therapy with drugs. 
2. Non-HDL cholesterol=Total Cholesterol-HDL Cholesterol and may be determined in the non-
fasting state. 
Triglycerides 
 
Triglycerides 
<150 mg/dl 
Optimal 
Recheck based on 
LDL Guidelines 
No additional action required. 
Triglycerides 
>
Borderline High 
Recheck based on 
LDL Guidelines 
150-199 
mg/dl 
May be eligible for GILS.  If ineligible or 
unwilling: 
Provide education on CVD risk factors, diet 
and exercise. Identify and discuss any other 
CVD risk factors present.   Encourage 
healthy lifestyle including weight control and 
physical activity.   
Triglycerides 
>
High 
Recheck within 3-
6 months  
200-499 
mg/dl 
Non-HDL cholesterol becomes a secondary 
target of therapy. Goals for non-HDL 
cholesterol are 30 mg/dL higher than those 
for LDL cholesterol. First the LDL 
cholesterol goal is attained, and if non-HDL 
remains elevated, additional therapy may be 
required to achieve the non-HDL goal. 
Consider higher doses of statin or add fibrate 
or niacin.   
May be eligible for GILS.    
If ineligible or unwilling in addition to 
above, provide education on CVD risk 
factors, diet and exercise. Identify and 
discuss any other CVD risk factors present 
and provide pamphlet as appropriate.    
Triglycerides 
>
Very High 
Evaluate as soon
as possible, 
recheck within 3
months  
 
Treat with fibrate or niacin to reduce risk of 
pancreatitis, then following ATP III.   
May be eligible for GILS.   If ineligible or 
unwilling in addition to above, provide 
education on CVD risk factors, diet and 
exercise. Identify and discuss any other CVD 
risk factors present and provide pamphlet as 
a
 500 mg/dl 
 
 
ppropriate..   
**** If Triglycerides > 150mg/dl ma  be eligible for GILS.  y
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HDL Cholesterol 
Women
HDL Optimal 
following LDL 
Guideli
No further action required. 
Cholesterol 
>50mg/dL 
Recheck 
nes
 
HDL 
Cholesterol 
<50mg/dL 
Low 
Recheck 
following LDL 
Guidelines 
May be eligible for GILS.  If 
ineligible or unwilling: 
Provide education on CVD risk 
factors, diet and exercise. Identify 
and discuss any other CVD risk 
factors present.   Encourage healthy 
lifestyle including weight control 
and physical activity.   
If the patient has CHD or CHD risk 
equivalents, consideration can be 
given to using a drug to raise HDL 
cholesterol (fibrate or nicotinic 
acid), following ATP III LDL-
lowering guidelines. 
Men
HDL 
Cholesterol 
>
Optimal 
Recheck 
following LDL 
Guidelines
No further action required. 
40mg/dL 
HDL 
Cholesterol 
<40mg/dL 
Low 
Recheck 
following LDL 
Guidelines 
May be eligible for GILS.  If 
ineligible or unwilling: 
Provide education on CVD risk 
factors, diet and exercise. Identify 
and discuss any other CVD risk 
factors present.   Encourage healthy 
lifestyle including weight control 
and physical activity.   
If the patient has CHD or CHD risk 
equivalents, consideration can be 
given to using a drug to raise HDL 
cholesterol (fibrate or nicotinic 
acid), following ATP III LDL-
lowering guidelines. 
**** If HDL< 40mg/dl for MEN or <50mg/dl for WOMEN may be eligible for GILS.  
 
  
STEP UP METABOLIC SYNDROME, PRE-DIABETES AND GILS ELIGIBILITY GUIDELINES 
 
1. Determine if patient has at least two of the following risk factors: 
• Triglycerides >150mg/dl OR history of treated (with medication) triglycerides 
• Blood Pressure >130 OR >85 OR previous diagnosis with hypertension (treated with 
medication) 
• HDL Cholesterol                     
a. Men <40mg/dl   
b. Women <50mg/dl   
• Waist circumference                
a. Men >102 cm (>40 inches)   
b. Women>88cm (>35 inches) 
 
If yes, proceed with #2.   
If no, patient does not meet criteria for metabolic syndrome nor is eligible for GILS.  Proceed as 
outlined above for individual risk factors identified. 
 
2. Does patient have previous diagnosis with diabetes?  If yes, not eligible for GILS, provide info on 
metabolic syndrome.  If no, continue and examine patient’s fasting glucose results:   
a. If fasting glucose > 110mg/dL and <126 mg/dL, patient is confirmed to meet 
criteria for the metabolic syndrome and may be eligible for the GILS, proceed 
to #3. 
b. If fasting glucose >100mg/dL and <110mg/dL, patient may be offered oral 
glucose tolerance test, repeat FBG or HbA1c according to the physician 
preference to determine eligibility.  If two-hour result >140 and <200, patient 
may be eligible for the GILS.  Proceed to #3.   
 
3. Women only:  Is patient currently pregnant or lactating? 
a. If no continue with question #4 
b. If yes, patient is not eligible for the GILS; provide appropriate counseling and 
health pamphlets. 
 
4. Is BMI > 25kg/mc2? 
a. If yes, patient is eligible for GILS, physician should confirm and refer.  
Continue with question #5 
b. If no, patient is not eligible for GILS.  Provide appropriate counseling and 
health pamphlets.  Proceed to question #5. 
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STEP UP FURTHER CARDIAC TESTING: 
 
5. 
 
 
 
eview completed Rose Angina and Cla
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider ECG and/or ABI for the following: 
Pulse Rate <50 OR Abnormal, ECG may be considered to assist 
in treatment considerations for blood 
pressure and/or lipids. 
>100,  O r
rhythm 
R i regular 
R
 
udication Questionnaire results: 
 
 
 
 
 
Abnormal, ECG may be considered to assist 
in treatm
Undetermined chest 
pain on Rose ent considerations for blood 
pressure and/or lipids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Questionnaire 
Abnormal, ABI may be considered to assist 
in treatment considerations for blood 
pressure and/or lipids. 
Rose Ques i
positive for 
claudica
t onnaire 
tion 
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APPENDIX B:  MODIFIED RPS-DD SURVEY 
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ATTITUDES ABOUT HEALTH 
 
This survey will provide important information about how people feel about the risk of 
getting a chronic disease, like diabetes. There are no right or wrong answers.  We are 
interested in your opinions and attitudes. Please answer each question as best as you 
can.  
 
1.  General Attitudes 
 
For each item, please circle the number below the response which BEST DESCRIBES YOUR 
OPINION.               
 
   
Strongly 
Agree 
 
Agree 
  
Disagree Strongly 
Disagree 
 
1. I feel that I have little control over risks to 
my health. 
1 2 3 4 
 
2. If I am going to get diabetes, there is not 
much I can do about it. 
 
1 2 3 4 
3. I think that my personal efforts will help 
control my risks of getting diabetes. 
1 2 3 4 
 
4. People who make a good effort to control 
the risks of getting diabetes are much less 
likely to get diabetes. 
1 2 3 4 
5. I worry about getting diabetes. 
 
1 2 3 4 
 
6. Compared to other people of    my same 
age and sex (gender), I am less likely than 
they are to get diabetes. 
1 2 3 4 
7. Compared to other people of my same age 
and sex (gender), I am less likely than they 
are to get a serious disease. 
1 2 3 4 
8. Worrying about getting diabetes is very 
upsetting. 
1 2 3 4 
 
Continue with next page. 
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2.  Your Attitudes about Healt
Below is a list of health problems and diseases.   For each one, please circle the number below 
the w ," 
"mo
h Risks 
ords to tell us if you think your own personal health is at "almost no risk," "slight risk
derate risk" or "high risk" from these problems.   
 
 
If you, or a family member, already have the disease 
(or had the disease in the past), please also check ( √ ) the 
appropriate line on the right. 
⇓     
     
 Almost 
No 
Risk 
Slight 
Risk 
Moderate 
Risk 
High  Have(or had) this 
Risk disease: 
                    Family 
   Myself      member 
9.   Arthritis 
 
1 2 3 4   
_____ _____ 
10.   Hea
 
1 2 3 4 rt Disease   
_____ _____ 
11.   
 
 4Cancer 
 
1 2 3    
_____ _____ 
12.   High blood pressure 
 
1 2 3 4   
_____ _____ 
13.   Hea 2 3 4 ring loss 1 
 
  
_____ _____ 
14.   h
 
4Ast ma 1 2 3    
_____ _____ 
15.   D b 2 3 4 ia
 
1 etes   
_____ _____ 
16.   Osteoporosis 1 2 3 4 
       (bone disease) 
  
_____ _____ 
17.   
 
4Stroke 1 2 3    
_____ _____ 
18.   B nli
 
1 2 3 4 dness   
_____ _____ 
19.   Foo 3 4 t amputation 1 2 
 
  
_____ _____ 
20.   
treatm ctor 
Infections needing          
ent by a do
1 2 3 4   
_____ _____ 
21.   Impotence(only in men) 
 
1 4 2 3   
_____ _____ 
22.   Kidney failure 
 
1 2 3 4   
_____ _____ 
23.   AIDS 
 
1 2 3 4   
_____ _____ 
Continue with next page 
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3.  Environmental Health Risks 
 
Below is a list of possible hazards or dangerous conditions in the environment around most of us.    
 
For each one, please circle the number below the words to tell us if your own personal health is 
at "almost no risk," "slight risk," "moderate risk"
hazards or conditions. 
 
 or "high risk" from each of the following 
 Almost No 
Risk 
Slight 
 Risk 
Moderate  High  
Risk Risk 
 
24.   Medical X-rays (radiation) 
 
 
2 3 4 1 
25.   Violent crime 
 
1  3 4 
 
2  
26.   Extreme weather  
 
1 2 3 4 
(hot or cold)
 
27.   Driving/riding in an 
 
automobile 1  3 4   
 
2  
28.   "Street" drugs  (illegal drugs)  1 
 
 
2 3 4 
29.   Air pollu
 
tion 1  3
 
2  4 
30.   Pesticides 
 
 
1 2 3 4 
31.   Household
 
 chemicals 1  3
 
2  4 
32.   Cigarette smoke from people    1 
smoking around you 
  
2 3 4 
Continue with next page 
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4. Individual Risk and Lifestyle Behaviors 
Lifestyle behaviors include such things as eating, exercising, smoking and dealing with stress.  
hange any of your current lifestyle behaviors, what is your chance of 
next ten years? (Choose one answer) 
 
____ Almost no chance of  diabetes
 
f getting diabetes   
 
____ Equal chance of getting diabetes 
____ Moderate chance of getting diabetes 
 
chance of getting diab s 
  
B. If you do not change any of your current lifestyle behaviors, what is your chance of 
 next year? (Choose one answer) 
 
____ Almost no chance of getting diabetes 
____ Slight chance of getting diabetes   
 
qual chance of getting diabetes 
 
____ Moderate chance of getting diabetes 
 
 any lifestyle beh or changes that you believe will lower your chanc
(Choose one answer) 
 
 _____ No  
If yes, are you continuing those lifestyle changes at the current time? 
 
_____ Yes __
D. ake any lifestyle behavior changes to prevent diabetes in the near 
  (Choose one answer) 
 
_____ Yes _____ Maybe  _____ No 
 
Please give us your best answer for the following questions about lifestyle behaviors: 
 
A. If you do not c
getting diabetes within the 
getting  
____ Slight chance o
 
____ High ete
getting diabetes within the
 
____ E
 
____ High chance of getting diabetes 
C. Have you made
of getting diabetes? 
avi e 
_____ Yes
 
___ No  
 
Do you plan to m
future?
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5. Treatments to Prevent Diabetes: 
BES 
YOUR OPI ION.   
 
 
 
 
For each item below, please circle the number below the response that BEST DESCRI
N
 
 
Strongly 
Agree 
Agree Neither 
Agree nor 
Disagree 
Disagree Strongly 
Disagree 
Doing regular exercise and following 
a diet take a 
effort. 
 
1 2 3 4 5 
 
 
lot of  
Regular exer se and diet will prevent 
diabetes from
developing. 
 
1 2 3 4 5 ci
  
The benefits 
diet and exercise program   
outweigh the
 
3 4 5 of following a     1 2 
 effort to do it. 
 
 
 
 
Thanks! 
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